<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "POLB.L",
  "generated_at": "2026-02-11T23:07:50.012952Z",
  "top_card": {
    "ticker": "POLB.L",
    "company_name": "Poolbeg Pharma PLC",
    "sector": "Healthcare",
    "market_cap_gbp": 32434773,
    "days_active": 187,
    "apex_score_100": 47,
    "confidence_score_100": 40,
    "ai_final_score_25": 12,
    "ai_strength": "MODERATE",
    "timing_regime": "CONFIRMED",
    "action": "HOLD/WATCH",
    "thesis_one_liner": "HOLD/WATCH - CONFIRMED timing with 47/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Poolbeg Pharma PLC",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 32434773,
      "current_close_price": 4.6
    },
    "basics": {
      "ticker": "POLB.L",
      "current_price": 4.6,
      "ath": 15.767,
      "atl": 2.25,
      "ath_date": "2024-05-07",
      "atl_date": "2025-04-07",
      "week_52_high": 5.2,
      "week_52_low": 2.25,
      "week_52_high_date": "2025-02-12",
      "week_52_low_date": "2025-04-07",
      "drawdown_from_ath_pct": 70.83,
      "data_start": "2021-07-19",
      "data_end": "2026-02-11",
      "total_bars": 1154
    },
    "latest_signal": {
      "date": "2025-08-08",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 2.55,
      "drawdown_pct": 80.68,
      "ai_score": 10.0,
      "rsi": 13.3,
      "cycle_position": 0.0385,
      "holding_period_days": 187,
      "current_pnl_pct": 80.39,
      "rally_state": "rallying",
      "distance_from_high_pct": -15.88,
      "Rally_Count": 1,
      "days_since_last_high": 10,
      "last_high_date": "2026-01-16",
      "lock_in_reached": true,
      "lock_in_date": "2026-01-15",
      "best_rally_pct": 98.04
    },
    "best_historical_signal": {
      "signal_date": "2025-08-08",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 2.55,
      "peak_price": 5.2,
      "peak_date": "2026-01-13",
      "rally_pct": 103.92,
      "days_to_peak": 158,
      "ai_score": 10.0
    },
    "all_historical_signals": [
      {
        "signal_id": "POLB.L_2025-03-11",
        "signal_date": "2025-03-11",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.75,
        "current_price": 4.248,
        "current_return_pct": 54.47,
        "best_rally_pct": 83.64,
        "best_rally_date": "2026-01-15",
        "rally_state": "rallying",
        "Rally_Count": 4,
        "distance_from_high_pct": -15.88,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 321,
        "status": "historical"
      },
      {
        "signal_id": "POLB.L_2025-05-20",
        "signal_date": "2025-05-20",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.6,
        "current_price": 4.248,
        "current_return_pct": 63.38,
        "best_rally_pct": 94.23,
        "best_rally_date": "2026-01-15",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -15.88,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 251,
        "status": "historical"
      },
      {
        "signal_id": "POLB.L_2025-06-23",
        "signal_date": "2025-06-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.65,
        "current_price": 4.248,
        "current_return_pct": 60.3,
        "best_rally_pct": 90.57,
        "best_rally_date": "2026-01-15",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -15.88,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 217,
        "status": "historical"
      },
      {
        "signal_id": "POLB.L_2025-08-04",
        "signal_date": "2025-08-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.6,
        "current_price": 4.248,
        "current_return_pct": 63.38,
        "best_rally_pct": 94.23,
        "best_rally_date": "2026-01-15",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -15.88,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 175,
        "status": "historical"
      },
      {
        "signal_id": "POLB.L_2025-08-08",
        "signal_date": "2025-08-08",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.55,
        "current_price": 4.248,
        "current_return_pct": 66.59,
        "best_rally_pct": 98.04,
        "best_rally_date": "2026-01-15",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -15.88,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 171,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 5,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 97.85,
      "median_rally_pct": 100.0,
      "best_rally_pct": 103.92,
      "worst_rally_pct": 89.09
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [],
    "last_updated": "2026-02-11 20:06:50 UTC",
    "volatility": {
      "atr_normalized": 8.67,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "UPTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 47/100 indicates moderate opportunity quality",
      "Timing regime: CONFIRMED",
      "Historical profile: 1 rallies, 98% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "POLB.L",
      "latest": [
        {
          "title": "Notification of Major Holdings",
          "announcement_date": "9th Feb 2026",
          "release_time": "3:13 pm",
          "source": "RNS",
          "content": "Today 15:13\nRNS Number : 2957S\nPoolbeg Pharma PLC\n09 February 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nPoolbeg Pharma PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nMichael Kelly\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n3 February 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n9 February 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.14%\n6.14%\n43,314,547\nPosition of previous notification (if\napplicable)\n5.03%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BKPG7Z60\n43,314,547\n6.14%\nSUBTOTAL 8. A\n43,314,547\n6.14%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMichael Kelly\n10. In case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nIreland\nDate of completion\n9 February 2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUPGPUPQGAB",
          "rns_number": "RNS Number : 2957S"
        },
        {
          "title": "POLB 001 LPS Challenge Trial Paper Published",
          "announcement_date": "28th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "28 Jan 2026 07:00\nRNS Number : 6274Q\nPoolbeg Pharma PLC\n28 January 2026\nPoolbeg Pharma plc\nPeer-Reviewed POLB 001 LPS Challenge Trial Paper Published in\nFrontiers in Immunology\n28 January 2026-\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in\nFrontiers in Immunology.\nKey conclusions from the paper include:\n\u00b7\nPOLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers\n\u00b7\nPOLB 001 was safe and well tolerated across all dose levels\n\u00b7\nStudy confirms POLB 001 potently inhibits p38 MAPK driven cytokine responses\n\u00b7\nPublication endorses significant potential of POLB 001 with the interim data anticipated from the\nTOPICAL trial\nthis summer\nThe paper entitled,\n\"POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following\u00a0in vivo\u00a0LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study\"\nby Digna T. de Bruin, et al is available in\nFrontiers in Immunology\n,\nDOI:\nhttps://doi.org/10.3389/fimmu.2025.1684307\nThe bacterial lipopolysaccharide (\"LPS\") challenge trial was a randomised, double-blind, placebo-controlled study, examining POLB 001's ability to suppress both local and systematic inflammatory responses in healthy volunteers. Key findings include:\n\u00b7\nThe suppression of immune cell recruitment was most pronounced in neutrophils (72.4%-81.5%, p = 0.0091), classical monocytes (68.4%-73.6%, p = 0.0036), CD3+ T cells (56.4%-65.9%, p = 0.0047), and myeloid dendritic cells (59%-64.4%, p = 0.0174).\n\u00b7\nThe suppression of cytokine responses was most pronounced for TNF (35.3%-65.1%, p = 0.0099).\n\u00b7\nOverall, POLB 001 did not substantially modulate the intradermal LPS-driven increase in local erythema and perfusion.\n\u00b7\nPOLB 001 significantly reduced the IV LPS-driven increase in IL-6, IL-8, and TNF (37.7%-80.7%, all p < 0.0003), p38 MAPK phosphorylation levels in target cells (16.7%-60.9%, all p < 0.0001), and heart rate increase (4-9.3 bpm, p < 0.0001).\nAs\npreviously announced\n, the trial demonstrated that POLB 001 was safe and well-tolerated, with a clear dose-response relationship, inhibition of p38 MAPK activation, and reduction in all measured pro-inflammatory cytokines. The results agree with previous observations that POLB 001 has the potential to prevent an excessive immune response without ablating normal immune function.\nThe findings provide strong validation of POLB 001's method of action and supports its progression towards further clinical development. The publication further strengthens the rationale for POLB 001 as a potential solution for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\").\nPOLB 001 to prevent CRS\nThe Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of CRS, a potentially life-threatening side effect. As such, POLB 001 could make these treatments more accessible to a broader patient population, increase the number of patients that can receive these life-saving treatments, and reduce the burden on healthcare systems.\nJeremy Skillington, PhD, CEO of Poolbeg Pharma, said:\n\"The publication of peer-reviewed clinical data from our LPS challenge trial in Frontiers in Immunology is an important milestone for Poolbeg. The positive data from this trial highlights that oral treatment of POLB 001 holds great promise in addressing cancer immunotherapy-induced CRS and supports further clinical development of the asset, including the POLB 001 TOPICAL clinical trial.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCAKOBKKBKBPDB",
          "rns_number": "RNS Number : 6274Q"
        },
        {
          "title": "Exercise of Options & Total Voting Rights",
          "announcement_date": "27th Jan 2026",
          "release_time": "2:30 pm",
          "source": "RNS",
          "content": "27 Jan 2026 14:30\nRNS Number : 5951Q\nPoolbeg Pharma PLC\n27 January 2026\nPoolbeg Pharma plc\nExercise of Options & Total Voting Rights\n27\nJanuary 2026 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has issued and allotted a total of 7,903,778 new ordinary shares of 0.02 pence each in the capital of the Company (\"Ordinary Shares\") following the exercise of options by former employees of the Company.\nApplication has been made to the London Stock Exchange for the 7,903,778 new Ordinary Shares to be admitted to trading on AIM (\"Admission\") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2026.\nTotal Voting Rights\nAfter Admission, the total number of Ordinary Shares in issue will be\n705,103,778\nand the total number of voting rights will therefore be\n705,103,778\n. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEEALFXAAPKEFA",
          "rns_number": "RNS Number : 5951Q"
        },
        {
          "title": "Letter to Shareholders \u2013 2025 a year of progress",
          "announcement_date": "18th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "18 Dec 2025 07:00\nRNS Number : 0140M\nPoolbeg Pharma PLC\n18 December 2025\nPoolbeg Pharma plc\nLetter to Shareholders - 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected\n18 December 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, publishes an end of year letter from the Company's Executive Chair, Cathal Friel, providing an overview of the significant progress made by the Company in 2025 and outlook for 2026.\nDear Shareholders,\nAs 2025 draws to a close, we wanted to reflect on the substantial progress made by Poolbeg this year, as we move POLB 001 into the clinic and anticipate data readouts from multiple clinical trials in 2026.\nOur oversubscribed and upsized fundraise in June 2025 raised gross proceeds of \u00a34.865 million, extending our cash runway into 2027. The Company's cash balance of \u00a310.0 million (as at 30 June 2025) will support the delivery of multiple key clinical milestones.\u00a0To align resourcing with these near-term clinical priorities, the Company implemented a series of operational efficiency measures, including selective headcount reductions during the year.\nPOLB 001 - Upcoming TOPICAL trial\nPreparations for the forthcoming POLB 001 TOPICAL trial have advanced at pace, with multiple key milestones achieved in rapid succession:\n\u00b7\nSecured the approved bispecific antibody, teclistamab, for the study from Johnson & Johnson, a top-five global pharmaceutical company, at no cost to the Company\n\u00b7\nSigned an agreement for Accelerating Clinical Trials (ACT) to conduct the trial, led by Dr Emma Searle, Consultant Haematologist at\u00a0The Christie NHS Foundation Trust\n\u00b7\nConfirmed participation from a number of additional cancer centres, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham\n\u00b7\nFinalised the protocol and preparing POLB 001 shipment to trial sites\n\u00b7\nSingle-arm, open-label design enables early insights and safety assessment; interim data expected in summer 2026\nIn December 2025, we announced that the TOPICAL trial will play a key role in the RISE programme, led by University of Manchester and The Christie, which is investigating cancer immunotherapy-induced CRS and the safer delivery of these treatments to patients. Poolbeg is the lead business partner alongside Johnson & Johnson and others. Greatly improved response and survival rates are turning the focus to how these truly lifesaving cancer immunotherapies can be made more widely available, with CRS being one of the largest bottlenecks. The continued growth and dominance of these CRS inducing cancer immunotherapies further enhances the value proposition of POLB 001.\nPartnering focused\nWe are continuing to progress partnering discussions with several major and mid-sized pharmaceutical companies regarding POLB 001 which, the directors believe, addresses a potential market opportunity of >US$10 billion1. We secured Orphan Drug Designation from the FDA earlier this year and also strengthened our intellectual property position with the granting of multiple new patents.\nOral GLP-1 programme\nTopline data from\nthe proof-of-concept clinical trial for our oral GLP-1 programme in up to 20 obese subjects is expected in H1 2026. The trial is due to take place at the\u00a0University of Ulster, led by a team that includes Professor\u00a0Carel le Roux, a notable figure in the field of metabolic medicine.\nWhilst we are currently prioritising the upcoming clinical trials for POLB 001 and our oral GLP-1 programme, we are seeking to progress potential collaborations in our AI-led programmes. AI-driven drug discovery is seeing continued global interest due to its potential in accelerating target identification, reducing costs, de-risking development, and improving success rates.\nOutlook\n2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026. We are well-funded through a catalyst-rich period, with a cash runway into 2027.\nWe would like to thank our shareholders for their continued support, and we look forward to reporting on our progress in 2026.\nCathal Friel,\nExecutive Chair\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout POLB 001\nPOLB 001 has the potential to transform the lives of late-stage cancer patients by preventing cancer immunotherapy-induced CRS, a life-threatening side effect that >70% of patients experience2. Due to the risk of CRS, patients have to travel long distances to specialist cancer hospitals and stay for weeks at a time. By preventing CRS, POLB 001 has the potential to allow administration of these drugs to take place in local community hospitals and in an outpatient setting, vastly improving patient quality of life, transforming healthcare systems, and increasing the addressable market for pharma companies.\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nReferences\n1. Independent research by Decisive Consulting Limited.\n2. Average rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRABRBDDCDBDGUR",
          "rns_number": "RNS Number : 0140M"
        },
        {
          "title": "POLB 001 to feature in CRS research programme",
          "announcement_date": "8th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "8 Dec 2025 07:00\nRNS Number : 5250K\nPoolbeg Pharma PLC\n08 December 2025\nPoolbeg Pharma plc\nPOLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme\nRISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant\nPoolbeg will act as the lead business partner\nalongside Johnson & Johnson and other partners\n8 December 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (\"CRS\") research programme.\nPoolbeg will act as the lead business partner,\nalongside Johnson & Johnson and other partners,\non The University of Manchester and The Christie NHS Foundation Trust research programme supported by a \u00a33.4 million Prosperity Partnership grant from the Medical Research Council (\"MRC\")\n.\nThe programme, titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies), will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.\nCentral to the RISE programme will be the\npreviously announced POLB 001 TOPICAL trial\n, for which Johnson & Johnson will provide the approved bispecific antibody, teclistamab. RISE will not impact the delivery of data from\nthe POLB 001 clinical trial, anticipated in\nsummer 2026. Poolbeg's participation in this programme will not impact the Company's cash runway into 2027.\nThe programme includes\nthe collection of clinical data from patients treated with bispecific antibodies and CAR T-cell therapies and will involve additional research beyond the TOPICAL trial into the potential of POLB 001 to prevent cancer immunotherapy-induced CRS. The programme reflects the growing recognition of the unmet medical need in the management of CRS and other serious adverse effects, which is a significant bottleneck to the broader availability and uptake of these breakthrough cancer immunotherapies.\nThe RISE programme will be under the leadership of Dr Jonathan Lim, Clinical Senior Lecturer and Honorary Consultant Medical Oncologist in Advanced Immunotherapy and Cell Therapy and conducted at The University of Manchester and The Christie.\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:\n\"\nAdvanced immunotherapies are the future of cancer treatment but can come with some severe adverse effects, such as CRS.\nThis programme will deepen the understanding of CRS and could be beneficial for POLB 001, as we seek to bring its potential benefits to patients.\nPoolbeg is delighted to be working alongside\nThe University of Manchester, The Christie, Johnson & Johnson and other leading partners, who are focussed on finding a solution for CRS. The Christie has an ambition to position the UK as a global leader in research focused on the safe delivery of cancer immunotherapies and we are very proud that POLB 001 can play a key part in this.\"\nDr Jonathan Lim, Clinical Senior Lecturer and Honorary Consultant Medical Oncologist in Advanced Immunotherapy and Cell Therapy at the Christie said\n\"RISE harnesses Manchester's multidisciplinary strengths to explore the biology behind both the power and the risks of modern cancer immunotherapies. Supported by the MRC Prosperity Partnership, this initiative exemplifies how academic-industry collaboration can accelerate discovery and ensure these therapies are delivered safely and responsibly.\"\nDr Glenn Wells, MRC Deputy Executive Chair, said:\n\"This project is part of a \u00a39 million public sector investment through MRC's first Prosperity Partnerships. With\nadditional contribution\nfrom industry and close collaboration with key regulatory bodies, we are addressing the safety and toxicity of advanced therapies. This research is critical to improving how gene, cell-based, and nucleic acid-dependent therapies are developed for conditions such as cancers and rare genetic disorders, so we can make meaningful improvements to patient outcomes.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout CRS\nCytokine Release Syndrome (CRS) is a severe and potentially life-threatening side effect of cancer immunotherapies. Over 70% of patients undergoing treatment with certain T-cell engaging bispecific antibodies or CAR T-cell therapies are affected.1\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nAbout The Christie NHS Foundation Trust\nThe Christie is a specialist cancer centre in Manchester and has more than 120 years of expertise in cancer care, research and education. It is one of Europe's leading cancer centres, treating over 60,000 patients a year. It is the largest provider of radiotherapy in the NHS (including high energy proton beam therapy and MR guided radiotherapy); it is home to the largest chemotherapy unit in the UK; and is a specialist surgical centre concentrating on rare cancers and complex procedures. The Christie is one of Europe's largest experimental cancer medicine centres and an international leader in research and development with around 750 clinical studies ongoing at any one time.\nThe Christie charity provides enhanced services for patients over and above what the NHS funds.\nVisit\nwww.christie.nhs.uk\nto find out more or follow The Christie on social media @TheChristieNHS\n[1]\nAverage rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey;\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFSUFMIEISELE",
          "rns_number": "RNS Number : 5250K"
        }
      ],
      "themes": []
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 793,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "UPTREND"
    },
    "volatility": {
      "atr_normalized": 8.67,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-18th Dec 2025-letterto",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696391Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Letter to Shareholders \u2013 2025 a year of progress",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/POLB/letter-to-shareholders-8211-2025-a-year-of-progress-fv82sqnqufxad55.html",
          "rns_number": "RNS Number : 0140M",
          "full_content": "18 Dec 2025 07:00\nRNS Number : 0140M\nPoolbeg Pharma PLC\n18 December 2025\nPoolbeg Pharma plc\nLetter to Shareholders - 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected\n18 December 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, publishes an end of year letter from the Company's Executive Chair, Cathal Friel, providing an overview of the significant progress made by the Company in 2025 and outlook for 2026.\nDear Shareholders,\nAs 2025 draws to a close, we wanted to reflect on the substantial progress made by Poolbeg this year, as we move POLB 001 into the clinic and anticipate data readouts from multiple clinical trials in 2026.\nOur oversubscribed and upsized fundraise in June 2025 raised gross proceeds of \u00a34.865 million, extending our cash runway into 2027. The Company's cash balance of \u00a310.0 million (as at 30 June 2025) will support the delivery of multiple key clinical milestones.\u00a0To align resourcing with these near-term clinical priorities, the Company implemented a series of operational efficiency measures, including selective headcount reductions during the year.\nPOLB 001 - Upcoming TOPICAL trial\nPreparations for the forthcoming POLB 001 TOPICAL trial have advanced at pace, with multiple key milestones achieved in rapid succession:\n\u00b7\nSecured the approved bispecific antibody, teclistamab, for the study from Johnson & Johnson, a top-five global pharmaceutical company, at no cost to the Company\n\u00b7\nSigned an agreement for Accelerating Clinical Trials (ACT) to conduct the trial, led by Dr Emma Searle, Consultant Haematologist at\u00a0The Christie NHS Foundation Trust\n\u00b7\nConfirmed participation from a number of additional cancer centres, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham\n\u00b7\nFinalised the protocol and preparing POLB 001 shipment to trial sites\n\u00b7\nSingle-arm, open-label design enables early insights and safety assessment; interim data expected in summer 2026\nIn December 2025, we announced that the TOPICAL trial will play a key role in the RISE programme, led by University of Manchester and The Christie, which is investigating cancer immunotherapy-induced CRS and the safer delivery of these treatments to patients. Poolbeg is the lead business partner alongside Johnson & Johnson and others. Greatly improved response and survival rates are turning the focus to how these truly lifesaving cancer immunotherapies can be made more widely available, with CRS being one of the largest bottlenecks. The continued growth and dominance of these CRS inducing cancer immunotherapies further enhances the value proposition of POLB 001.\nPartnering focused\nWe are continuing to progress partnering discussions with several major and mid-sized pharmaceutical companies regarding POLB 001 which, the directors believe, addresses a potential market opportunity of >US$10 billion1. We secured Orphan Drug Designation from the FDA earlier this year and also strengthened our intellectual property position with the granting of multiple new patents.\nOral GLP-1 programme\nTopline data from\nthe proof-of-concept clinical trial for our oral GLP-1 programme in up to 20 obese subjects is expected in H1 2026. The trial is due to take place at the\u00a0University of Ulster, led by a team that includes Professor\u00a0Carel le Roux, a notable figure in the field of metabolic medicine.\nWhilst we are currently prioritising the upcoming clinical trials for POLB 001 and our oral GLP-1 programme, we are seeking to progress potential collaborations in our AI-led programmes. AI-driven drug discovery is seeing continued global interest due to its potential in accelerating target identification, reducing costs, de-risking development, and improving success rates.\nOutlook\n2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026. We are well-funded through a catalyst-rich period, with a cash runway into 2027.\nWe would like to thank our shareholders for their continued support, and we look forward to reporting on our progress in 2026.\nCathal Friel,\nExecutive Chair\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout PO",
          "content_length": 9533
        },
        "ingested_at": "2026-01-16T22:48:16.696428Z"
      },
      {
        "event_id": "RNS-8th Dec 2025-polb001t",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696447Z",
        "source": "LSE_RNS",
        "data": {
          "title": "POLB 001 to feature in CRS research programme",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/POLB/polb-001-to-feature-in-crs-research-programme-qogogjv2na65iw6.html",
          "rns_number": "RNS Number : 5250K",
          "full_content": "8 Dec 2025 07:00\nRNS Number : 5250K\nPoolbeg Pharma PLC\n08 December 2025\nPoolbeg Pharma plc\nPOLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme\nRISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant\nPoolbeg will act as the lead business partner\nalongside Johnson & Johnson and other partners\n8 December 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (\"CRS\") research programme.\nPoolbeg will act as the lead business partner,\nalongside Johnson & Johnson and other partners,\non The University of Manchester and The Christie NHS Foundation Trust research programme supported by a \u00a33.4 million Prosperity Partnership grant from the Medical Research Council (\"MRC\")\n.\nThe programme, titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies), will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.\nCentral to the RISE programme will be the\npreviously announced POLB 001 TOPICAL trial\n, for which Johnson & Johnson will provide the approved bispecific antibody, teclistamab. RISE will not impact the delivery of data from\nthe POLB 001 clinical trial, anticipated in\nsummer 2026. Poolbeg's participation in this programme will not impact the Company's cash runway into 2027.\nThe programme includes\nthe collection of clinical data from patients treated with bispecific antibodies and CAR T-cell therapies and will involve additional research beyond the TOPICAL trial into the potential of POLB 001 to prevent cancer immunotherapy-induced CRS. The programme reflects the growing recognition of the unmet medical need in the management of CRS and other serious adverse effects, which is a significant bottleneck to the broader availability and uptake of these breakthrough cancer immunotherapies.\nThe RISE programme will be under the leadership of Dr Jonathan Lim, Clinical Senior Lecturer and Honorary Consultant Medical Oncologist in Advanced Immunotherapy and Cell Therapy and conducted at The University of Manchester and The Christie.\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:\n\"\nAdvanced immunotherapies are the future of cancer treatment but can come with some severe adverse effects, such as CRS.\nThis programme will deepen the understanding of CRS and could be beneficial for POLB 001, as we seek to bring its potential benefits to patients.\nPoolbeg is delighted to be working alongside\nThe University of Manchester, The Christie, Johnson & Johnson and other leading partners, who are focussed on finding a solution for CRS. The Christie has an ambition to position the UK as a global leader in research focused on the safe delivery of cancer immunotherapies and we are very proud that POLB 001 can play a key part in this.\"\nDr Jonathan Lim, Clinical Senior Lecturer and Honorary Consultant Medical Oncologist in Advanced Immunotherapy and Cell Therapy at the Christie said\n\"RISE harnesses Manchester's multidisciplinary strengths to explore the biology behind both the power and the risks of modern cancer immunotherapies. Supported by the MRC Prosperity Partnership, this initiative exemplifies how academic-industry collaboration can accelerate discovery and ensure these therapies are delivered safely and responsibly.\"\nDr Glenn Wells, MRC Deputy Executive Chair, said:\n\"This project is part of a \u00a39 million public sector investment through MRC's first Prosperity Partnerships. With\nadditional contribution\nfrom industry and close collaboration with key regulatory bodies, we are addressing the safety and toxicity of advanced therapies. This research is critical to improving how gene, cell-based, and nucleic acid-dependent therapies are developed for conditions such as cancers and rare genetic disorders, so we can make meaningful improvements to patient outcomes.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout CRS\nCytokine Release Syndrome (CRS) is a severe and potentially life-threatening side effect of cancer immunotherapies. Over 70% of patients undergoing treatment with certain T-cell eng",
          "content_length": 9834
        },
        "ingested_at": "2026-01-16T22:48:16.696466Z"
      },
      {
        "event_id": "RNS-20th Nov 2025-polb001e",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696481Z",
        "source": "LSE_RNS",
        "data": {
          "title": "POLB 001 European Patent granted",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/polb-001-european-patent-granted-4dv6a94ea8p26ug.html",
          "rns_number": "RNS Number : 2434I",
          "full_content": "20 Nov 2025 07:00\nRNS Number : 2434I\nPoolbeg Pharma PLC\n20 November 2025\nPoolbeg Pharma plc\nPOLB 001 European Patent granted\nFurther strengthens Poolbeg's global intellectual property portfolio\n20 November 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg's European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza.\nPOLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including\u00a0the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\"), a potential market opportunity of over US$10 billion, and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally.\nPoolbeg is actively building a comprehensive, worldwide IP portfolio, with patents covering use of p38 MAPK inhibitors in patients with severe influenza and for the prevention and treatment of cancer immunotherapy-induced CRS. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:\n\"\nThis patent grant from the European Patent Office highlights the strong progress we continue to make in developing and strengthening our IP portfolio for POLB 001 across multiple disease indications. This further enhances the value and attractiveness of POLB 001 for potential partners.\n\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an",
          "content_length": 6109
        },
        "ingested_at": "2026-01-16T22:48:16.696497Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696512Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Results for the six months to 30 June 2025",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/interim-results-for-the-six-months-to-30-june-2025-tjnm59zeatdtdvv.html",
          "rns_number": "RNS Number : 0910B",
          "full_content": "29 Sep 2025 07:00\nRNS Number : 0910B\nPoolbeg Pharma PLC\n29 September 2025\nPoolbeg Pharma plc\nInterim Results for the six months to 30 June 2025\nWell-funded with multiple upcoming clinical milestones\n29 September 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025.\nHighlights & Updates\n\u2022\nCash balance of \u00a310.0 million as at 30 June 2025, including \u00a34.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise\n\u2022\nCash runway extended into 2027, supporting the delivery of multiple key clinical milestones\n\u2022\nSpecialist blood cancer trials organisation Accelerating Clinical Trials Limited appointed to conduct POLB 001 Phase 2a trial, and supply of an approved bispecific antibody drug secured for the trial at no cost to the Company\n\u2022\nTrial due to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres, with interim data expected summer 2026\n\u2022\nPOLB 001 granted Orphan Drug Designation by FDA as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (\"CRS\"), further validating POLB 001's scientific rationale and enhancing its commercial appeal\n\u2022\nPositive data from an\nin vivo\nanimal study in H1 2025 supported the use of POLB 001 to prevent CRS induced by T-cell engaging bispecific antibody therapies\n\u2022\nProgress made towards commencement of oral GLP-1 proof of concept trial at University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects, with\ntopline data expected H1 2026\n\u2022\nThe Company's pipeline programmes are in areas of significant interest to the pharmaceutical industry\u00a0and as such, Poolbeg anticipates strong potential for partnering on positive data from the forthcoming clinical trials\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented:\n\"We have made excellent progress this year and have entered a catalyst-rich period for Poolbeg. Preparations for the POLB 001 Phase 2a trial are well advanced, with the approved bispecific antibody secured at no cost to the Company. The data from this study will further strengthen our extensive preclinical and clinical package, supported by the recent FDA Orphan Drug Designation, which underscores the strong scientific rationale behind POLB 001 and enhances its commercial appeal with prospective partners.\n\"Looking ahead, we anticipate a series of potential value-creating milestones as data emerges from our POLB 001 and Oral GLP-1 trials in 2026. This, combined with a robust cash runway and a team with proven expertise in clinical trial execution and deal-making, means that we believe we are well positioned to deliver value for shareholders. We look forward to providing further updates to the market in due course.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre\n(Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u202fplc\u202f(AIM: POLB) is a clinical-stage biopharmaceutical\u202fcompany with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u202fAs such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward",
          "content_length": 29783
        },
        "ingested_at": "2026-01-16T22:48:16.696528Z"
      },
      {
        "event_id": "RNS-25th Sep 2025-polb001p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696542Z",
        "source": "LSE_RNS",
        "data": {
          "title": "POLB 001 Phase 2a Trial Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/polb-001-phase-2a-trial-update-a6h3o6m16j9tj1v.html",
          "rns_number": "RNS Number : 7038A",
          "full_content": "25 Sep 2025 07:00\nRNS Number : 7038A\nPoolbeg Pharma PLC\n25 September 2025\nPoolbeg Pharma plc\nACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost\nTrial to take place at\nThe\nChristie NHS Foundation Trust\nand other leading UK specialist cancer centres\n25 September 20\n25 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation,\nAccelerating Clinical Trials Limited\n(\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company.\nThe trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate.\nThe Phase 2a first-in-patient\nopen-label, single-arm trial is titled TOPICAL (Trial\u00a0of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of\nCytokine Release Syndrome (\"CRS\")\nin approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody.\nT\nhe Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones.\nThe Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.\nJeremy Skillington, PhD, Chief Executive Officer of\u00a0Poolbeg Pharma, said:\n\"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our shareholders.\"\n\"We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by expanding administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes. This shift could make these life-saving treatments more widely accessible. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of potentially life-threatening cancer immunotherapy-induced cytokine release syndrome.\"\nDr\u00a0Emma Searle, MBChB MA MRCP FRCPath PhD, Consultant Haematologist at The Christie NHS Foundation Trust, and Chief Investigator of the forthcoming POLB 001 trial said:\n\"I have seen first-hand the challenges that CRS presents to the delivery of cancer immunotherapies, requiring many of our patients to be hospitalised for treatment. These transformative therapies will continue to be restricted until there is a way to administer them more safely. POLB 001 holds great promise in tackling this issue; potentially leading to improved patient wellbeing, reducing the strain on healthcare systems while making these treatments more accessible to a broader patient population.\"\nDr Paul Sherrington, CEO of Accelerating Clinical Trials Ltd said:\n\"At ACT we work hand-in-hand with the haematological community to accelerate the delivery of clinical trials of new therapies, leveraging our wide network of research centres in the UK. We look forward to completing this study with POLB 001 which holds great potential to transform the cancer immunotherapy field and address this critical unmet medical need.\"\nMarket Opportunity\nThe demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees\nstrong potential for partnering on positive data from the forthcoming trial\n. The\u00a0recent FDA Orphan Drug Design",
          "content_length": 9915
        },
        "ingested_at": "2026-01-16T22:48:16.696560Z"
      },
      {
        "event_id": "RNS-1st Jul 2025-notifica",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696574Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notification of Major Holdings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/notification-of-major-holdings-6gk1ovvv8pokndn.html",
          "rns_number": "RNS Number : 2819P",
          "full_content": "1 Jul 2025 16:24\nRNS Number : 2819P\nPoolbeg Pharma PLC\n01 July 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nPoolbeg Pharma PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nMichael Kelly\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n25 June 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n1 July 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.08%\n5.08%\n35,443,132\nPosition of previous notification (if\napplicable)\n7.09%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BKPG7Z60\n35,443,132\n5.08%\nSUBTOTAL 8. A\n35,443,132\n5.08%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMichael Kelly\n10. In case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nIreland\nDate of completion\n1 July 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUWPMUPAGAG",
          "content_length": 4326
        },
        "ingested_at": "2026-01-16T22:48:16.696587Z"
      },
      {
        "event_id": "RNS-26th Jun 2025-notifica",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696600Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notification of Major Holdings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/notification-of-major-holdings-3bzvbks18b6tzo6.html",
          "rns_number": "RNS Number : 4566O",
          "full_content": "26 Jun 2025 07:00\nRNS Number : 4566O\nPoolbeg Pharma PLC\n26 June 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nPoolbeg Pharma plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nRoaring Waters Capital\nCity and country of registered office (if applicable)\nDublin, Ireland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n25/06/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n25/06/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.74%\n0%\n5.74%\n5.74%\nPosition of previous notification (if\napplicable)\n0%\n0%\n0%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BKPG7Z60\n40,000,000\n0\n5.74%\n0%\nSUBTOTAL 8. A\n40,000,000\n5.74%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nDublin, Ireland\nDate of completion\n25/06/2025\nNotes\ni\nPlease note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link:\nhttps://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter\nii\nFull name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.\niii\nOther reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.\niv\nThis should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.\nAs the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.\nIn relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the pe",
          "content_length": 10856
        },
        "ingested_at": "2026-01-16T22:48:16.696614Z"
      },
      {
        "event_id": "RNS-25th Jun 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696627Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/directorpdmr-shareholding-zdhocbabhy9seh6.html",
          "rns_number": "RNS Number : 2637O",
          "full_content": "25 Jun 2025 08:00\nRNS Number : 2637O\nPoolbeg Pharma PLC\n25 June 2025\nPoolbeg Pharma plc\nDirector Dealing\n25\nJune 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n, confirms that as announced on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price). Following the AGM earlier this week, the New Ordinary Shares issued pursuant to the Fundraising were admitted to trading at 8am today.\nFollowing this transaction, Cathal Friel holds a total of\n41,219,757\nordinary shares in the Company, representing approximately 5.91% of the Company's issued share capital.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na.\nName of PDMR\nCathal Friel\n2\nReason for notification\na.\nPosition/Status\nExecutive Chair\nb.\nInitial notification/\nAmendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na.\nName\nPoolbeg Pharma plc\nb.\nLEI\n213800UZ8WJLWYHBFL52\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na.\nDescription of the financial instrument, type of instrument\nIdentification Code\nOrdinary shares of 0.02 pence each\nISIN\u00a0GB00BKPG7Z60\nb.\nNature of the transaction\nPurchase of ordinary shares in connection with the fundraising initially announced on 20 May 2025.\nc.\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n2.5p\n4,000,000\nd.\nAggregated information\n- Aggregated Volume\n- Price\nAs in 4c) above\ne.\nDate of the transaction\n25 June 2025\nf.\nPlace of the transaction\nLondon Stock Exchange, AIM Market (XLON)\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (\"MAR\") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service (\"RIS\"), this inside information is now considered to be in the public domain.\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\") and metabolic conditions such as obesity with the development of an oral encapsulated GLP-1.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or ",
          "content_length": 6212
        },
        "ingested_at": "2026-01-16T22:48:16.696644Z"
      },
      {
        "event_id": "RNS-23rd Jun 2025-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696657Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of GM and AGM Meetings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/results-of-gm-and-agm-meetings-asfbzrgppzp6k21.html",
          "rns_number": "RNS Number : 0271O",
          "full_content": "23 Jun 2025 14:57\nRNS Number : 0271O\nPoolbeg Pharma PLC\n23 June 2025\nPoolbeg Pharma plc\nResults of Meetings\n23\nJune 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n,\nannounces that all resolutions put to shareholders at the Company's Annual General Meeting and General Meeting (together, the \"Meetings\") held earlier today were duly passed.\nThe voting results of the Meetings will be published on the Company's website shortly:\nhttps://www.poolbegpharma.com/investors/documents/\nAdmission and Total Voting Rights\nPursuant to the Company's fundraising\nto raise\ntotal gross proceeds of \u00a34.865 million, as initially announced on 20 May 2025, application has been made to the London Stock Exchange for 197,200,000 new ordinary shares to be admitted to trading on AIM. Admission is expected to occur, and dealings in the new ordinary shares are expected to commence, at 8.00 a.m. on 25 June 2025 (\"Admission\").\nFollowing Admission, the Company's issued share capital will consist of 697,200,000 ordinary shares with voting rights. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 697,200,000 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\") and metabolic conditions such as obesity with the development of an oral encapsulated GLP-1.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.",
          "content_length": 5421
        },
        "ingested_at": "2026-01-16T22:48:16.696673Z"
      },
      {
        "event_id": "RNS-27th May 2025-fdaorpha",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696687Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA Orphan Drug Designation granted for POLB 001",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/fda-orphan-drug-designation-granted-for-polb-001-cohsqbhxkqazp3x.html",
          "rns_number": "RNS Number : 0878K",
          "full_content": "27 May 2025 07:01\nRNS Number : 0878K\nPoolbeg Pharma PLC\n27 May 2025\nPoolbeg Pharma plc\nPoolbeg granted FDA Orphan Drug Designation for POLB 001\n27 May 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n, anno\nunces\nthat the US Food and Drug Administration (\"FDA\") has granted Orphan Drug Designation (\"ODD\") to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (\"CRS\").\nThe FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000 people in the US. ODD provides Poolbeg with clinical development and commercialisation benefits including the potential for a seven-year period of US market exclusivity following regulatory approval of POLB 001,\npotential waiver\nexemption of\nPrescription Drug User Fee Act\napplication fees, and the potential for tax credits for qualifying clinical trials.\nPOLB 001 is a Phase 2 ready oral p38 MAP kinase inhibitor\nto prevent or treat cancer immunotherapy-induced CRS, a severe side-effect that occurs in more than 70%1 of patients and which may lead to multi-organ failure and death. There are currently no approved preventative therapies for CRS. This\nODD further validates POLB 001's scientific rationale and data which, if approved\n, has the potential to revolutionise cancer immunotherapy delivery by making it safer, enabling outpatient administration, reducing healthcare burden, and ultimately expanding patient access to these breakthrough immunotherapies.\nPoolbeg expects the first patient to be dosed in its proposed Phase 2a in H2 2025, with interim analysis expected in H1 2026 and Phase 2a topline data in H2 2026. There are strong indications from Big Pharma to provide the necessary bispecific antibody, free of charge, to support the Phase 2a trial which represents a significant validation of the industry interest in POLB 001 and its potential. ODD strengthens POLB 001's commercial appeal for prospective partners and the Company sees potential for partnering on positive data from its Phase 2a trial.\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:\n\"POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives. We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster. If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies.\"\nProfessor Brendan Buckley, Non-Executive Director and Scientific Advisory Board Member added\n\"\nOrphan Drug Designation from the FDA underscores the urgency and importance of developing innovative therapies for this critical unmet medical need. We look forward to progressing POLB 001 in our upcoming Phase 2a clinical trial and working closely with prospective partners and regulatory agencies to bring this potential therapy to patients as quickly as possible.\"\nInvestor presentation\nPoolbeg Pharma will provide a live presentation\u00a0via the\u00a0Investor Meet Company\u00a0platform on Wednesday 28 May 2025 at 1:00pm BST.\nThe presentation is open to analysts and investors, those who already follow Poolbeg on the\u00a0Investor Meet Company\u00a0platform will automatically be invited.\u00a0Investors can sign up to Investor Meet for free and add\u00a0Poolbeg Pharma plc\u00a0to their company dashboard\nhere\n.\nReferences\n1. Average rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey\nThis announcement was deemed by the company to contain inside information as stipulated under the Market Abuse Regulations (EU) no. 596/2014 as they form part of UK domestic law by virtue of the European Union (withdrawal) Act 2018. With the publication of this announcement, this information is now considered to be in the public domain.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre, Isobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0(AIM:",
          "content_length": 8112
        },
        "ingested_at": "2026-01-16T22:48:16.696704Z"
      },
      {
        "event_id": "RNS-27th May 2025-annualre",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696717Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Annual Report, AGM Notice & Circular",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/annual-report-agm-notice-circular-9dij2nzwcclcvb0.html",
          "rns_number": "RNS Number : 0619K",
          "full_content": "27 May 2025 07:00\nRNS Number : 0619K\nPoolbeg Pharma PLC\n27 May 2025\nPoolbeg Pharma plc\nAnnual Report, AGM Notice & Circular\n27\nMay 2025 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n,\nconfirms that the Company's Annual Report and Accounts for the period ended 31 December 2024 and the notice of Annual General Meeting (\"AGM\") will be posted to shareholders today.\nThe 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website:\nwww.poolbegpharma.com\nThe Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom at 1\n2pm on 23 June 2025\n.\nFurther to the Company's announcement on\n20 May 2025\n, a Circular containing details of the Fundraising and convening a general meeting, along with an accompanying form of proxy, will also be posted to Shareholders today. The Circular is available on the Company's website at\nwww.poolbegpharma.com\n.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\") and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAQXLFLEELXBBB",
          "content_length": 4936
        },
        "ingested_at": "2026-01-16T22:48:16.696730Z"
      },
      {
        "event_id": "RNS-23rd May 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696743Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of upsized oversubscribed BookBuild Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/result-of-upsized-oversubscribed-bookbuild-offer-tkck3325b6lcj2z.html",
          "rns_number": "RNS Number : 8784J",
          "full_content": "23 May 2025 07:00\nRNS Number : 8784J\nPoolbeg Pharma PLC\n23 May 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE BOOKBUILD OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF POOLBEG PHARMA PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF POOLBEG PHARMA PLC.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.\nFOR IMMEDIATE RELEASE.\n23 May 2025\nPoolbeg Pharma PLC\nResult of upsized and oversubscribed BookBuild Offer\n\u00b7\nConditionally raised\u00a0gross proceeds of \u00a3150,000 from the upsized and oversubscribed BookBuild Offer\n\u00b7\nTotal gross proceeds conditionally raised pursuant to the Fundraising therefore increased to \u00a34.865 million\n\u00b7\nUse of net proceeds from the Fundraising:\no\nPhase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS)\no\nOral GLP-1 proof-of-concept clinical trial\no\nCash runway extended through to 2027\nPoolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n,\nannounces that, further to the announcements made on 20 May 2025, regarding the proposed BookBuild Offer (the \"\nBookBuild Offer Announcement\n\"), and on 22 May 2025, regarding the increased size of the BookBuild Offer to \u00a3150,000, and, following the closing of the BookBuild Offer on 22 May 2025, 6,000,000\u00a0BookBuild Offer Shares will be issued at 2.5 pence per BookBuild Offer Share, conditionally raising gross proceeds for the Company of \u00a3150,000.\nIn aggregate, following the closing of the BookBuild Offer, together with the previously announced Placing and Subscription, the Company has conditionally raised total gross proceeds of \u00a34.865 million.\nThe BookBuild Offer was oversubscribed and allocations were therefore made to shareholders applying the principles of soft pre-emption. Shareholders whose orders matched or exceeded their soft pre-emptive allowance\nreceived 100 per cent of their allowance, with all orders in excess of the allowance scaled back equally.\nCapitalised terms not defined in this announcement (this \"\nAnnouncement\n\") have the meanings given to them in the BookBuild Offer Announcement.\nThe BookBuild Offer is subject to the passing of certain resolutions at a general meeting of the Company to be held at\u00a0the offices of DAC Beachcroft LLP at The Walbrook Building, 25 Walbrook, London, England, EC4N 8AF, UK at 2.00 p.m. on 23 June 2025 and conditional upon, amongst other things, the New Ordinary Shares being admitted to trading on the AIM market (\"\nAIM\n\") operated by London Stock Exchange plc (the \"\nLondon Stock Exchange\n\") (\"\nAdmission\n\").\nAdmission, settlement and dealings\nApplication will be made to the London Stock Exchange for the BookBuild Offer Shares to be admitted to trading on AIM.\nAdmission is expected to take place at 8.00 a.m. on 25 June 2025 and dealings in the BookBuild Offer Shares are expected to commence at 8.00 a.m. on 25 June 2025 or, in each case, such later time and/or date as Shore Capital and the Company agree (being in any event no later than 8.00 a.m. on 23 July 2025).\nThe BookBuild Offer Shares, when issued, will be credited as fully paid and will rank\npari passu\nin all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.\nTotal Voting Rights\nFollowing Admission of the 197,200,000 New Ordinary Shares (being the Placing Shares, the Subscription Shares, the BookBuild Offer Shares and the Fee Shares), the total issued capital of the Company will consist of 697,200,000 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 697,200,000 and this figure may be used by shareholde",
          "content_length": 13001
        },
        "ingested_at": "2026-01-16T22:48:16.696760Z"
      },
      {
        "event_id": "RNS-22nd May 2025-increase",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696773Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Increase of BookBuild Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/increase-of-bookbuild-offer-35fc7dtiem30mow.html",
          "rns_number": "RNS Number : 8338J",
          "full_content": "22 May 2025 13:44\nRNS Number : 8338J\nPoolbeg Pharma PLC\n22 May 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE\nBOOKBUILD\nOFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF POOLBEG PHARMA PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF POOLBEG PHARMA PLC.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, SUCH INFORMATION WILL NO LONGER CONSTITUTE INSIDE INFORMATION.\n22 May 2025\nPoolbeg Pharma plc\nIncrease of BookBuild Offer\nPoolbeg Pharma plc (AIM: POLB, '\nPoolbeg Pharma\n' or the '\nCompany\n'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to the announcement made on 20 May 2025 regarding the proposed BookBuild Offer (the \"\nBookBuild Offer Announcement\n\"), the BookBuild Offer is significantly oversubscribed and therefore the Company is increasing the number of BookBuild Offer Shares made available at the Issue Price to 6,000,000, which, if fully subscribed, would raise gross proceeds of \u00a3150,000.\nA separate announcement was released by the Company on\n20 May 2025\nwhich sets out the terms of the BookBuild Offer. The Company will use the net proceeds of the BookBuild Offer, the Placing and Subscription to realise the following meaningful expected value inflection points whilst, together with the Company's existing resources, providing financial runway into 2027:\n\u00b7\nPOLB 001's Phase 2a trial: First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026, including interim analysis in H1 2026.\nPOLB 001 is a potentially breakthrough, orally delivered p38 MAPK inhibitor designed to prevent cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\"), a severe, potentially life-threatening side effect of cancer immunotherapies. Poolbeg's decision to expand into oncology with POLB 001 has unlocked a significant market opportunity expected to exceed US$10 billion, as confirmed by independent research commissioned by Poolbeg. There are strong indications from Big Pharma to provide the necessary bispecific antibody, free of charge, to support the Phase 2a trial which represents a significant validation as to the industry interest in POLB 001 and its potential. The Company sees potential for partnering on positive data from this trial.\n\u00b7\nOral GLP-1 proof of concept trial: The trial expected to start in the coming months and topline proof of concept data expected H1 2026\n. The oral GLP-1 programme is comprised of a proprietary encapsulation technology to potentially offer an effective oral GLP-1 alternative for the growing obesity market and overcome oral delivery challenges of peptide-based biologicals. The Company believes that successful results from the trial may support partnering and multiple opportunities for value creation.\nThe BookBuild Offer is open to eligible investors in the United Kingdom and is expected to close at 4.30 p.m. today, 22 May 2025. Investors should note that Intermediaries may have earlier closing times. For further information in relation to the BookBuild Offer, please refer to the\nBookBuild Offer Announcement\n.\nThe New Ordinary Shares to be issued pursuant to the Fundraising (including the BookBuild Offer Shares), remain subject to the passing of certain resolutions at a general meeting of the Company to be held at the offices of DAC Beachcroft LLP at The Walbrook Building, 25 Walbrook, London, England, EC4N 8AF, UK at 2.00 p.m. on 23 June 2025.\nFor the avoidance of doubt, the BookBuild Offer is not part of the Placing or Subscription. Completion of the Placing is not conditional on the completion of the BookBuild Offer but completion of the BookBuild Offer is conditional, inter alia, upon the completion of the Placing and the New Ordinary Shares being admitted to trading on the AIM market (\"",
          "content_length": 20879
        },
        "ingested_at": "2026-01-16T22:48:16.696790Z"
      },
      {
        "event_id": "RNS-20th May 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696803Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of Placing and Notice of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/result-of-placing-and-notice-of-general-meeting-mfqy9upcmbxj11k.html",
          "rns_number": "RNS Number : 4428J",
          "full_content": "20 May 2025 12:26\nRNS Number : 4428J\nPoolbeg Pharma PLC\n20 May 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF POOLBEG PHARMA PLC IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.\nFOR IMMEDIATE RELEASE.\n20 May 2025\nPoolbeg Pharma PLC\nResult of Placing\nand\nNotice of General Meeting\nKey Highlights of the Placing\n\u00b7\nConditionally raised \u00a34.715 million pursuant to a significantly oversubscribed Placing, which was upsized due to strong investor demand, and Subscription comprising of:\no\nPlacing of 134.8 million new Ordinary Shares, raising gross proceeds of \u00a33.370 million at the Issue Price\no\nSubscription of 53.8 million new Ordinary Shares, raising gross proceeds of \u00a31.345 million at the Issue Price\n\u00b7\nBookBuild Offer remains open until 4.30pm on 22 May 2025, with the potential to raise up to an additional \u00a3100,000\n\u00b7\nUse of net proceeds from the Fundraising:\no\nPhase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS)\no\nOral GLP-1 proof-of-concept clinical trial\no\nCash runway extended through to 2027\nPoolbeg Pharma plc (AIM: POLB, '\nPoolbeg Pharma\n' or the\n'Company'\n), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n,\nannounces that, further to the announcement made earlier today regarding the Fundraising (the \"\nLaunch Announcement\n\"), it has conditionally raised gross proceeds of \u00a34.715 million, including \u00a3\n3.370\nmillion by way of a placing (the \"\nPlacing\n\") of\n134,800,000 new\nordinary shares of 0.02 pence each (the \"\nOrdinary Shares\n\") in the capital of the Company, with the Placing upsized due to strong investor demand, and \u00a31.345 million through the direct subscription of 53,800,000 new Ordinary Shares, each at a price of\n2.5\npence per new Ordinary Share (the \"\nIssue Price\n\")\n.\nAs detailed in the Launch Announcement earlier today, the Company also launched the BookBuild Offer through the Bookbuild Platform to raise gross proceeds of up to \u00a3\n100,000\n. The BookBuild Offer provides existing retail Shareholders in the United Kingdom with an opportunity to participate in the Fundraising at the same price as the Placing. The Retail Offer is expected to be open until 4.30 p.m. on 22 May 2025 and the results of the BookBuild Offer are expected to be announced on 23 May 2025.\nThe Company will use the net proceeds of the Fundraising to realise the following meaningful expected value inflection points whilst, together with the Company's existing resources, providing financial runway into 2027:\n\u00b7\nPOLB 001's Phase 2a trial: First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026, including interim analysis in H1 2026.\nPOLB 001 is a potentially breakthrough, orally delivered p38 MAPK inhibitor designed to prevent cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\"), a severe, potentially life-threatening side effect of cancer immunotherapies. Poolbeg's decision to expand into oncology with POLB 001 has unlocked a significant market opportunity expected to exceed US$10 billion, as confirmed by independent research commissioned by Poolbeg. There are strong indications from Big Pharma to provide the necessary bispecific antibody, free of charge, to support the Phase 2a trial which represents a significant validation as to the industry interest in POLB 001 and its potential. The Company sees potential for partnering on positive data from this trial.\n\u00b7\nOral GLP-1 proof of concept trial: The trial is expected to start in the coming months and topline proof of concept data expected H1 2026.\nThe oral GLP-1 programme is comprised of a proprietary encapsulation technology to potentially offer an effective oral GLP-1 alternative for the growing obesity market and overcome oral delivery challenges of peptide-based biologicals. The Company believes that successful results from the trial may support partnering and multiple opportunities for value creation.\nCommenting on the Fundraising,\nJeremy Skillington PhD, Chief Executive Officer, said:\n\"It is a ",
          "content_length": 14018
        },
        "ingested_at": "2026-01-16T22:48:16.696821Z"
      },
      {
        "event_id": "RNS-20th May 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696836Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Retail Offer to raise up to \u00a3100,000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/proposed-retail-offer-to-raise-up-to-163100000-frsdfmd2shbrah4.html",
          "rns_number": "RNS Number : 3058J",
          "full_content": "20 May 2025 07:02\nRNS Number : 3058J\nPoolbeg Pharma PLC\n20 May 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE\nBOOKBUILD\nOFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF POOLBEG PHARMA PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF POOLBEG PHARMA PLC.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, SUCH INFORMATION WILL NO LONGER CONSTITUTE INSIDE INFORMATION.\n20 May 2025\nPoolbeg Pharma plc\nProposed Retail Offer to raise up to \u00a3100,000\nPoolbeg Pharma plc (AIM: POLB, '\nPoolbeg Pharma\n' or the '\nCompany\n'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, is pleased to announce a retail offer via the BookBuild Platform (the \"\nBookBuild Offer\n\") of new ordinary shares of 0.02 pence each (the \"\nOrdinary Shares\n\") in the capital of the Company (the \"\nBookBuild Offer Shares\n\") to raise gross proceeds of up to \u00a3100,000. Pursuant to the BookBuild Offer, up to 4,000,000 BookBuild Offer Shares will be made available at an issue price of 2.5 pence per BookBuild Offer Share (the \"\nIssue Price\n\").\nIn addition to the BookBuild Offer, and as announced by the Company earlier today, the Company is conducting a placing of new Ordinary Shares (the \"\nPlacing\n\") and a subscription of new Ordinary Shares (the \"\nSubscription\n\") (the new Ordinary Shares to be issued under the Placing and the Subscription, together with the BookBuild Offer Shares, being the \"\nNew Ordinary Shares\n\") at the Issue Price (the \"\nFundraising\n\") to raise gross proceeds of approximately \u00a34.1 million. A separate announcement has been made regarding the Placing and its terms.\nKey Highlights\n\u00b7\nThe Company values its retail shareholder base, which has supported the Company for many years. Given the support of retail shareholders, the Company believes that it is appropriate to provide its eligible shareholders in the United Kingdom the opportunity to participate in the\nBookBuild\nOffer.\n\u00b7\nThe BookBuild Offer will be open to eligible shareholders in the United Kingdom from 8.00 a.m. on 20 May 2025. The BookBuild Offer is expected to close at 4.30 p.m. on 22 May 2025. Investors should note that Intermediaries may have earlier closing times. The BookBuild Offer may close early if it is oversubscribed.\n\u00b7\nThe Issue Price is the same as the Placing and the Subscription which represents a discount of approximately 12 per cent. to the closing mid-market price of 2.85 pence per existing Ordinary Share on 19 May 2025, being the latest practicable date prior to the publication of this announcement.\n\u00b7\nExisting retail shareholders in the Company can contact their broker or wealth manager (\"\nIntermediary\n\" and \"\nIntermediaries\n\" shall be construed accordingly) to participate in the BookBuild Offer.\n\u00b7\nThere is a minimum subscription of \u00a3100.00 per investor under the terms of the BookBuild Offer which is open to eligible shareholders in the United Kingdom subscribing via the Intermediaries which will be listed, subject to certain access restrictions, on the following website:\nhttps://www.bookbuild.live/deals/674NMQ/authorised-intermediaries\n\u00b7\nThe Company will use the net proceeds of the\nBookBuild\nOffer, the Placing and Subscription to realise the following meaningful expected value inflection points whilst, together with the Company's existing resources, providing financial runway into 2027:\no\nPOLB 001's Phase 2a trial: First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026, including interim analysis in H1 2026.\nPOLB 001 is a potentially breakthrough, orally delivered p38 MAPK inhibitor designed to prevent cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\"), a severe, potentially life-threatening side effect of cancer immunotherapies. Poolbeg's decision to expand into oncology wit",
          "content_length": 29843
        },
        "ingested_at": "2026-01-16T22:48:16.696852Z"
      },
      {
        "event_id": "RNS-20th May 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696866Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Fundraising to raise approximately \u00a34.1M",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/proposed-fundraising-to-raise-approximately-16341m-h9ccahs6k4mxeqk.html",
          "rns_number": "RNS Number : 3065J",
          "full_content": "20 May 2025 07:01\nRNS Number : 3065J\nPoolbeg Pharma PLC\n20 May 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF POOLBEG PHARMA PLC IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.\nFOR IMMEDIATE RELEASE.\n20 May 2025\nPoolbeg Pharma plc\nProposed Fundraising to raise approximately \u00a34.1 million\nLaunch of Placing via accelerated bookbuild\nand\nNotice of General Meeting\nPoolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces a proposed conditional fundraising (the \"\nFundraising\n\") to raise gross proceeds of, in aggregate, approximately \u00a34.1 million through the issue of new ordinary shares of 0.02 pence each in the capital of the Company (\"\nOrdinary Shares\n\"). The Fundraising comprises:\n\u00b7\na placing of new Ordinary Shares (the \"\nPlacing Shares\n\") to raise not less than \u00a32.655 million via an accelerated bookbuild process (the \"\nPlacing\n\");\n\u00b7\ndirect subscriptions for new Ordinary Shares (the \"\nSubscription Shares\n\") to raise approximately \u00a31.345 million (the \"\nSubscription\n\"); and\n\u00b7\na conditional offer of new Ordinary Shares (the \"\nBookBuild Offer Shares\n\") to existing eligible retail investors (the \"\nBookBuild Offer\n\") via the BookBuild Platform to raise up to \u00a3100,000, announced separately.\nThe Placing Shares and the Subscription Shares are expected, based on advice received by the Company, to qualify for EIS and VCT relief, although no assurance has been obtained from HMRC. For further details, please see paragraph 5.4 of \"Extracts from the draft Circular\", below.\nThe new Ordinary Shares will be issued at a price of 2.5 pence per share (the \"\nIssue Price\n\"). The Issue Price represents a discount of approximately 12% to the closing mid-market price on 19 May 2025 of 2.85 pence per Ordinary Share, being the latest practicable date prior to the publication of this Announcement.\nThe bookbuilding process for the Placing (the \"\nBookbuilding Process\n\") will commence immediately following this Announcement and will be conducted by Shore Capital, acting as sole bookrunner, subject to terms and conditions set out in the Appendix, which forms part of this Announcement.\nUse of net proceeds\n\u00b7\nThe Company will use the net proceeds of the Fundraising to realise the following meaningful expected value inflection points whilst, together with the Company's existing resources, providing financial runway into 2027:\no\nPOLB 001's Phase 2a trial: First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026, including interim analysis in H1 2026.\nPOLB\n001 is a potentially breakthrough, orally delivered p38 MAPK inhibitor designed to prevent cancer immunotherapy-induced Cytokine Release Syndrome (\"\nCRS\n\"), a severe, potentially life-threatening side effect of cancer immunotherapies. Poolbeg's decision to expand into oncology with POLB 001 has unlocked a significant market opportunity expected to exceed US$10 billion, as confirmed by independent research commissioned by Poolbeg. There are strong indications from Big Pharma to provide the necessary bispecific antibody, free of charge, to support the Phase 2a trial which represents a significant validation as to the industry interest in POLB 001 and its potential. The Company sees potential for partnering on positive data from this trial.\no\nOral GLP-1 proof of concept trial: The trial is expected to start in the coming months and topline proof of concept data expected H1 2026.\nThe oral GLP-1\nprogramme is comprised of a proprietary encapsulation technology to potentially offer an effective oral GLP-1 alternative for the growing obesity marke",
          "content_length": 133134
        },
        "ingested_at": "2026-01-16T22:48:16.696883Z"
      },
      {
        "event_id": "RNS-20th May 2025-resultsf",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696896Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results for the year ended 31 December 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/results-for-the-year-ended-31-december-2024-3ogsrxg88p5blbu.html",
          "rns_number": "RNS Number : 3026J",
          "full_content": "20 May 2025 07:00\nRNS Number : 3026J\nPoolbeg Pharma PLC\n20 May 2025\nPoolbeg Pharma plc\nResults for the year ended 31 December 2024\n20 May 2025-\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs,\nanno\nunces its audited results for the year ended\u00a031 December 2024.\n2024 Highlights\n\u2022\nCash balance of \u00a37.8 million as at 31 December 2024, reflecting disciplined capital allocation to drive pipeline advancements\n\u2022\nCathal Friel appointed as Executive Chair to drive performance and seek to replicate the success of other companies he co-founded, including hVIVO plc and Amryt Pharma plc\n\u2022\nPOLB 001's potential to improve patient access to cancer immunotherapies validated by an independent committee of international key opinion leaders\n\u2022\nIndependent research confirmed a potential market opportunity of more than US$10 billion for POLB 001 as an oral preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\")\n\u2022\nPositive preclinical data demonstrated statistically significant cytokine inhibition of POLB 001 and a dose dependent reduction in clinical CRS score - facilitating the expansion of patent applications and supporting its development in a Phase 2 clinical trial\n\u2022\nThe preclinical data was also presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition and garnered interest from industry leaders and potential partners\n\u2022\nThe US Patent Office granted the Immunomodulator II patent application covering a class of drugs, including POLB 001, to treat or prevent hypercytokinemia (cytokine storm) induced in any disease indication\n\u2022\nAmid sustained global interest in glucagon-like peptide 1 receptor agonists, the Company progressed towards commencement of a proof of concept trial for its oral GLP-1 programme in the coming months\n\u2022\nPoolbeg's artificial intelligence (\"AI\") led drug discovery programmes have successfully identified potential drug targets and treatments - discussions with potential partners are ongoing\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented:\n\"2024 was marked by a growing understanding of the potential impact of POLB 001 as an oral preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome. Not only is there a potential market opportunity of more than US$10 billion, but we believe POLB 001 could greatly enhance the uptake of cancer immunotherapy treatments by preventing CRS. We are pleased to have seen such interest and engagement in our programmes from prospective partners in 2024 and into 2025.\n\"Our existing cash balance of \u00a36.2 million as at the end of March 2025*, alongside a proposed fundraising of approximately \u00a34.1 million that will shortly be announced, will support our anticipated POLB 001 Phase 2a trial and the proof of concept trial for our oral GLP-1 programme, both of which represent major potential value inflection points for the Company.\"\n* Unaudited management accounts as at 31 March 2025\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\") and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may",
          "content_length": 42422
        },
        "ingested_at": "2026-01-16T22:48:16.696912Z"
      },
      {
        "event_id": "RNS-27th Mar 2025-conferen",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696926Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Conference Participation in March & April 2025",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/POLB/conference-participation-in-march-april-2025-tphuizqdb0dyfgm.html",
          "rns_number": "RNS Number : 3836C",
          "full_content": "27 Mar 2025 07:00\nRNS Number : 3836C\nPoolbeg Pharma PLC\n27 March 2025\nPoolbeg Pharma plc\nPoolbeg to Participate in Key Conferences in March and April 2025\nPoolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress\n27 March 2025\n-\nPoolbeg Pharma\n(AIM: POLB\n, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry conferences in March and April 2025:\nMaster Investor Show -\nBusiness Design Centre, London, UK\nPresentation details:\n29 March, Showcase Stage (Ground Floor), 1.00pm - 1.10pm\nPoolbeg Pharma will be located at Booth M30.\nBioTrinity - Convene, 133 Houndsditch, London, UK\nPresentation details:\n2 April, Science Spotlight 8 - Rare Disease, 9.30am - 11am\nPoolbeg Pharma's presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.\nLSX World Congress - Business Design Centre, London, UK\nPanel title:\n\"Thriving Amidst Turbulence: Building Resilience in Life Sciences\"\nPanel date & time:\n30 April, 2pm\nIf you would like to meet the Poolbeg team at any of the above events, please contact us at\nir@poolbegpharma.com\n.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash,\u00a0Camilla Hume, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc is a\nclinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n. Poolbeg comprises a strong and growing portfolio of development assets.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFLFSDVTIRFIE",
          "content_length": 4919
        },
        "ingested_at": "2026-01-16T22:48:16.696939Z"
      },
      {
        "event_id": "RNS-20th Mar 2025-polb001p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696952Z",
        "source": "LSE_RNS",
        "data": {
          "title": "POLB 001 Patent Granted in Korea",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/POLB/polb-001-patent-granted-in-korea-9wzbnzwulbk0l9g.html",
          "rns_number": "RNS Number : 4632B",
          "full_content": "20 Mar 2025 07:00\nRNS Number : 4632B\nPoolbeg Pharma PLC\n20 March 2025\nPoolbeg Pharma plc\nPOLB 001 Patent Granted in Korea\nGrant further strengthens Poolbeg's global intellectual property (\"IP\") portfolio\n20 March 2025\n-\nPoolbeg Pharma\n(AIM: POLB\n, 'Poolbeg' or the 'Company'), a\nclinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n,\nannounces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg's Republic of Korea Immunomodulator II patent application providing protection to\nPOLB 001 for the treatment of severe influenza\nto December 2038.\nPOLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including\nthe prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\") and severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens Poolbeg's IP portfolio.\nPoolbeg has a robust portfolio of patents in place covering p38 MAP kinase inhibitors for the treatment of severe influenza; and for POLB 001 for the prevention or treatment of hypercytokinemia. Additional patent applications have been filed to strengthen and complement Poolbeg's POLB 001 patent portfolio, particularly for cytokine release syndrome caused by cancer immunotherapies. Developing a strong intellectual property portfolio remains a key priority for Poolbeg, enhancing POLB 001's value and appeal to potential partners.\nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented:\n\"This latest patent grant reflects our commitment to further strengthening POLB 001's global IP portfolio, enhancing its value and attractiveness to prospective partners.\nAs a Phase 2 ready oral therapy,\nPOLB 001 holds the potential to significantly benefit patients and healthcare systems globally, and this patent represents another step forward in our mission to positively impact the lives of patients.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash,\u00a0Camilla Hume, Trisyia Jamaludin\u00a0(Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd\u00a0(Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre,\nIsobel Jones (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc is a\nclinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs\n. Poolbeg comprises a strong and growing portfolio of development assets.\nFor more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided ",
          "content_length": 5687
        },
        "ingested_at": "2026-01-16T22:48:16.696967Z"
      },
      {
        "event_id": "RNS-25th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.696980Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/NON-RI)",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptnon-ri-b837qgdbayc8edz.html",
          "rns_number": "RNS Number : 3636Y",
          "full_content": "25 Feb 2025 08:50\nRNS Number : 3636Y\nCavendish Securities PLC\n25 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nCavendish Securities Plc\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPOOLBEG PHARMA PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPOOLBEG PHARMA PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n24/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nORD 0.1P\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n383598\n0.08\n(2) Cash-settled derivatives:\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nTOTAL:\n383598\n0.08\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nDetails, including nature of the rights concerned and relevant percentages:\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nORD 0.1P\nSales\n4391\n4.078\n4.07\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(c) Attachments\nIs a Supplemental Form 8 (Open Positions) attached?\nNO\nDate of disclosure:\n25/02/2025\nContact name:\nUmika Patel\nTelephone number:\n+44 (0)\n207 220 0594\nPublic disclosures under Rule 8 of the Code must be m",
          "content_length": 6040
        },
        "ingested_at": "2026-01-16T22:48:16.696994Z"
      },
      {
        "event_id": "RNS-24th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697006Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/NON-RI)",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptnon-ri-mhcdf1qh9i80pmc.html",
          "rns_number": "RNS Number : 1918Y",
          "full_content": "24 Feb 2025 08:48\nRNS Number : 1918Y\nCavendish Securities PLC\n24 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nCavendish Securities Plc\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPOOLBEG PHARMA PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPOOLBEG PHARMA PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n21/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nORD 0.1P\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n387989\n0.08\n(2) Cash-settled derivatives:\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nTOTAL:\n387989\n0.08\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nDetails, including nature of the rights concerned and relevant percentages:\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nORD 0.1P\nORD 0.1P\nSales\nPurchase\n622439\n1007839\n4.37\n3.86\n3.745\n3.7351\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(c) Attachments\nIs a Supplemental Form 8 (Open Positions) attached?\nNO\nDate of disclosure:\n24/02/2025\nContact name:\nUmika Patel\nTelephone number:\n+44 (0)\n207 220 0594\nPublic disclo",
          "content_length": 6080
        },
        "ingested_at": "2026-01-16T22:48:16.697020Z"
      },
      {
        "event_id": "RNS-21st Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697033Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-6a5biwmbnu6vshm.html",
          "rns_number": null,
          "full_content": "21 Feb 2025 11:53\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n20 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n18,575\n4.75p\n4.75p\nOrdinary\nSales\n781\n4.8698p\n4.8698p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n21 February 2025\nContact name:\nLaura Parmenter\nTelephone number:\n0207 647 8154\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3783
        },
        "ingested_at": "2026-01-16T22:48:16.697046Z"
      },
      {
        "event_id": "RNS-21st Feb 2025-terminat",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697059Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Termination of proposed combination with HOOKIPA",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/termination-of-proposed-combination-with-hookipa-zhfgaojohlek3e7.html",
          "rns_number": "RNS Number : 9431X",
          "full_content": "21 Feb 2025 07:00\nRNS Number : 9431X\nPoolbeg Pharma PLC\n21 February 2025\n21 February 2025\nPoolbeg Pharma plc\nTermination of proposed combination with HOOKIPA Pharma Inc.\nFurther to the 2.4 announcement on 2 January 2025 on the potential combination of Poolbeg Pharma (\"Poolbeg\" or the \"Company\") and HOOKIPA Pharma Inc (\"HOOKIPA\"), the Board of Poolbeg announces that it was informed yesterday that HOOKIPA has terminated discussions on the proposed combination of the two companies.\nCathal Friel, Executive Chairman of Poolbeg, said:\n\"We were surprised and disappointed to hear of HOOKIPA's decision to withdraw from the combination discussions. Throughout this process, we have seen strong interest in the potential of POLB 001 and we continue to be focused on maximising the potential of our in-house programmes and exploring new opportunities to generate value for our shareholders.\"\nENDS\nEnquiries\n:\nPoolbeg Pharma Plc\n+44 (0) 207 183 1499\nCathal Friel, Chairman\nir@Poolbegpharma.com\nJeremy Skillington, CEO\nIan O'Connell, CFO\nCavendish\u202fCapital Markets Ltd\n(Joint Financial Adviser and Rule 3 Adviser to Poolbeg, NOMAD & Joint Broker)\n+44 (0) 207 220 0500\nCorporate Finance\nGeoff Nash\nHenrik Persson\nHamish Waller\nTrisyia Jamaludin\n\u200b\nShore Capital\n(Joint Broker)\n+44 (0) 207 408 4090\nCorporate Advisory\nDavid Coaten\nHarry Davies-Ball\nCorporate Broking\nMalachy McEntyre\nIsobel Jones\nJ&E Davy\n(Joint Broker)\n+353 (0) 1 679 6363\nAnthony Farrell\nNiall Gilchrist\n\u200b\nOptimum Strategic Communications\n+44 (0) 208 078 4357\nNick Bastin\nPoolbeg@optimumcomms.com\nVici Rabbetts\nElena Bates\nAbout Poolbeg Pharma plc\nPoolbeg Pharma plc\u00a0is\u00a0a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets.\u00a0For more information, please go to\nwww.poolbegpharma.com\nor follow us on\nTwitter\nand\nLinkedIn\n@PoolbegPharma.\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSOAFZGZZGGFGKZZ",
          "content_length": 4656
        },
        "ingested_at": "2026-01-16T22:48:16.697071Z"
      },
      {
        "event_id": "RNS-20th Feb 2025-hookipap",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697086Z",
        "source": "LSE_RNS",
        "data": {
          "title": "HOOKIPA Pharma Inc. (\u201cHOOKIPA\u201d) Statement regarding potential combination for Poolbeg Pharma plc (\u201cPoolbeg\u201d)",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/hookipa-pharma-inc-8220hookipa8221-statement-regarding-potential-combination-for-poolbeg-pharma-plc-8220poolbeg8221-jjvnl300ywxaodo.html",
          "rns_number": null,
          "full_content": "20 Feb 2025 20:06\nHOOKIPA Pharma Inc. (\u201cHOOKIPA\u201d) Statement regarding potential combination for Poolbeg Pharma plc (\u201cPoolbeg\u201d)\nNEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) --\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.\nTHIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (\u201cTHE CODE\u201d).\nTHIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.\nFor immediate release\n20 February 2025\nHOOKIPA Pharma Inc. (\u201cHOOKIPA\u201d)\nStatement regarding potential combination for Poolbeg Pharma plc (\u201cPoolbeg\u201d)\nFurther to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg and the announcement on 30 January 2025 regarding the PUSU extension, the HOOKIPA Board has determined that it does not intend to make an offer for Poolbeg under Rule 2.7 of the Code.\nThis announcement is made in accordance with Rule 2.8 of the Code.\nUnder Note 2 on Rule 2.8 of the Code, HOOKIPA and any person(s) acting in concert with it reserve the right to set aside the restrictions in Rule 2.8 of the Code in the following circumstances:\na) with the agreement of the board of Poolbeg;\nb) following the announcement of a firm intention to make an offer for Poolbeg, by or on behalf of a third party;\nc) following the announcement by Poolbeg of a Rule 9 waiver (as described in Note 1 on the Notes on Dispensations from Rule 9 of the Code) or a reverse takeover (as defined in the Code); or\nd) where the Panel on Takeovers and Mergers has determined that there has been a material change of circumstances.\nThe person responsible for arranging the release of this announcement on behalf of HOOKIPA is Malte Peters, Chief Executive Officer of HOOKIPA.\nEnquiries:\nHOOKIPA Pharma Inc.\n+43 1 890 63 60\nMalte Peters, CEO\nIR@hookipapharma.com\nTerry Coelho, EVP & CFO\nChuck@LifeSciAdvisors.com\nMoelis & Company\n+44 (0) 207 634 3500\n(Financial Adviser to HOOKIPA)\nLondon Chris Raff Simon Chaudhuri\nNew York Ashish Contractor\nImportant information\nThis announcement is not intended to, and does not, constitute or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction, whether pursuant to this announcement or otherwise.\nThe release, distribution or publication of this announcement in jurisdictions outside the United Kingdom may be restricted by laws of the relevant jurisdictions and therefore persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.\nDisclaimer\nMoelis & Company LLC (\u201cMoelis\u201d) is acting as financial adviser to HOOKIPA in connection with the matters set out in this announcement and for no one else and will not be responsible to anyone other than HOOKIPA for providing the protections afforded to its clients nor for providing advice in relation to the matters set out in this announcement. Neither Moelis nor any of its subsidiaries, branches or affiliates and their respective directors, officers, employees or agents owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Moelis in connection with this announcement, any statement contained herein or otherwise\nPublication on Website\nA copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on HOOKIPA\u2019s website -\nhttps://ir.hookipapharma.com/potential-combination#\nby no later than 12 noon (London time) on the business day following the release of this announcement in accordance with Rule 26.1 of the Code. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.\nThis announcement is not intended to, and does not, constitute, represent or form part of any offer, invitation or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction whether pursuant to this announcement or otherwise.",
          "content_length": 4709
        },
        "ingested_at": "2026-01-16T22:48:16.697109Z"
      },
      {
        "event_id": "RNS-20th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697124Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-44qsj763kfv9y01.html",
          "rns_number": "RNS Number : 8638X",
          "full_content": "20 Feb 2025 09:03\nRNS Number : 8638X\nJ & E Davy (UK) Limited\n20 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n19/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n210,564\n0.04\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n210,564\n0.04\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n1148\n4.80 GBX\n4.80 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, st",
          "content_length": 6264
        },
        "ingested_at": "2026-01-16T22:48:16.697138Z"
      },
      {
        "event_id": "RNS-20th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697151Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/NON-RI)",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptnon-ri-axxihuwhle7nxjb.html",
          "rns_number": "RNS Number : 8620X",
          "full_content": "20 Feb 2025 08:53\nRNS Number : 8620X\nCavendish Securities PLC\n20 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nCavendish Securities Plc\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPOOLBEG PHARMA PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPOOLBEG PHARMA PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n19/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nORD 0.1P\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n2589\n0\n(2) Cash-settled derivatives:\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nTOTAL:\n2589\n0\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nDetails, including nature of the rights concerned and relevant percentages:\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nORD 0.1P\nPurchase\n2589\n4.8\n4.8\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(c) Attachments\nIs a Supplemental Form 8 (Open Positions) attached?\nNO\nDate of disclosure:\n20/02/2025\nContact name:\nUmika Patel\nTelephone number:\n+44 (0)\n207 220 0594\nPublic disclosures under Rule 8 of the Code must be made to a R",
          "content_length": 6030
        },
        "ingested_at": "2026-01-16T22:48:16.697165Z"
      },
      {
        "event_id": "RNS-20th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697178Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-op9dxt9xc6q6vzj.html",
          "rns_number": null,
          "full_content": "20 Feb 2025 07:49\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n19 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n11,445\n4.75p\n4.75p\nOrdinary\nSales\n30,648\n4.92p\n4.863p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n20 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3779
        },
        "ingested_at": "2026-01-16T22:48:16.697191Z"
      },
      {
        "event_id": "RNS-19th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697203Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-07z8z9003r6uyf8.html",
          "rns_number": null,
          "full_content": "19 Feb 2025 12:35\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n18 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n61,856\n4.85p\n4.85p\nOrdinary\nSales\nN/A\nN/A\nN/A\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n19 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3771
        },
        "ingested_at": "2026-01-16T22:48:16.697216Z"
      },
      {
        "event_id": "RNS-18th Feb 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697229Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/holdings-in-company-7en59a6ql3fwnhu.html",
          "rns_number": "RNS Number : 5877X",
          "full_content": "18 Feb 2025 17:35\nRNS Number : 5877X\nPoolbeg Pharma PLC\n18 February 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nPoolbeg Pharma PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nMichael Kelly\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n10 January 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n18 February 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.09%\n7.09%\n35,443,132\nPosition of previous notification (if\napplicable)\n6.18%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BKPG7Z60\n35,443,132\n7.09%\nSUBTOTAL 8. A\n35,443,132\n7.09%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMichael Kelly\n10. In case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nIreland\nDate of completion\n18 February 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLEAXAPFDASEFA",
          "content_length": 4344
        },
        "ingested_at": "2026-01-16T22:48:16.697241Z"
      },
      {
        "event_id": "RNS-18th Feb 2025-form8.3-",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697254Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.3 - Poolbeg Pharma plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-83-poolbeg-pharma-plc-j8fjsxn8hrwkwji.html",
          "rns_number": "RNS Number : 5805X",
          "full_content": "18 Feb 2025 17:04\nRNS Number : 5805X\nPoolbeg Pharma PLC\n18 February 2025\nFORM 8.3\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY\nA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE\nRule 8.3 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Full name of discloser:\nMichael Kelly\n(b) Owner or controller of interests and short positions disclosed, if different from 1(a):\nThe naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.\n(c) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma plc\n(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:\nN/A\n(e) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n10 January 2025\n(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nNO\n2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nOrdinary Shares of 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n35,443,132\n7.09%\n(2) Cash-settled derivatives:\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nTOTAL:\n35,443,132\n7.09%\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nDetails, including nature of the rights concerned and relevant percentages:\n3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchase/sale\nNumber of securities\nPrice per unit\nOrdinary Shares of 0.02p\nPurchase\n728,191\n0.4836\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(c) Attachments\nIs a Supplemental Form 8 (Open Positions) attached?\nNO\nDate of disclosure:\n18 February 2025\nContact n",
          "content_length": 6311
        },
        "ingested_at": "2026-01-16T22:48:16.697268Z"
      },
      {
        "event_id": "RNS-18th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697281Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-ck2nrre7ijcfzsx.html",
          "rns_number": null,
          "full_content": "18 Feb 2025 10:17\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n17 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n81,435\n4.8675p\n4.833p\nOrdinary\nSales\n75,000\n4.88p\n4.88p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n18 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3781
        },
        "ingested_at": "2026-01-16T22:48:16.697293Z"
      },
      {
        "event_id": "RNS-17th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697306Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-0kqhewdw1ym5vci.html",
          "rns_number": null,
          "full_content": "17 Feb 2025 10:28\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n14 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n25,051\n4.8625p\n4.8625p\nOrdinary\nSales\n125,928\n5p\n4.909p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n17 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3781
        },
        "ingested_at": "2026-01-16T22:48:16.697319Z"
      },
      {
        "event_id": "RNS-14th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697332Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-u6tkclysyo9ln3j.html",
          "rns_number": null,
          "full_content": "14 Feb 2025 10:25\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n13 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n6,958\n4.8375p\n4.8375p\nOrdinary\nSales\nNA\nNA\nNA\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n14 February 2025\nContact name:\nLaura Parmenter\nTelephone number:\n0207 647 8154\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3775
        },
        "ingested_at": "2026-01-16T22:48:16.697344Z"
      },
      {
        "event_id": "RNS-14th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697357Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-9icmjrxgpsgkcz6.html",
          "rns_number": "RNS Number : 1900X",
          "full_content": "14 Feb 2025 09:11\nRNS Number : 1900X\nJ & E Davy (UK) Limited\n14 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n13/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n209,416\n0.04\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n209,416\n0.04\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n40,240\n5.00 GBX\n5.00 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, ",
          "content_length": 6266
        },
        "ingested_at": "2026-01-16T22:48:16.697371Z"
      },
      {
        "event_id": "RNS-13th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697384Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-u17dg98ocyoodwk.html",
          "rns_number": null,
          "full_content": "13 Feb 2025 11:17\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n12 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n100,000\n5.082p\n5.082p\nOrdinary\nSales\nNA\nNA\nNA\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n13 February 2025\nContact name:\nClare Gamble-Dale\nTelephone number:\n0207 601 6132\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3777
        },
        "ingested_at": "2026-01-16T22:48:16.697396Z"
      },
      {
        "event_id": "RNS-13th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697409Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-u4s20coaektkwd3.html",
          "rns_number": "RNS Number : 0400X",
          "full_content": "13 Feb 2025 10:30\nRNS Number : 0400X\nJ & E Davy (UK) Limited\n13 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n12/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n169,176\n0.03\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n169,176\n0.03\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n143,914\n5.05 GBX\n5.00 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings,",
          "content_length": 6267
        },
        "ingested_at": "2026-01-16T22:48:16.697423Z"
      },
      {
        "event_id": "RNS-12th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697436Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-qom2k8mrxgeuf2f.html",
          "rns_number": null,
          "full_content": "12 Feb 2025 10:52\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n11 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n5,361\n5.082p\n5.082p\nOrdinary\nSales\n55,361\n5.138p\n5.1p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n12 February 2025\nContact name:\nLaura Parmenter\nTelephone number:\n0207 647 8154\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3783
        },
        "ingested_at": "2026-01-16T22:48:16.697449Z"
      },
      {
        "event_id": "RNS-12th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697461Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-nns4rjvyj8alyiw.html",
          "rns_number": "RNS Number : 8488W",
          "full_content": "12 Feb 2025 09:08\nRNS Number : 8488W\nJ & E Davy (UK) Limited\n12 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n11/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n25,262\n0.01\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n25,262\n0.01\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n367\n5.10 GBX\n5.10 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, state",
          "content_length": 6261
        },
        "ingested_at": "2026-01-16T22:48:16.697475Z"
      },
      {
        "event_id": "RNS-11th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697488Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-naf85z4ai7zw41n.html",
          "rns_number": null,
          "full_content": "11 Feb 2025 09:46\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n10 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n1,998\n5.1p\n5.1p\nOrdinary\nSales\n84,419\n5.163p\n5.1p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n11 February 2025\nContact name:\nClare Gamble-Dale\nTelephone number:\n0207 601 6132\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3781
        },
        "ingested_at": "2026-01-16T22:48:16.697500Z"
      },
      {
        "event_id": "RNS-11th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697513Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-6c7gbidd3km6t9b.html",
          "rns_number": "RNS Number : 6791W",
          "full_content": "11 Feb 2025 08:42\nRNS Number : 6791W\nJ & E Davy (UK) Limited\n11 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n10/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n24,895\n0.01\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n24,895\n0.01\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n15,278\n5.14 GBX\n5.08 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings, st",
          "content_length": 6264
        },
        "ingested_at": "2026-01-16T22:48:16.697527Z"
      },
      {
        "event_id": "RNS-10th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697540Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-m3s98u36kwjg9u0.html",
          "rns_number": null,
          "full_content": "10 Feb 2025 10:59\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n07 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n112,832\n5.151p\n5.146p\nOrdinary\nSales\n96,568\n5.167p\n5.148p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n10 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3783
        },
        "ingested_at": "2026-01-16T22:48:16.697553Z"
      },
      {
        "event_id": "RNS-10th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697566Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-5dx4cuae5r9zssi.html",
          "rns_number": "RNS Number : 5125W",
          "full_content": "10 Feb 2025 08:56\nRNS Number : 5125W\nJ & E Davy (UK) Limited\n10 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n07/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n9617\n0.00192%\nNA\nNA\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n9617\n0.00192%\nNA\nNA\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n61,677\n5.14 GBX\n5.14 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings",
          "content_length": 6268
        },
        "ingested_at": "2026-01-16T22:48:16.697580Z"
      },
      {
        "event_id": "RNS-7th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697593Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-6w1kt3680tvq4du.html",
          "rns_number": null,
          "full_content": "7 Feb 2025 11:40\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n06 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\nNA\nNA\nNA\nOrdinary\nSales\n19\n5.156p\n5.156p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n07 February 2025\nContact name:\nClare Gamble-Dale\nTelephone number:\n0207 601 6132\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3771
        },
        "ingested_at": "2026-01-16T22:48:16.697606Z"
      },
      {
        "event_id": "RNS-6th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697619Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-e97ql7gzu48xa2f.html",
          "rns_number": null,
          "full_content": "6 Feb 2025 10:36\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n05 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n100,000\n5.121p\n5.121p\nOrdinary\nSales\n6,200\n5.16p\n5.156p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n06 February 2025\nContact name:\nLaura Parmenter\nTelephone number:\n0207 647 8154\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3784
        },
        "ingested_at": "2026-01-16T22:48:16.697631Z"
      },
      {
        "event_id": "RNS-5th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697644Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-nnip2rr84q6om5l.html",
          "rns_number": null,
          "full_content": "5 Feb 2025 10:26\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n04 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\nN/A\nN/A\nN/A\nOrdinary\nSales\n67,690\n5.107p\n5.104p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n05 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3772
        },
        "ingested_at": "2026-01-16T22:48:16.697656Z"
      },
      {
        "event_id": "RNS-5th Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697669Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-t4ftdi8agoyn9xt.html",
          "rns_number": "RNS Number : 0094W",
          "full_content": "5 Feb 2025 09:20\nRNS Number : 0094W\nJ & E Davy (UK) Limited\n05 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n04/02/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\nN/A\nN/A\n(52,060)\n(0.01%)\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(52,060)\n(0.01%)\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n-\n-\n-\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n137,300\n5.4 GBX\n5.4 GBX\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or unders",
          "content_length": 6276
        },
        "ingested_at": "2026-01-16T22:48:16.697683Z"
      },
      {
        "event_id": "RNS-4th Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697696Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-4x7surbd10caqc3.html",
          "rns_number": null,
          "full_content": "4 Feb 2025 11:40\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n03 February 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\nN/A\nN/A\nN/A\nOrdinary\nSales\n25,231\n5.143p\n5.143p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n04 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3772
        },
        "ingested_at": "2026-01-16T22:48:16.697708Z"
      },
      {
        "event_id": "RNS-3rd Feb 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697721Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-dn5b9zrycn5uwki.html",
          "rns_number": null,
          "full_content": "3 Feb 2025 11:28\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n31 January 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n112,372\n5.0638p\n5.0638p\nOrdinary\nSales\n57,680\n5.1475p\n5.143p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n03 February 2025\nContact name:\nJustin Ball\nTelephone number:\n0207 647 8130\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3784
        },
        "ingested_at": "2026-01-16T22:48:16.697734Z"
      },
      {
        "event_id": "RNS-3rd Feb 2025-form8.5p",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697747Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 Poolbeg Pharma Plc",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-poolbeg-pharma-plc-p89x9btphyy78n3.html",
          "rns_number": "RNS Number : 6754V",
          "full_content": "3 Feb 2025 10:59\nRNS Number : 6754V\nJ & E Davy (UK) Limited\n03 February 2025\nFORM 8.5 (EPT/NON-RI)\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN\nEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (\"RI\") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)\nRule 8.5 of the Takeover Code (the \"Code\")\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nJ&E\nDavy (UK) Limited\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates:\nUse a separate form for each offeror/offeree\nPoolbeg Pharma PLC\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma PLC\n(d) Date position held/dealing undertaken:\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n31/01/2025\n(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?\nIf it is a cash offer or possible cash offer, state \"N/A\"\nN/A\n2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\nClass of relevant security:\nPoolbeg Pharma PLC Ordinary 0.02p\nInterests\nShort positions\nNumber\n%\nNumber\n%\n(1) Relevant securities owned and/or controlled:\n85,240\n0.02%\nN/A\nN/A\n(2) Cash-settled derivatives:\nN/A\nN/A\nN/A\nN/A\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\nN/A\nN/A\nN/A\nN/A\n85,240\n0.02%\nN/A\nN/A\nAll interests and all short positions should be disclosed.\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08 (Open Positions).\n(b) Rights to subscribe for new securities (including directors' and other employee options)\nClass of relevant security in relation to which subscription right exists:\nN/A\nDetails, including nature of the rights concerned and relevant percentages:\nN/A\n3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\nThe currency of all prices and other monetary amounts should be stated.\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nPoolbeg Pharma PLC Ordinary 0.02p\nPurchase\n9,162\n5.06 GBX\n5.06 GBX\nPoolbeg Pharma PLC Ordinary 0.02p\nSale\n-\n-\n-\n(b) Cash-settled derivative transactions\nClass of relevant security\nProduct description\ne.g. CFD\nNature of dealing\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(c) Stock-settled derivative transactions (including options)\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description\ne.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType\ne.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\nN/A\n(ii) Exercise\nClass of relevant security\nProduct description\ne.g. call option\nExercising/ exercised against\nNumber of securities\nExercise price per unit\nN/A\nN/A\nN/A\nN/A\nN/A\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing\ne.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nN/A\nN/A\nN/A\nN/A\n4. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:\n(i) the voting rights of any relevant securities under any option; or\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\nIf there are no such agreements, arrangements or understandings",
          "content_length": 6268
        },
        "ingested_at": "2026-01-16T22:48:16.697761Z"
      },
      {
        "event_id": "RNS-31st Jan 2025-form8.5(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:16.697774Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Form 8.5 (EPT/RI) - Poolbeg Pharma Plc",
          "category": "GNW",
          "url": "https://www.lse.co.uk/rns/POLB/form-85-eptri-poolbeg-pharma-plc-cly3jdgzlvumce7.html",
          "rns_number": null,
          "full_content": "31 Jan 2025 11:46\nForm 8.5 (EPT/RI) - Poolbeg Pharma Plc\nFORM 8.5 (EPT/RI)\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \u201cCode\u201d)\n1. KEY INFORMATION\n(a) Name of exempt principal trader:\nShore Capital Stockbrokers Ltd\n(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree\nPoolbeg Pharma Plc\n(c) Name of the party to the offer with which exempt principal trader is connected:\nPoolbeg Pharma Plc\n(d) Date dealing undertaken:\n30 January 2025\n(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?\nNo\n2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n(a) Purchases and sales\nClass of relevant security\nPurchases/ sales\nTotal number of securities\nHighest price per unit paid/received\nLowest price per unit paid/received\nOrdinary\nPurchases\n262,351\n5.3053p\n5.0425p\nOrdinary\nSales\n79,679\n5.3025p\n5.3025p\n(b) Derivatives transactions (other than option)\nClass of relevant security\nProduct description e.g. CFD\nNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position\nNumber of reference securities\nPrice per unit\n(c) Options transactions in respect of existing securities\n(i) Writing, selling, purchasing or varying\nClass of relevant security\nProduct description e.g. call option\nWriting, purchasing, selling, varying etc.\nNumber of securities to which option relates\nExercise price per unit\nType e.g. American, European etc.\nExpiry date\nOption money paid/ received per unit\n(ii) Exercising\nClass of relevant security\nProduct description e.g. call option\nNumber of securities\nExercise price per unit\n(d) Other dealings (including subscribing for new securities)\nClass of relevant security\nNature of dealing e.g. subscription, conversion\nDetails\nPrice per unit (if applicable)\nThe currency of all prices and other monetary amounts should be stated.\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n3. OTHER INFORMATION\n(a) Indemnity and other dealing arrangements\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\n(b) Agreements, arrangements or understandings relating to options or derivatives\nDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d\nNone\nDate of disclosure:\n31 January 2025\nContact name:\nLaura Parmenter\nTelephone number:\n0207 647 8154\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at\nmonitoring@disclosure.org.uk\n. The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel\u2019s website at\nwww.thetakeoverpanel.org.uk\n.",
          "content_length": 3789
        },
        "ingested_at": "2026-01-16T22:48:16.697786Z"
      },
      {
        "event_id": "SOCIAL-9Sep20252021-ThinIce--1564193",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.710377",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "2M shares bought today and negligible sells. Pretty much been the pattern for the last few trading days. Someone is certainly accumulating and yet the share is fairly static. Think we may be in for a more substantial rise soon. Two broker tips at 19p gives a MC of \u00a3150M which is not unreasonable for a company with two great products and one about to start a phase 2A (with assistance (FOC) from big pharma). I would say this is as good a prospect for a 5 bagger from here as any! Check out Hemagenyx and immupharma over the last few days who are at a similar stage with their products.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.30",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721915+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20250925-Lewis66--6973610",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.709942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Great that the rises are steady. I wondered / worried on Friday (5th) if it would drop back down but appears to be getting higher and higher. Let\u2019s get back to teens by the end of the yr?!",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.60",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721897+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20251045-MaryBr19--2580434",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.709531",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Momentum, director buying, potential bagger. Finance sorted, updates due. Great mix for a harrier move up.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.70",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721879+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20251050-MaryBr19--5359808",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.709121",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Poolbeg Pharma is experiencing significant momentum due to its advancements in drug development, particularly in oncology and metabolic diseases. The company is focused on innovative treatments that address unmet medical needs, which has garnered attention from investors and analysts alike. Key Developments \u2022 Pipeline Advancements: Poolbeg's lead asset, POLB 001, is designed to target cytokine release syndrome (CRS), a serious condition affecting many cancer patients undergoing immunotherapy. This oral therapy could potentially transform treatment options, as there are currently few effective preventative measures for CRS. \u2022 Funding and Partnerships: The company recently raised at least \u00a34 million to accelerate its key programs, including POLB 001 and an oral GLP-1 receptor agonist project aimed at obesity treatment. This funding is crucial for advancing clinical trials and attracting commercial partners. \u2022 Upcoming Trials: The Phase 2a trial for POLB 001 is expected to begin soon, with interim results anticipated in the first half of 2026. The involvement of major pharmaceutical companies in supplying key biologics for the trial indicates strong confidence in Poolbeg's strategy. \u2022 Innovative Approaches: Poolbeg is also exploring an oral encapsulated formulation of GLP-1, which aims to improve the bioavailability of peptide-based therapies. This project is set to enter a proof-of-concept trial later this year. \u2022 AI-Driven Drug Discovery: Beyond its primary programs, Poolbeg is leveraging AI for drug discovery, focusing on significant health threats like influenza and RSV, which reflects its broader ambition to utilize data-driven science for impactful solutions. Overall, Poolbeg Pharma is at a pivotal point, with its lead programs advancing into human trials and a strong pipeline that could lead to transformative treatments in the near future.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.70",
          "thread_title": "Multi bagger",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=77FF67EC-B4C5-437E-9426-4F45D219A47B"
        },
        "ingested_at": "2026-01-22T21:16:33.721862+00:00"
      },
      {
        "event_id": "SOCIAL-11Sep20250914-Nubex-83442870",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.708662",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nubex",
          "content": "Leadership team share holdings are small so where did  you get the Director buying from only some to cf at last raise ...you smoking something or just pump and dump",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "4.60",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721845+00:00"
      },
      {
        "event_id": "SOCIAL-13Sep20250822-stanleyb-49711887",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.708252",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "That the news that Polb needed...but it doesn't seem to have anything like this? https://www.lse.co.uk/rns/immupharma-files-new-patent-application-for-p140-gw9x8ej2tocqv3h.html",
          "sentiment": 0.0,
          "engagement": "3,676",
          "price_at_post": "4.50",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721827+00:00"
      },
      {
        "event_id": "SOCIAL-14Sep20251718-GeordieC-63043743",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.707811",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "I think if the results of POLB001 trial end up positive, then we will see a similar jump in share price as that of ImmuPharma. We are just going to have to wait until the end of H1 next year before we know..",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "4.50",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721809+00:00"
      },
      {
        "event_id": "SOCIAL-15Sep20251601-nessab-65796224",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.707403",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/PoolbegPharma/status/1967528734216397065",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.40",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-22T21:16:33.721791+00:00"
      },
      {
        "event_id": "SOCIAL-16Sep20251159-BurtonD--9043873",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.706979",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udce2 Conference Update #POLB CEO, Jeremy Skillington, will be speaking at the Optimum Strategic Communications 17th Annual Healthcare Investor Conference. \ud83d\udccd The King\u2019s Fund, London \ud83d\uddd3\ufe0f Thursday 9 October \u231a 14:15 \ud83d\udde3\ufe0f Panel: Thriving in the tough times: scaling smart and staying strong Jeremy will join: \u2022Nicole Mather, IBM Consulting \u2022Nick Keher, CFO, Oxford Nanopore Chaired by Krisin-Anne Rutter, Cambridge University Health Partners Register here : https://www.optimumcomms.com/irconference2025/#register",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.15",
          "thread_title": "POLB conference details",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=9F11C6D9-B79D-46F9-B3E9-45F27E61D489"
        },
        "ingested_at": "2026-01-22T21:16:33.721774+00:00"
      },
      {
        "event_id": "SOCIAL-16Sep20251206-BurtonD--6717310",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.706517",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83c\udf99\ufe0f Podcast Alert Tune in to the #POLB Deep Tech Digest \u2013 Base to Base Biotech podcast where CEO Jeremy Skillington, PhD talks all things @PoolbegPharma \ud83d\udc49 From 37:26: deeptechdigest.com/biotech/base-t\u2026 Highlights include: \u2705 Company overview & history \ud83d\udc8a POLB 001 in cancer immunotherapy-induced CRS \ud83d\udd0d Understanding Cytokine Release Syndrome \ud83e\uddd1\u200d\ud83d\udd2c Upcoming Phase 2a & Proof of Concept trials \ud83d\ude80 Oral, patient-friendly obesity treatment in development",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.15",
          "thread_title": "VERY worth a listen :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5B205D0-4971-488E-B498-2790FC3D31F3"
        },
        "ingested_at": "2026-01-22T21:16:33.721756+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD--7009376",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.706059",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-01-22T21:16:33.721738+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19--4697457",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.705638",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-01-22T21:16:33.721721+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19-15319241",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.705183",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-01-22T21:16:33.721703+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD--9024837",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.704717",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721685+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb--3713116",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.704269",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,676",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721667+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma-47000686",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.703806",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "355",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721650+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21-11550012",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.703394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721632+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21--8486660",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.702961",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721614+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug-69915351",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.702543",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721596+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21-46987449",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.702127",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721578+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan-35459589",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.701704",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-22T21:16:33.721560+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-35381214",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.701289",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-22T21:16:33.721542+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly--4309397",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.700866",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,636",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-01-22T21:16:33.721525+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19-58009108",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.700437",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-01-22T21:16:33.721506+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan-58648204",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:33.699973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-22T21:16:33.721486+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC--8166907",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.689753",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "191",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-01-22T21:16:33.721468+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD--4219897",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.689340",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-22T21:16:33.721449+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit--8215748",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.688916",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-22T21:16:33.721431+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD-10129493",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.688507",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-22T21:16:33.721413+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan--6692367",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.688058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-22T21:16:33.721395+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD-78134634",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.687649",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721377+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho--3025390",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.687217",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721359+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug-18028283",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.686795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721341+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7--1799765",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.686376",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721323+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-28233220",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.685937",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721304+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti--5750345",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.685531",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721286+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54--8152068",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.685111",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "357",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-22T21:16:33.721268+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54--8136914",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.684669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "357",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-22T21:16:33.721250+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7-10100652",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.684257",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721232+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma--8885506",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.683829",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "355",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721213+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19-19498298",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.683379",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721195+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma--6650020",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.682925",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "355",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-22T21:16:33.721177+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD--5634968",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.682508",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-01-22T21:16:33.721158+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly--7928418",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.682041",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,636",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-22T21:16:33.721140+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66--8820832",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.681627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-22T21:16:33.721120+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130--4518012",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.681212",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-22T21:16:33.721087+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD-90488747",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.680782",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-22T21:16:33.721069+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-20988836",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.680338",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-22T21:16:33.721051+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66-62687965",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.679901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-22T21:16:33.721033+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-28830010",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:28.679452",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,676",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-22T21:16:33.721015+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe-54199325",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.009055",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-22T21:16:33.720997+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--8736718",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.008647",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-22T21:16:33.720980+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-75824673",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.008237",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-22T21:16:33.720962+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD-64764012",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.007783",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720944+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-47836715",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.007313",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-22T21:16:33.720926+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--8596049",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.006889",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-22T21:16:33.720908+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab-60249473",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.006481",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720890+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--5571982",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.006058",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,676",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720872+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19-15766082",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.005650",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720854+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--5027404",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.005242",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720836+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce-49839009",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.004816",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-22T21:16:33.720819+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--7056707",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.004400",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,636",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-22T21:16:33.720801+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--7645298",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.003972",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-22T21:16:33.720782+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6-24536127",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.003237",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-22T21:16:33.720765+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce-79189430",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.002815",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-22T21:16:33.720747+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD--5863125",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.002408",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-22T21:16:33.720729+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD-65848733",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.001952",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-22T21:16:33.720711+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--8369626",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.001499",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-22T21:16:33.720692+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--3344692",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.001071",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720674+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66--6998004",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.000665",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720656+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66--6998004",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:25.000256",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720638+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--3274824",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:24.999839",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720619+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-39060123",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:24.999424",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720596+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti--5410263",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:24.998994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-22T21:16:33.720573+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD-48901470",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:24.998561",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,704",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-22T21:16:33.720536+00:00"
      },
      {
        "event_id": "SOCIAL-9Jun20250748-BurtonD--1543201",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.092942",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.investormeetcompany.com/companies/poolbeg-pharma-plc",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.70",
          "thread_title": "New presentation - 23/6/25",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=D6AFB8CE-89F0-4344-8BE3-D01DE122652B"
        },
        "ingested_at": "2026-01-21T21:26:50.109627+00:00"
      },
      {
        "event_id": "SOCIAL-18Jun20251042-BurtonD-23897924",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.092535",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.linkedin.com/posts/poolbeg-pharma_polb-eha2025-milan-activity-7340981668649873408-v5r9/?utm_source=share&utm_medium=member_desktop&rcm=ACoAABWe2eUBXV6uCB8cMpVGTuYlj8X9a2EAjOw",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.30",
          "thread_title": "Poolbeg shared a sneak peak into the team\u2019s attendance at the EHA...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7164C7CE-D09B-4DB3-BFB4-AA43E46F2302"
        },
        "ingested_at": "2026-01-21T21:26:50.109609+00:00"
      },
      {
        "event_id": "SOCIAL-20Jun20251241-AIMMCC--3745320",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.092122",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "Morning guys -  Hope everyone is keeping well! what are you most excited about with your investment in Poolbeg?",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T21:26:50.109591+00:00"
      },
      {
        "event_id": "SOCIAL-20Jun20251807-Id10t--1784848",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.091702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Id10t",
          "content": "Selling it last may!!! Will most likely buy back in next spring.",
          "sentiment": 0.0,
          "engagement": "144",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T21:26:50.109574+00:00"
      },
      {
        "event_id": "SOCIAL-22Jun20251907-Cashinti-49668872",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.091293",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "AGM tomorrow @12.00pm. We will see if it coincides with any announcement of what the future holds in store for this of late poor performing company",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T21:26:50.109556+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251551-BurtonD--7461667",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.090876",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Dear David, This is a reminder that POOLBEG PHARMA PLC will be holding the meeting Company Presentation tomorrow at 23rd Jun 2025 at 5:00pm BST. Please click on the button below accept the meeting invitation... (Click on IMC Website to register/join ; https://www.investormeetcompany.com/meetings/company-presentation-7 )",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.15",
          "thread_title": "IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T21:26:50.109538+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251649-jimbren-38912932",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.090451",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Rehearsal during market hours revealed some (bad) news? Or was bad news given to some institutional investors in meetings this afternoon? Or a liquid lunch resulted in some loose talk?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T21:26:50.109520+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251652-jimbren--5851947",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.090034",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Or just a stray negative comment at the AGM?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T21:26:50.109502+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251800-RoyRoy--3204380",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.089624",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "Hmm, so (if i heard correctly) no longer pushing for a listing on the NASDAQ and will unwind all the work on that front ? \"Cost cutting\". Over the past 4 years there have been many great sounding words (Skillington is an excellent wordsmith) but IMO very little progress. Lots of time, effort, and money will I'm sure have been spent on preparing for NASDAQ listing. And for what...? I wonder if the management thought with all this buzz on AI, they could jump on the bandwagon, and with a high profile pharma NASDAQ listing see the share price rocket before cashing out after a takeover ... ? Pure speculation on my part obvisouly but it seems to me this company has focussed a lot of its recent effort  on a NAZ listing which has probably impacted the progress on the drug research side. When will we see genuine progress ? I just want to see some evidence of this company moving forward on the pharma... Happy to hear all view points and be corrected of course.",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "2.65",
          "thread_title": "U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-21T21:26:50.109485+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251838-Cashinti--8430180",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.089201",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Big sell of 11million shares is the reason for the 20% drop. If things weren't bad enough already.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.65",
          "thread_title": "RE: U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-21T21:26:50.109466+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20251902-BurtonD-79760605",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.088786",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=V42uSTAvgTI",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "2.65",
          "thread_title": "IMC presentation from 5pm tonight",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E96FAEEA-B656-4D87-AA55-A068B70FBF67"
        },
        "ingested_at": "2026-01-21T21:26:50.109448+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20252035-Marcboug-54542990",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.088377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Are people honestly thinking this will come good or just so down it barely matters? What's the newsflow going to be here for the months ahead? They've pretty much admitted there won't be any = drift = fall below raise = capitulation; isn't this the most likely scenario here. How long do people keep buying that POLB-001 is worth anything at all? They hven't had a single approach in how many years? It's not really how pharma works when there is a genuine asset available.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T21:26:50.109431+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20252136-HotChip--3685378",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.087951",
        "source": "LSE_CHAT",
        "data": {
          "author": "HotChip",
          "content": "I don't buy the story, I sold out ages ago at a profit.",
          "sentiment": 0.0,
          "engagement": "960",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T21:26:50.109413+00:00"
      },
      {
        "event_id": "SOCIAL-23Jun20252326-Marcboug-91214764",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.087545",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Did the massive fall coincide with the AGM? You have to wonder what was said there that made people realise it was done for",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T21:26:50.109396+00:00"
      },
      {
        "event_id": "SOCIAL-24Jun20250851-Ironman2--5532873",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.087137",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ironman22",
          "content": "Oh look the massive loser Marc is back. Thinking that just because someone has sold some shares that means it's all over.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T21:26:50.109378+00:00"
      },
      {
        "event_id": "SOCIAL-24Jun20251129-Marcboug-28697713",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.086719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "No, I'm thinking that it's over because they've achieved nothing for years except pulling the wool over your eyes continuously. I'm thinking that it's over because if they had anything with any remote potential it would have been swallowed up years ago. I'm thinking it's over because they don't have a single company to partner them and even the terrible one that was going to, pulled out.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T21:26:50.109360+00:00"
      },
      {
        "event_id": "SOCIAL-25Jun20251637-nessab--5063629",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.086312",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1073603/poolbeg-investor-backing-clears-the-path-for-development-and-deliver-brokers-say-1073603.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.20",
          "thread_title": "Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109342+00:00"
      },
      {
        "event_id": "SOCIAL-26Jun20250852-UserStev--5081650",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.085885",
        "source": "LSE_CHAT",
        "data": {
          "author": "UserSteve",
          "content": "Institutional investor bought a bit over \u00a31m worth of shares. That's a nice vote of confidence",
          "sentiment": 0.0,
          "engagement": "2,567",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109325+00:00"
      },
      {
        "event_id": "SOCIAL-26Jun20250911-ThinIce-30801389",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.085473",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "One of CF\u2019s mates.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109307+00:00"
      },
      {
        "event_id": "SOCIAL-26Jun20250936-stanleyb-79010006",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.085049",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Unfortunately it appears that CF has lost the midas touch with Poolbeg..Hvivo not looking very good either since CF walked away at 30p...Glad I got out last year before the wheels fell off both..Good luck those holding. You never know Poolbegs Polb-001 might come Good?JAO Adyor.",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "3.50",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109289+00:00"
      },
      {
        "event_id": "SOCIAL-26Jun20251240-RoyRoy--4336228",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.084642",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "I don't understand your post ...  \"Hvivo not looking very good either since CF walked away\" Your use of the word _either_ here suggests that CF has \"walked away\" but infact the opposite is true. He's just upped his holding by \u00a3100k. Can you clarify your point ?",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "3.35",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109271+00:00"
      },
      {
        "event_id": "SOCIAL-29Jun20251257-NoAdvice-69570476",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.084219",
        "source": "LSE_CHAT",
        "data": {
          "author": "NoAdvices",
          "content": "Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed \u00a34.7 million equity raise and a series of high-impact developments across its key programmes. https://tinyurl.com/2bze5fnb",
          "sentiment": 0.0,
          "engagement": "128",
          "price_at_post": "3.30",
          "thread_title": "New Catalysts as POLB 001 Advances Toward the Clinic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=82CF4494-DD48-44FE-B271-71C1FA6FDB60"
        },
        "ingested_at": "2026-01-21T21:26:50.109254+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251005-nessab-31592802",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.083787",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/PoolbegPharma/status/1939597489583116385/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.30",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T21:26:50.109235+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251238-BurtonD-44349211",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.083328",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=YK6GXs1qUCs",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.30",
          "thread_title": "Shares Magazine investor presentation video :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=89872864-8F5F-4F5D-BE5C-D2685DD438FA"
        },
        "ingested_at": "2026-01-21T21:26:50.109218+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251652-Bazzaman--1806204",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:50.082884",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bazzaman",
          "content": "Michael Kelly reducing his holdings, maybe losing patience with how long it is all taking here.",
          "sentiment": 0.0,
          "engagement": "6,162",
          "price_at_post": "3.30",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-21T21:26:50.109200+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20252040-AIMMCC--7890614",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.127817",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "I suspect it\u2019s a change in voting rights due to placing dilution, not sale of shares",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-21T21:26:50.109182+00:00"
      },
      {
        "event_id": "SOCIAL-3Jul20250651-BurtonD--4507277",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.127412",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "cashed up and charging ahead : poolbeg pharma\u2019s value runway is clear.... full feature article and video link : **********************************/2025/07/poolbeg-pharma-plc-july-2025/ interview link only : https://youtu.be/pmbnlvwpxfc",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.25",
          "thread_title": "NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-21T21:26:50.109165+00:00"
      },
      {
        "event_id": "SOCIAL-3Jul20250852-ThinIce--5730551",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.126983",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "I\u2019d love to ask: 1. Why this relatively small amount of money they now have compared to the \u00a320m+ they did have is expected to make all the difference, and 2. Whatever happened to their secondary revenue generating plans which they announced some 2+ years ago that never appeared to materialise.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.25",
          "thread_title": "RE: NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-21T21:26:50.109147+00:00"
      },
      {
        "event_id": "SOCIAL-7Jul20251103-BurtonD--7421490",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.126569",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.share-talk.com/poolbeg-pharma-new-capital-new-catalysts-as-polb-001-advances-in-the-clinic/",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.30",
          "thread_title": "Worth a read from ShareTalk Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=40297FC2-0811-4710-AFCB-751AE3BEBFDA"
        },
        "ingested_at": "2026-01-21T21:26:50.109129+00:00"
      },
      {
        "event_id": "SOCIAL-8Jul20250904-BurtonD--8828902",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.126158",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "POLB are presenting at the @MelloEventsUK webinar \ud83d\udcc528 July at 5pm \ud83d\udd35Speakers: CEO & CFO \ud83d\udcbbVirtual Presentation Register to attend: https://www.tickettailor.com/events/melloeventslimited/1738551",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.25",
          "thread_title": "POLB at Mello!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1FB6780B-328C-431A-AE6C-32F39B2CAB45"
        },
        "ingested_at": "2026-01-21T21:26:50.109108+00:00"
      },
      {
        "event_id": "SOCIAL-16Jul20251019-BurtonD--5406141",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.125714",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "POLB 001 is a Phase 2-ready, orally-administered p38 MAP Kinase inhibitor designed to prevent cancer immunotherapy-induced CRS, a severe, potentially life-threatening side effect of cancer immunotherapies. Check out our overview: \u2705Phase 2-ready oral small molecule \ud83d\udc49\u202fSelectively prevent excessive inflammation without immunosuppression \ud83d\udd2cFavourable safety and tolerability profile, and has demonstrated potent inhibition of CRS-related cytokines, such as TNF-\u03b1 and IL-6, in clinical and preclinical studies \ud83d\udcaaStrong patent portfolio \ud83d\ude80Awarded FDA Orphan Drug Designation \u26d4No approved therapy for CRS prevention \u2013 a >US$10bn market opportunity Learn more about POLB 001 in oncology here: https://www.poolbegpharma.com/pipeline/polb-001-oncology/",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.15",
          "thread_title": "Worth some time to read\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=D0404776-88CF-4310-9280-2FEEECD69649"
        },
        "ingested_at": "2026-01-21T21:26:50.109077+00:00"
      },
      {
        "event_id": "SOCIAL-22Jul20251029-MelloDan--5167137",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.125270",
        "source": "LSE_CHAT",
        "data": {
          "author": "MelloDaniel",
          "content": "Poolbeg are presenting on MelloMonday on 28th July. Webinar starts at 5pm. Jeremy Skillington, CEO, & Ian O\u2019Connell, CFO, of POLB presenting around 6:10pm after our keynote. Do join us to view their presentation & ask your questions. Tickets available via our website: Use code LSE40 for 40% off (\u00a312 usually \u00a320). If you are a POLB shareholder, you are eligible for a free ticket. Use code MMSHComp25 for a free ticket.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "3.10",
          "thread_title": "Poolbeg MelloMonday Webinar",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=BC137DD4-3EE2-43EB-AB2A-2E4132D76732"
        },
        "ingested_at": "2026-01-21T21:26:50.109059+00:00"
      },
      {
        "event_id": "SOCIAL-24Jul20251243-2reincar-23247898",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.124843",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Can see this drop to 0.25p before it takes off.",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "2.85",
          "thread_title": "This one reminds me of Oxford Biodynamics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=ED0F14CB-48E9-46D3-9E48-45096D19916D"
        },
        "ingested_at": "2026-01-21T21:26:50.109041+00:00"
      },
      {
        "event_id": "SOCIAL-29Jul20250847-stanleyb--5037148",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.124437",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Think it was all just a bit of a speculative pipe dream, 0.25p before it drops to 0.15p wouldn't you say?",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "2.70",
          "thread_title": "RE: This one reminds me of Oxford Biodynamics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=ED0F14CB-48E9-46D3-9E48-45096D19916D"
        },
        "ingested_at": "2026-01-21T21:26:50.109023+00:00"
      },
      {
        "event_id": "SOCIAL-29Jul20251059-ThinIce--3124126",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.124018",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "don\u2019t get tricked into another placing - they are just ******* our money down the drain.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "2.65",
          "thread_title": "RE: This one reminds me of Oxford Biodynamics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=ED0F14CB-48E9-46D3-9E48-45096D19916D"
        },
        "ingested_at": "2026-01-21T21:26:50.109005+00:00"
      },
      {
        "event_id": "SOCIAL-1Aug20251034-Lewis66-25318904",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.123607",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I cant help thinking that this is being intentionally kept low. Not that there's many daily trades being shown on here, but soon after any buys take place, really low volume sells occur at much lower values. Take a look at ydays . A massive 52 shares sold at 2.6!!",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "2.70",
          "thread_title": "Being kept low",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7426DEB6-CB8A-4247-A441-230B32CFEDC7"
        },
        "ingested_at": "2026-01-21T21:26:50.108988+00:00"
      },
      {
        "event_id": "SOCIAL-1Aug20251512-Cashinti--2003766",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.123200",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "That HOOKIPA deal really hurt the shareprice,once when announcement made and again when it failed,now looking for a near X4 to get back to IPO price.Poir performance.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.70",
          "thread_title": "RE: Being kept low",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7426DEB6-CB8A-4247-A441-230B32CFEDC7"
        },
        "ingested_at": "2026-01-21T21:26:50.108970+00:00"
      },
      {
        "event_id": "SOCIAL-1Aug20251515-ThinIce--8593204",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.122788",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "It was a terrible deal.  It was dressed up to be something it wasn't but shareholders saw through it.  It was na\u00efve on the part of the board to think they could hoodwink the market and we are now paying the price  - with a general lack of trust.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "2.70",
          "thread_title": "RE: Being kept low",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7426DEB6-CB8A-4247-A441-230B32CFEDC7"
        },
        "ingested_at": "2026-01-21T21:26:50.108952+00:00"
      },
      {
        "event_id": "SOCIAL-6Aug20250910-ThinIce--3416548",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.122382",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Looing bad for Immupharma and maybe that should be a lesson to us!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "2.60",
          "thread_title": "Immupharma",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=85FB44FE-585F-4903-AA6E-4376DA3FAF20"
        },
        "ingested_at": "2026-01-21T21:26:50.108934+00:00"
      },
      {
        "event_id": "SOCIAL-6Aug20251341-BurtonD--8787638",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.121962",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83c\udf99\ufe0f Must-listen for biotech investors \ud83d\udc47 @PoolbegPharma CEO Jeremy Skillington joins the @Citeline In Vivo podcast to talk: \ud83e\udde0 Smart pivots in biotech \ud83d\udc8a Tackling CRS & obesity with oral therapies \ud83d\udcc8 Early data, big partnerships \ud83d\udcb7 Investor confidence post-raise \ud83c\udfa7 Tune in now: \ud83d\udd17 m.soundcloud.com/citelinesounds\u2026 #Biotech #CRS #GLP1 #ClinicalTrials #SmallCaps #Pharma #PoolbegPharma #DrugDevelopment #Innovation #POLB",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "2.60",
          "thread_title": "A must listen interview\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=793492DA-A085-4238-8878-FB985E6DDB08"
        },
        "ingested_at": "2026-01-21T21:26:50.108916+00:00"
      },
      {
        "event_id": "SOCIAL-21Aug20251349-silverho-41439720",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.121515",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "Starting to move up a bit 5p yearend - next year good news over 10p would be great - Are we still betting on a buyout?",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.00",
          "thread_title": "RE: A must listen interview\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=793492DA-A085-4238-8878-FB985E6DDB08"
        },
        "ingested_at": "2026-01-21T21:26:50.108898+00:00"
      },
      {
        "event_id": "SOCIAL-3Sep20251519-silverho-46065354",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.121107",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "We are due a positive update soon - buy now rewarded later",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.20",
          "thread_title": "RE: A must listen interview\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=793492DA-A085-4238-8878-FB985E6DDB08"
        },
        "ingested_at": "2026-01-21T21:26:50.108881+00:00"
      },
      {
        "event_id": "SOCIAL-3Sep20251757-ThinIce--8753448",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.120691",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "I sincerely hope you are right. The last placing gave them a good runway and I wouldn\u2019t want to give them any more of my hard earned cash!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.25",
          "thread_title": "RE: A must listen interview\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=793492DA-A085-4238-8878-FB985E6DDB08"
        },
        "ingested_at": "2026-01-21T21:26:50.108863+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20251521-ThinIce-34928658",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.120284",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "How long before the rampers arrive? Hopefully they are all too busy on Hemogenyx",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "RE: A must listen interview\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=793492DA-A085-4238-8878-FB985E6DDB08"
        },
        "ingested_at": "2026-01-21T21:26:50.108845+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20252041-MaryBr19-16814329",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.119854",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Analyst Updates \u2022 MarketBeat: Analysts have indicated a consensus price target of 19 GBX for Poolbeg Pharma, suggesting a potential upside of 381.01% from current levels. This target reflects optimism about the company's growth prospects and ongoing clinical developments. \u2022 Investing.com: According to their analysis, the average 12-month price target for Poolbeg Pharma is also set at 19 GBX, with a high estimate of 19 GBX. This reinforces the bullish sentiment among analysts regarding the company's future performance. \u2022 Stockscan: They project a more aggressive forecast, estimating that Poolbeg Pharma could reach an average price of 0.6497 USD in the next 30 days, representing a 1,429% increase from its current price. The highest target from this analysis is 0.6988 USD, while the lowest is 0.6006 USD.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.875",
          "thread_title": "Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108827+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20252246-Brooko19--2148647",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.119422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "19p would still be under \u00a3150m Mcap so not the most unrealistic targets you usually see happy to just hold and see here in no rush",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.875",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108809+00:00"
      },
      {
        "event_id": "SOCIAL-8Sep20251006-Bazzaman--2241059",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.119000",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bazzaman",
          "content": "Are due on 16th September, SP creeping up with some big buys. Good news to come maybe?",
          "sentiment": 0.0,
          "engagement": "6,162",
          "price_at_post": "4.10",
          "thread_title": "Half-year results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=BF5DEFB7-4033-4200-B884-06D82DAC011A"
        },
        "ingested_at": "2026-01-21T21:26:50.108791+00:00"
      },
      {
        "event_id": "SOCIAL-8Sep20251027-PeterS23--8920736",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.118592",
        "source": "LSE_CHAT",
        "data": {
          "author": "PeterS23",
          "content": "Cathal Friel attended and spoke at Saturdays Tom Winnifrith investors all day event on Saturday 6th and maybe he\u2019s said a few positive things in private which the 130 or so investors have picked up on? GLA",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "4.30",
          "thread_title": "RE: Half-year results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=BF5DEFB7-4033-4200-B884-06D82DAC011A"
        },
        "ingested_at": "2026-01-21T21:26:50.108773+00:00"
      },
      {
        "event_id": "SOCIAL-8Sep20251045-formerly--9039692",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.118176",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar of institutional investors for now but I have a small stake and am willing to be patient.  UK biotechs seem to be having a good year imo.",
          "sentiment": 0.0,
          "engagement": "1,631",
          "price_at_post": "4.30",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108755+00:00"
      },
      {
        "event_id": "SOCIAL-8Sep20251536-ThinIce--6918228",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:45.117736",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Assuming there is no big seller in the wings, surely this price is being held back.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.15",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108737+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252021-ThinIce-56915657",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.686758",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "2M shares bought today and negligible sells. Pretty much been the pattern for the last few trading days. Someone is certainly accumulating and yet the share is fairly static. Think we may be in for a more substantial rise soon. Two broker tips at 19p gives a MC of \u00a3150M which is not unreasonable for a company with two great products and one about to start a phase 2A (with assistance (FOC) from big pharma). I would say this is as good a prospect for a 5 bagger from here as any! Check out Hemagenyx and immupharma over the last few days who are at a similar stage with their products.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.30",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108719+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20250925-Lewis66--3486429",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.686345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Great that the rises are steady. I wondered / worried on Friday (5th) if it would drop back down but appears to be getting higher and higher. Let\u2019s get back to teens by the end of the yr?!",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.60",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108701+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20251045-MaryBr19-46038859",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.685932",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Momentum, director buying, potential bagger. Finance sorted, updates due. Great mix for a harrier move up.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.70",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108683+00:00"
      },
      {
        "event_id": "SOCIAL-10Sep20251050-MaryBr19--7391908",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.685530",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Poolbeg Pharma is experiencing significant momentum due to its advancements in drug development, particularly in oncology and metabolic diseases. The company is focused on innovative treatments that address unmet medical needs, which has garnered attention from investors and analysts alike. Key Developments \u2022 Pipeline Advancements: Poolbeg's lead asset, POLB 001, is designed to target cytokine release syndrome (CRS), a serious condition affecting many cancer patients undergoing immunotherapy. This oral therapy could potentially transform treatment options, as there are currently few effective preventative measures for CRS. \u2022 Funding and Partnerships: The company recently raised at least \u00a34 million to accelerate its key programs, including POLB 001 and an oral GLP-1 receptor agonist project aimed at obesity treatment. This funding is crucial for advancing clinical trials and attracting commercial partners. \u2022 Upcoming Trials: The Phase 2a trial for POLB 001 is expected to begin soon, with interim results anticipated in the first half of 2026. The involvement of major pharmaceutical companies in supplying key biologics for the trial indicates strong confidence in Poolbeg's strategy. \u2022 Innovative Approaches: Poolbeg is also exploring an oral encapsulated formulation of GLP-1, which aims to improve the bioavailability of peptide-based therapies. This project is set to enter a proof-of-concept trial later this year. \u2022 AI-Driven Drug Discovery: Beyond its primary programs, Poolbeg is leveraging AI for drug discovery, focusing on significant health threats like influenza and RSV, which reflects its broader ambition to utilize data-driven science for impactful solutions. Overall, Poolbeg Pharma is at a pivotal point, with its lead programs advancing into human trials and a strong pipeline that could lead to transformative treatments in the near future.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.70",
          "thread_title": "Multi bagger",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=77FF67EC-B4C5-437E-9426-4F45D219A47B"
        },
        "ingested_at": "2026-01-21T21:26:50.108665+00:00"
      },
      {
        "event_id": "SOCIAL-11Sep20250914-Nubex-84376662",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.685082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Nubex",
          "content": "Leadership team share holdings are small so where did  you get the Director buying from only some to cf at last raise ...you smoking something or just pump and dump",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "4.60",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108648+00:00"
      },
      {
        "event_id": "SOCIAL-13Sep20250822-stanleyb-30207601",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.684679",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "That the news that Polb needed...but it doesn't seem to have anything like this? https://www.lse.co.uk/rns/immupharma-files-new-patent-application-for-p140-gw9x8ej2tocqv3h.html",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "4.50",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108630+00:00"
      },
      {
        "event_id": "SOCIAL-14Sep20251718-GeordieC--3486921",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.684274",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "I think if the results of POLB001 trial end up positive, then we will see a similar jump in share price as that of ImmuPharma. We are just going to have to wait until the end of H1 next year before we know..",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "4.50",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108612+00:00"
      },
      {
        "event_id": "SOCIAL-15Sep20251601-nessab-32951353",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.683862",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/PoolbegPharma/status/1967528734216397065",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.40",
          "thread_title": "RE: Updates last few days 1-3 Sep",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F1167155-1BD9-42ED-A7F3-3EC54974F209"
        },
        "ingested_at": "2026-01-21T21:26:50.108594+00:00"
      },
      {
        "event_id": "SOCIAL-16Sep20251159-BurtonD-89896209",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.683461",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udce2 Conference Update #POLB CEO, Jeremy Skillington, will be speaking at the Optimum Strategic Communications 17th Annual Healthcare Investor Conference. \ud83d\udccd The King\u2019s Fund, London \ud83d\uddd3\ufe0f Thursday 9 October \u231a 14:15 \ud83d\udde3\ufe0f Panel: Thriving in the tough times: scaling smart and staying strong Jeremy will join: \u2022Nicole Mather, IBM Consulting \u2022Nick Keher, CFO, Oxford Nanopore Chaired by Krisin-Anne Rutter, Cambridge University Health Partners Register here : https://www.optimumcomms.com/irconference2025/#register",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.15",
          "thread_title": "POLB conference details",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=9F11C6D9-B79D-46F9-B3E9-45F27E61D489"
        },
        "ingested_at": "2026-01-21T21:26:50.108577+00:00"
      },
      {
        "event_id": "SOCIAL-16Sep20251206-BurtonD--7111392",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.682997",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83c\udf99\ufe0f Podcast Alert Tune in to the #POLB Deep Tech Digest \u2013 Base to Base Biotech podcast where CEO Jeremy Skillington, PhD talks all things @PoolbegPharma \ud83d\udc49 From 37:26: deeptechdigest.com/biotech/base-t\u2026 Highlights include: \u2705 Company overview & history \ud83d\udc8a POLB 001 in cancer immunotherapy-induced CRS \ud83d\udd0d Understanding Cytokine Release Syndrome \ud83e\uddd1\u200d\ud83d\udd2c Upcoming Phase 2a & Proof of Concept trials \ud83d\ude80 Oral, patient-friendly obesity treatment in development",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.15",
          "thread_title": "VERY worth a listen :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5B205D0-4971-488E-B498-2790FC3D31F3"
        },
        "ingested_at": "2026-01-21T21:26:50.108558+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD-29607732",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.682552",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-01-21T21:26:50.108541+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19--7119250",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.682138",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-01-21T21:26:50.108522+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--2940240",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.681688",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-01-21T21:26:50.108505+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD-40431535",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.681267",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108487+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb-43718835",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.680817",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108469+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma--5453095",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.680411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "354",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108452+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21--7946955",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.679992",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108434+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21--7476433",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.679577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108416+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug-39547500",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.679164",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108397+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21--3296633",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.678749",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108379+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan--8848365",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.678341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,391",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-21T21:26:50.108361+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-29407642",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.677917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "244",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-21T21:26:50.108343+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-79363267",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.677510",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,631",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-01-21T21:26:50.108325+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19-70679593",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.677078",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-01-21T21:26:50.108307+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan-89951019",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:39.676637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,391",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-21T21:26:50.108289+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC--8488856",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.402861",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "191",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-01-21T21:26:50.108271+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD--3620842",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.402453",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-21T21:26:50.108253+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit--6491173",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.402033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-21T21:26:50.108234+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD--7408280",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.401625",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-21T21:26:50.108214+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan-80473754",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.401191",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,391",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-21T21:26:50.108196+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD--3773025",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.400773",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108178+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho--6573208",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.400346",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108160+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug--2099294",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.399928",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108142+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7--5641619",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.399513",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108122+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-61132371",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.399082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108087+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti-12099443",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.398679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108069+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54--3856155",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.398270",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "357",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-21T21:26:50.108051+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54--9179040",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.397854",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "357",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-21T21:26:50.108033+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7--5586649",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.397448",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.108014+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma--9179830",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.397032",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "354",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.107996+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19--8152509",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.396629",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.107978+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma--1484718",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.396190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "354",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-21T21:26:50.107960+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD-57479133",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.395767",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-01-21T21:26:50.107941+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly-47648014",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.395316",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,631",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-21T21:26:50.107923+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66--1627222",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.394891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-21T21:26:50.107904+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130--1570354",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.394481",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T21:26:50.107887+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD-20284546",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.394053",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-21T21:26:50.107869+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-21569695",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.393608",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-21T21:26:50.107851+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66-88529830",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.393056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T21:26:50.107833+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-41854198",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:36.392581",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T21:26:50.107815+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--4144565",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.501667",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T21:26:50.107797+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--8491430",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.501262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T21:26:50.107778+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-86682600",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.500845",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-21T21:26:50.107760+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD-57665932",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.500404",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107742+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce--5524418",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.499924",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-21T21:26:50.107724+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--8194579",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.499514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,391",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-21T21:26:50.107706+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--5879720",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.499105",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107688+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb-19044876",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.498689",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,670",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107670+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19--3439406",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.498281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107651+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1-12401329",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.497864",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107633+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce--4889412",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.497446",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-21T21:26:50.107615+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--7511298",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.496910",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,631",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-21T21:26:50.107598+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--8164515",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.496508",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-21T21:26:50.107580+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6-73713410",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.495888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "244",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T21:26:50.107561+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce-42722274",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.495482",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-21T21:26:50.107544+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-15474476",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.495066",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-21T21:26:50.107526+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--1050672",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.494630",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-21T21:26:50.107509+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab-83214904",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.494180",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-21T21:26:50.107491+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce-47396689",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.493759",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107473+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-18719171",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.493355",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107455+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-18719171",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.492939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107437+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti-66945754",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.492537",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107419+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-56829002",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.492122",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107396+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-54085648",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.491699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T21:26:50.107376+00:00"
      },
      {
        "event_id": "SOCIAL-Today1028-BurtonD-86798747",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:32.491273",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,701",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-21T21:26:50.107346+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD-44763167",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:48.141115",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,700",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-21T01:13:59.385238Z"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-58390106",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:48.140664",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-21T01:13:59.385212Z"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--5118360",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:48.140230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T01:13:59.385186Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-39840173",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.717756",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,667",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T01:13:59.385159Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--8271719",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.717349",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T01:13:59.385132Z"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--6254115",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.716928",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-21T01:13:59.385089Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-51661226",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.716518",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-21T01:13:59.385063Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--9053151",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.716064",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,700",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.385037Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce--1475143",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.715597",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-21T01:13:59.385011Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan-38073062",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.715190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,338",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-21T01:13:59.384985Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab-38704817",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.714771",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.384958Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb-63996042",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.714362",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,667",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.384931Z"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19-88014077",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.713944",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.384905Z"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--9136247",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.713539",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.384878Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce--4142656",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.713122",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-21T01:13:59.384851Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--3928421",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,629",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-21T01:13:59.384825Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--3488031",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.712293",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-21T01:13:59.384797Z"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--6124833",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "244",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-21T01:13:59.384771Z"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce--3598860",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.711262",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-21T01:13:59.384744Z"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD--2540074",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.710842",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,700",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-21T01:13:59.384714Z"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--3883482",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.710397",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,700",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-21T01:13:59.384665Z"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--1733319",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.709931",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-21T01:13:59.384637Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--8753862",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.709519",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384611Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-25513896",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.709109",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384584Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-25513896",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.708685",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384556Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--1492676",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.708271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384519Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce--6987215",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.707843",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384468Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-15589616",
        "event_type": "social_post",
        "date": "2026-01-21T01:13:45.707416",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-21T01:13:59.384435Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti-47104065",
        "event_type": "social_post",
        "date": "2026-01-16T22:48:21.845993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-16T22:48:39.917977Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce--5707427",
        "event_type": "social_post",
        "date": "2026-01-16T22:48:21.845585",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "500",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-16T22:48:39.917949Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-44307570",
        "event_type": "social_post",
        "date": "2026-01-16T22:48:21.845154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-16T22:48:39.917917Z"
      },
      {
        "event_id": "SOCIAL-3Jun20250931-Element1--5508952",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.970695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Element101",
          "content": "Cavendish maintains a 19p target on the shares, implying significant upside from the current 2.9p. But for that to materialise, the next 12 to 18 months will need to deliver more than just well-funded plans. They will need hard data.",
          "sentiment": 0.0,
          "engagement": "50",
          "price_at_post": "3.50",
          "thread_title": "19p target Cavendish",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=0DE27322-BB1B-4A89-A11E-067ADF603A24"
        },
        "ingested_at": "2026-01-16T22:48:39.921360Z"
      },
      {
        "event_id": "SOCIAL-3Jun20250931-Element1-72712209",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.970695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Element101",
          "content": "Cavendish maintains a 19p target on the shares, implying significant upside from the current 2.9p. But for that to materialise, the next 12 to 18 months will need to deliver more than just well-funded plans. They will need hard data.",
          "sentiment": 0.0,
          "engagement": "50",
          "price_at_post": "3.50",
          "thread_title": "19p target Cavendish",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=0DE27322-BB1B-4A89-A11E-067ADF603A24"
        },
        "ingested_at": "2026-01-21T01:13:59.387987Z"
      },
      {
        "event_id": "SOCIAL-4Jun20250736-BurtonD-51783086",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.970279",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We are attending @EHA_Hematology European Hematology Congress 2025 in Milan. \ud83d\udcc5 12-16 June 2025 \ud83d\udccd Allianz MiCo \u2013 Milano Convention Centre Meet with to learn more about Poolbeg Pharma: \ud83d\udd39Jeremy Skillington \u2013 CEO \ud83d\udd39Liam Tremble \u2013 Principal Scientist \ud83d\udd39Laura Maher \u2013 VP, Clinical Operations EHA2025 is set to be a dynamic platform for sharing cutting-edge research, fostering collaborations, and advancing patient care.",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.40",
          "thread_title": "Good visability this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4D4849F1-843C-470C-A1DC-A910A1D90EE4"
        },
        "ingested_at": "2026-01-16T22:48:39.921333Z"
      },
      {
        "event_id": "SOCIAL-4Jun20250736-BurtonD-16218670",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.970279",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We are attending @EHA_Hematology European Hematology Congress 2025 in Milan. \ud83d\udcc5 12-16 June 2025 \ud83d\udccd Allianz MiCo \u2013 Milano Convention Centre Meet with to learn more about Poolbeg Pharma: \ud83d\udd39Jeremy Skillington \u2013 CEO \ud83d\udd39Liam Tremble \u2013 Principal Scientist \ud83d\udd39Laura Maher \u2013 VP, Clinical Operations EHA2025 is set to be a dynamic platform for sharing cutting-edge research, fostering collaborations, and advancing patient care.",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.40",
          "thread_title": "Good visability this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4D4849F1-843C-470C-A1DC-A910A1D90EE4"
        },
        "ingested_at": "2026-01-21T01:13:59.387960Z"
      },
      {
        "event_id": "SOCIAL-4Jun20252217-Peterrr-40551847",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Peterrr",
          "content": "Still no clinical trials registered Burton.  Are they really going to be funding their own trials and if so why do they need to attend the same conferences rattling the can 3 years in a row with no new data to report?",
          "sentiment": 0.0,
          "engagement": "344",
          "price_at_post": "3.25",
          "thread_title": "RE: Good visability this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4D4849F1-843C-470C-A1DC-A910A1D90EE4"
        },
        "ingested_at": "2026-01-16T22:48:39.921307Z"
      },
      {
        "event_id": "SOCIAL-4Jun20252217-Peterrr--4683566",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Peterrr",
          "content": "Still no clinical trials registered Burton.  Are they really going to be funding their own trials and if so why do they need to attend the same conferences rattling the can 3 years in a row with no new data to report?",
          "sentiment": 0.0,
          "engagement": "344",
          "price_at_post": "3.25",
          "thread_title": "RE: Good visability this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4D4849F1-843C-470C-A1DC-A910A1D90EE4"
        },
        "ingested_at": "2026-01-21T01:13:59.387934Z"
      },
      {
        "event_id": "SOCIAL-6Jun20251204-BurtonD--8379284",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969422",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.sharesmagazine.co.uk/events/event/shares-spotlight-event-manchester-240625",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.65",
          "thread_title": "Poolbeg will be presenting at an in-person Shares Spotlight event i...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=8FE5F289-7699-4CA6-BE07-B9DF570FEC12"
        },
        "ingested_at": "2026-01-16T22:48:39.921280Z"
      },
      {
        "event_id": "SOCIAL-6Jun20251204-BurtonD--1631013",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969422",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.sharesmagazine.co.uk/events/event/shares-spotlight-event-manchester-240625",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.65",
          "thread_title": "Poolbeg will be presenting at an in-person Shares Spotlight event i...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=8FE5F289-7699-4CA6-BE07-B9DF570FEC12"
        },
        "ingested_at": "2026-01-21T01:13:59.387908Z"
      },
      {
        "event_id": "SOCIAL-9Jun20250748-BurtonD--6591991",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969001",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.investormeetcompany.com/companies/poolbeg-pharma-plc",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.70",
          "thread_title": "New presentation - 23/6/25",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=D6AFB8CE-89F0-4344-8BE3-D01DE122652B"
        },
        "ingested_at": "2026-01-16T22:48:39.921254Z"
      },
      {
        "event_id": "SOCIAL-9Jun20250748-BurtonD-30099837",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.969001",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.investormeetcompany.com/companies/poolbeg-pharma-plc",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.70",
          "thread_title": "New presentation - 23/6/25",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=D6AFB8CE-89F0-4344-8BE3-D01DE122652B"
        },
        "ingested_at": "2026-01-21T01:13:59.387882Z"
      },
      {
        "event_id": "SOCIAL-18Jun20251042-BurtonD-89068348",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.968594",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.linkedin.com/posts/poolbeg-pharma_polb-eha2025-milan-activity-7340981668649873408-v5r9/?utm_source=share&utm_medium=member_desktop&rcm=ACoAABWe2eUBXV6uCB8cMpVGTuYlj8X9a2EAjOw",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Poolbeg shared a sneak peak into the team\u2019s attendance at the EHA...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7164C7CE-D09B-4DB3-BFB4-AA43E46F2302"
        },
        "ingested_at": "2026-01-16T22:48:39.921226Z"
      },
      {
        "event_id": "SOCIAL-18Jun20251042-BurtonD-18306799",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.968594",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.linkedin.com/posts/poolbeg-pharma_polb-eha2025-milan-activity-7340981668649873408-v5r9/?utm_source=share&utm_medium=member_desktop&rcm=ACoAABWe2eUBXV6uCB8cMpVGTuYlj8X9a2EAjOw",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Poolbeg shared a sneak peak into the team\u2019s attendance at the EHA...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7164C7CE-D09B-4DB3-BFB4-AA43E46F2302"
        },
        "ingested_at": "2026-01-21T01:13:59.387855Z"
      },
      {
        "event_id": "SOCIAL-20Jun20251241-AIMMCC-65382356",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.968180",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "Morning guys -  Hope everyone is keeping well! what are you most excited about with your investment in Poolbeg?",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-16T22:48:39.921200Z"
      },
      {
        "event_id": "SOCIAL-20Jun20251241-AIMMCC--1367914",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.968180",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "Morning guys -  Hope everyone is keeping well! what are you most excited about with your investment in Poolbeg?",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T01:13:59.387829Z"
      },
      {
        "event_id": "SOCIAL-20Jun20251807-Id10t--9807560",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.967765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Id10t",
          "content": "Selling it last may!!! Will most likely buy back in next spring.",
          "sentiment": 0.0,
          "engagement": "142",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-16T22:48:39.921174Z"
      },
      {
        "event_id": "SOCIAL-20Jun20251807-Id10t--6061722",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.967765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Id10t",
          "content": "Selling it last may!!! Will most likely buy back in next spring.",
          "sentiment": 0.0,
          "engagement": "142",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T01:13:59.387803Z"
      },
      {
        "event_id": "SOCIAL-22Jun20251907-Cashinti--8670593",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.967356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "AGM tomorrow @12.00pm. We will see if it coincides with any announcement of what the future holds in store for this of late poor performing company",
          "sentiment": 0.0,
          "engagement": "850",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-16T22:48:39.921147Z"
      },
      {
        "event_id": "SOCIAL-22Jun20251907-Cashinti--7445219",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.967356",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "AGM tomorrow @12.00pm. We will see if it coincides with any announcement of what the future holds in store for this of late poor performing company",
          "sentiment": 0.0,
          "engagement": "850",
          "price_at_post": "3.30",
          "thread_title": "RE: Excitement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=DA75895A-03AD-40CE-939B-B1E189678B80"
        },
        "ingested_at": "2026-01-21T01:13:59.387777Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251551-BurtonD--5614476",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966936",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Dear David, This is a reminder that POOLBEG PHARMA PLC will be holding the meeting Company Presentation tomorrow at 23rd Jun 2025 at 5:00pm BST. Please click on the button below accept the meeting invitation... (Click on IMC Website to register/join ; https://www.investormeetcompany.com/meetings/company-presentation-7 )",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.15",
          "thread_title": "IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-16T22:48:39.921120Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251551-BurtonD-32031239",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966936",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Dear David, This is a reminder that POOLBEG PHARMA PLC will be holding the meeting Company Presentation tomorrow at 23rd Jun 2025 at 5:00pm BST. Please click on the button below accept the meeting invitation... (Click on IMC Website to register/join ; https://www.investormeetcompany.com/meetings/company-presentation-7 )",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.15",
          "thread_title": "IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T01:13:59.387750Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251649-jimbren--8665784",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966515",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Rehearsal during market hours revealed some (bad) news? Or was bad news given to some institutional investors in meetings this afternoon? Or a liquid lunch resulted in some loose talk?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-16T22:48:39.921084Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251649-jimbren--2113578",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966515",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Rehearsal during market hours revealed some (bad) news? Or was bad news given to some institutional investors in meetings this afternoon? Or a liquid lunch resulted in some loose talk?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T01:13:59.387724Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251652-jimbren--7184694",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966105",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Or just a stray negative comment at the AGM?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-16T22:48:39.921058Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251652-jimbren-56182082",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.966105",
        "source": "LSE_CHAT",
        "data": {
          "author": "jimbren",
          "content": "Or just a stray negative comment at the AGM?",
          "sentiment": 0.0,
          "engagement": "308",
          "price_at_post": "2.65",
          "thread_title": "RE: IMC Q&A Tonight at 5pm (Link below)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B1BFE2FD-2FE7-4D28-89A2-D2A09EEBDE9F"
        },
        "ingested_at": "2026-01-21T01:13:59.387698Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251800-RoyRoy--2744962",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.965692",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "Hmm, so (if i heard correctly) no longer pushing for a listing on the NASDAQ and will unwind all the work on that front ? \"Cost cutting\". Over the past 4 years there have been many great sounding words (Skillington is an excellent wordsmith) but IMO very little progress. Lots of time, effort, and money will I'm sure have been spent on preparing for NASDAQ listing. And for what...? I wonder if the management thought with all this buzz on AI, they could jump on the bandwagon, and with a high profile pharma NASDAQ listing see the share price rocket before cashing out after a takeover ... ? Pure speculation on my part obvisouly but it seems to me this company has focussed a lot of its recent effort  on a NAZ listing which has probably impacted the progress on the drug research side. When will we see genuine progress ? I just want to see some evidence of this company moving forward on the pharma... Happy to hear all view points and be corrected of course.",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "2.65",
          "thread_title": "U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-16T22:48:39.921032Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251800-RoyRoy-77874287",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.965692",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "Hmm, so (if i heard correctly) no longer pushing for a listing on the NASDAQ and will unwind all the work on that front ? \"Cost cutting\". Over the past 4 years there have been many great sounding words (Skillington is an excellent wordsmith) but IMO very little progress. Lots of time, effort, and money will I'm sure have been spent on preparing for NASDAQ listing. And for what...? I wonder if the management thought with all this buzz on AI, they could jump on the bandwagon, and with a high profile pharma NASDAQ listing see the share price rocket before cashing out after a takeover ... ? Pure speculation on my part obvisouly but it seems to me this company has focussed a lot of its recent effort  on a NAZ listing which has probably impacted the progress on the drug research side. When will we see genuine progress ? I just want to see some evidence of this company moving forward on the pharma... Happy to hear all view points and be corrected of course.",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "2.65",
          "thread_title": "U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-21T01:13:59.387671Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251838-Cashinti-67226816",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.965274",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Big sell of 11million shares is the reason for the 20% drop. If things weren't bad enough already.",
          "sentiment": 0.0,
          "engagement": "850",
          "price_at_post": "2.65",
          "thread_title": "RE: U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-16T22:48:39.921006Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251838-Cashinti--1517818",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.965274",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Big sell of 11million shares is the reason for the 20% drop. If things weren't bad enough already.",
          "sentiment": 0.0,
          "engagement": "850",
          "price_at_post": "2.65",
          "thread_title": "RE: U-turn on the NASDAQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C5DE5CE9-84A9-4706-8A57-CAFF7014D46F"
        },
        "ingested_at": "2026-01-21T01:13:59.387645Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251902-BurtonD-28169387",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964852",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=V42uSTAvgTI",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "2.65",
          "thread_title": "IMC presentation from 5pm tonight",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E96FAEEA-B656-4D87-AA55-A068B70FBF67"
        },
        "ingested_at": "2026-01-16T22:48:39.920979Z"
      },
      {
        "event_id": "SOCIAL-23Jun20251902-BurtonD-64734735",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964852",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=V42uSTAvgTI",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "2.65",
          "thread_title": "IMC presentation from 5pm tonight",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E96FAEEA-B656-4D87-AA55-A068B70FBF67"
        },
        "ingested_at": "2026-01-21T01:13:59.387619Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252035-Marcboug-48117621",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Are people honestly thinking this will come good or just so down it barely matters? What's the newsflow going to be here for the months ahead? They've pretty much admitted there won't be any = drift = fall below raise = capitulation; isn't this the most likely scenario here. How long do people keep buying that POLB-001 is worth anything at all? They hven't had a single approach in how many years? It's not really how pharma works when there is a genuine asset available.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-16T22:48:39.920953Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252035-Marcboug--5539576",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Are people honestly thinking this will come good or just so down it barely matters? What's the newsflow going to be here for the months ahead? They've pretty much admitted there won't be any = drift = fall below raise = capitulation; isn't this the most likely scenario here. How long do people keep buying that POLB-001 is worth anything at all? They hven't had a single approach in how many years? It's not really how pharma works when there is a genuine asset available.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T01:13:59.387593Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252136-HotChip--5820746",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964019",
        "source": "LSE_CHAT",
        "data": {
          "author": "HotChip",
          "content": "I don't buy the story, I sold out ages ago at a profit.",
          "sentiment": 0.0,
          "engagement": "959",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-16T22:48:39.920926Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252136-HotChip-26361191",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.964019",
        "source": "LSE_CHAT",
        "data": {
          "author": "HotChip",
          "content": "I don't buy the story, I sold out ages ago at a profit.",
          "sentiment": 0.0,
          "engagement": "959",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T01:13:59.387566Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252326-Marcboug--8575143",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.963615",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Did the massive fall coincide with the AGM? You have to wonder what was said there that made people realise it was done for",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-16T22:48:39.920900Z"
      },
      {
        "event_id": "SOCIAL-23Jun20252326-Marcboug-83841515",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.963615",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Did the massive fall coincide with the AGM? You have to wonder what was said there that made people realise it was done for",
          "sentiment": 0.0,
          "engagement": "113",
          "price_at_post": "2.65",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T01:13:59.387540Z"
      },
      {
        "event_id": "SOCIAL-24Jun20250851-Ironman2--9135264",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.963210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ironman22",
          "content": "Oh look the massive loser Marc is back. Thinking that just because someone has sold some shares that means it's all over.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-16T22:48:39.920874Z"
      },
      {
        "event_id": "SOCIAL-24Jun20250851-Ironman2-34700792",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.963210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ironman22",
          "content": "Oh look the massive loser Marc is back. Thinking that just because someone has sold some shares that means it's all over.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T01:13:59.387514Z"
      },
      {
        "event_id": "SOCIAL-24Jun20251129-Marcboug--7201787",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.962792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "No, I'm thinking that it's over because they've achieved nothing for years except pulling the wool over your eyes continuously. I'm thinking that it's over because if they had anything with any remote potential it would have been swallowed up years ago. I'm thinking it's over because they don't have a single company to partner them and even the terrible one that was going to, pulled out.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-16T22:48:39.920847Z"
      },
      {
        "event_id": "SOCIAL-24Jun20251129-Marcboug--7814893",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.962792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "No, I'm thinking that it's over because they've achieved nothing for years except pulling the wool over your eyes continuously. I'm thinking that it's over because if they had anything with any remote potential it would have been swallowed up years ago. I'm thinking it's over because they don't have a single company to partner them and even the terrible one that was going to, pulled out.",
          "sentiment": -0.5,
          "engagement": "113",
          "price_at_post": "2.90",
          "thread_title": "RE: Have People Not Tweaked Yet?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=92AA0A75-4375-4FB1-8D58-D829955E36C3"
        },
        "ingested_at": "2026-01-21T01:13:59.387487Z"
      },
      {
        "event_id": "SOCIAL-25Jun20251637-nessab--8960467",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.962383",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1073603/poolbeg-investor-backing-clears-the-path-for-development-and-deliver-brokers-say-1073603.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.20",
          "thread_title": "Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920821Z"
      },
      {
        "event_id": "SOCIAL-25Jun20251637-nessab-75612811",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.962383",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1073603/poolbeg-investor-backing-clears-the-path-for-development-and-deliver-brokers-say-1073603.html",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.20",
          "thread_title": "Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387461Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250852-UserStev-55782324",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961959",
        "source": "LSE_CHAT",
        "data": {
          "author": "UserSteve",
          "content": "Institutional investor bought a bit over \u00a31m worth of shares. That's a nice vote of confidence",
          "sentiment": 0.0,
          "engagement": "2,555",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920794Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250852-UserStev-53710070",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961959",
        "source": "LSE_CHAT",
        "data": {
          "author": "UserSteve",
          "content": "Institutional investor bought a bit over \u00a31m worth of shares. That's a nice vote of confidence",
          "sentiment": 0.0,
          "engagement": "2,555",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387434Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250911-ThinIce-34195425",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961547",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "One of CF\u2019s mates.",
          "sentiment": 0.0,
          "engagement": "496",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920767Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250911-ThinIce--1044286",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961547",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "One of CF\u2019s mates.",
          "sentiment": 0.0,
          "engagement": "496",
          "price_at_post": "3.55",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387408Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250936-stanleyb-51075688",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961124",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Unfortunately it appears that CF has lost the midas touch with Poolbeg..Hvivo not looking very good either since CF walked away at 30p...Glad I got out last year before the wheels fell off both..Good luck those holding. You never know Poolbegs Polb-001 might come Good?JAO Adyor.",
          "sentiment": 0.0,
          "engagement": "3,550",
          "price_at_post": "3.50",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920741Z"
      },
      {
        "event_id": "SOCIAL-26Jun20250936-stanleyb--6759755",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.961124",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Unfortunately it appears that CF has lost the midas touch with Poolbeg..Hvivo not looking very good either since CF walked away at 30p...Glad I got out last year before the wheels fell off both..Good luck those holding. You never know Poolbegs Polb-001 might come Good?JAO Adyor.",
          "sentiment": 0.0,
          "engagement": "3,550",
          "price_at_post": "3.50",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387381Z"
      },
      {
        "event_id": "SOCIAL-26Jun20251240-RoyRoy-64215396",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.960672",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "I don't understand your post ...  \"Hvivo not looking very good either since CF walked away\" Your use of the word _either_ here suggests that CF has \"walked away\" but infact the opposite is true. He's just upped his holding by \u00a3100k. Can you clarify your point ?",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "3.35",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920715Z"
      },
      {
        "event_id": "SOCIAL-26Jun20251240-RoyRoy--4521398",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:34.960672",
        "source": "LSE_CHAT",
        "data": {
          "author": "RoyRoy",
          "content": "I don't understand your post ...  \"Hvivo not looking very good either since CF walked away\" Your use of the word _either_ here suggests that CF has \"walked away\" but infact the opposite is true. He's just upped his holding by \u00a3100k. Can you clarify your point ?",
          "sentiment": 0.0,
          "engagement": "145",
          "price_at_post": "3.35",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387355Z"
      },
      {
        "event_id": "SOCIAL-29Jun20251257-NoAdvice--7088410",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.143524",
        "source": "LSE_CHAT",
        "data": {
          "author": "NoAdvices",
          "content": "Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed \u00a34.7 million equity raise and a series of high-impact developments across its key programmes. https://tinyurl.com/2bze5fnb",
          "sentiment": 0.0,
          "engagement": "128",
          "price_at_post": "3.30",
          "thread_title": "New Catalysts as POLB 001 Advances Toward the Clinic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=82CF4494-DD48-44FE-B271-71C1FA6FDB60"
        },
        "ingested_at": "2026-01-16T22:48:39.920689Z"
      },
      {
        "event_id": "SOCIAL-29Jun20251257-NoAdvice-55882567",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.143524",
        "source": "LSE_CHAT",
        "data": {
          "author": "NoAdvices",
          "content": "Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed \u00a34.7 million equity raise and a series of high-impact developments across its key programmes. https://tinyurl.com/2bze5fnb",
          "sentiment": 0.0,
          "engagement": "128",
          "price_at_post": "3.30",
          "thread_title": "New Catalysts as POLB 001 Advances Toward the Clinic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=82CF4494-DD48-44FE-B271-71C1FA6FDB60"
        },
        "ingested_at": "2026-01-21T01:13:59.387329Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251005-nessab-29743809",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.143117",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/PoolbegPharma/status/1939597489583116385/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.30",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-16T22:48:39.920662Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251005-nessab--5726007",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.143117",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/PoolbegPharma/status/1939597489583116385/photo/1",
          "sentiment": 0.0,
          "engagement": "726",
          "price_at_post": "3.30",
          "thread_title": "RE: Investor backing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E5AB59CF-D072-4C0E-9064-DC1DA0F9967F"
        },
        "ingested_at": "2026-01-21T01:13:59.387302Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251238-BurtonD--1018430",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.142699",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=YK6GXs1qUCs",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Shares Magazine investor presentation video :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=89872864-8F5F-4F5D-BE5C-D2685DD438FA"
        },
        "ingested_at": "2026-01-16T22:48:39.920636Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251238-BurtonD--8716690",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.142699",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.youtube.com/watch?v=YK6GXs1qUCs",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Shares Magazine investor presentation video :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=89872864-8F5F-4F5D-BE5C-D2685DD438FA"
        },
        "ingested_at": "2026-01-21T01:13:59.387276Z"
      },
      {
        "event_id": "SOCIAL-1Jul20251652-Bazzaman--7805882",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.142289",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bazzaman",
          "content": "Michael Kelly reducing his holdings, maybe losing patience with how long it is all taking here.",
          "sentiment": 0.0,
          "engagement": "6,095",
          "price_at_post": "3.30",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-16T22:48:39.920610Z"
      },
      {
        "event_id": "SOCIAL-1Jul20251652-Bazzaman--7465407",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.142289",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bazzaman",
          "content": "Michael Kelly reducing his holdings, maybe losing patience with how long it is all taking here.",
          "sentiment": 0.0,
          "engagement": "6,095",
          "price_at_post": "3.30",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-21T01:13:59.387250Z"
      },
      {
        "event_id": "SOCIAL-1Jul20252040-AIMMCC--2309494",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141870",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "I suspect it\u2019s a change in voting rights due to placing dilution, not sale of shares",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-16T22:48:39.920583Z"
      },
      {
        "event_id": "SOCIAL-1Jul20252040-AIMMCC--4466755",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141870",
        "source": "LSE_CHAT",
        "data": {
          "author": "AIMMCC",
          "content": "I suspect it\u2019s a change in voting rights due to placing dilution, not sale of shares",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "3.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=FED61946-BE2B-414F-88EA-D25DE8255CE2"
        },
        "ingested_at": "2026-01-21T01:13:59.387223Z"
      },
      {
        "event_id": "SOCIAL-3Jul20250651-BurtonD-47894634",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "cashed up and charging ahead : poolbeg pharma\u2019s value runway is clear.... full feature article and video link : **********************************/2025/07/poolbeg-pharma-plc-july-2025/ interview link only : https://youtu.be/pmbnlvwpxfc",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.25",
          "thread_title": "NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-16T22:48:39.920556Z"
      },
      {
        "event_id": "SOCIAL-3Jul20250651-BurtonD--2165110",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "cashed up and charging ahead : poolbeg pharma\u2019s value runway is clear.... full feature article and video link : **********************************/2025/07/poolbeg-pharma-plc-july-2025/ interview link only : https://youtu.be/pmbnlvwpxfc",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.25",
          "thread_title": "NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-21T01:13:59.387197Z"
      },
      {
        "event_id": "SOCIAL-3Jul20250852-ThinIce--7553176",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141007",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "I\u2019d love to ask: 1. Why this relatively small amount of money they now have compared to the \u00a320m+ they did have is expected to make all the difference, and 2. Whatever happened to their secondary revenue generating plans which they announced some 2+ years ago that never appeared to materialise.",
          "sentiment": 0.0,
          "engagement": "496",
          "price_at_post": "3.25",
          "thread_title": "RE: NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-16T22:48:39.920530Z"
      },
      {
        "event_id": "SOCIAL-3Jul20250852-ThinIce-97992382",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.141007",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "I\u2019d love to ask: 1. Why this relatively small amount of money they now have compared to the \u00a320m+ they did have is expected to make all the difference, and 2. Whatever happened to their secondary revenue generating plans which they announced some 2+ years ago that never appeared to materialise.",
          "sentiment": 0.0,
          "engagement": "496",
          "price_at_post": "3.25",
          "thread_title": "RE: NEW Q&A Interview with @TMSreach / Sarah Lowther",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=A5FA87A7-DA98-4911-A751-C53E22170C4B"
        },
        "ingested_at": "2026-01-21T01:13:59.387170Z"
      },
      {
        "event_id": "SOCIAL-7Jul20251103-BurtonD-84374573",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.140592",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.share-talk.com/poolbeg-pharma-new-capital-new-catalysts-as-polb-001-advances-in-the-clinic/",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Worth a read from ShareTalk Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=40297FC2-0811-4710-AFCB-751AE3BEBFDA"
        },
        "ingested_at": "2026-01-16T22:48:39.920503Z"
      },
      {
        "event_id": "SOCIAL-7Jul20251103-BurtonD--3998538",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.140592",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Https://www.share-talk.com/poolbeg-pharma-new-capital-new-catalysts-as-polb-001-advances-in-the-clinic/",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.30",
          "thread_title": "Worth a read from ShareTalk Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=40297FC2-0811-4710-AFCB-751AE3BEBFDA"
        },
        "ingested_at": "2026-01-21T01:13:59.387143Z"
      },
      {
        "event_id": "SOCIAL-8Jul20250904-BurtonD--7962074",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.140184",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "POLB are presenting at the @MelloEventsUK webinar \ud83d\udcc528 July at 5pm \ud83d\udd35Speakers: CEO & CFO \ud83d\udcbbVirtual Presentation Register to attend: https://www.tickettailor.com/events/melloeventslimited/1738551",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.25",
          "thread_title": "POLB at Mello!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1FB6780B-328C-431A-AE6C-32F39B2CAB45"
        },
        "ingested_at": "2026-01-16T22:48:39.920476Z"
      },
      {
        "event_id": "SOCIAL-8Jul20250904-BurtonD-52695272",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.140184",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "POLB are presenting at the @MelloEventsUK webinar \ud83d\udcc528 July at 5pm \ud83d\udd35Speakers: CEO & CFO \ud83d\udcbbVirtual Presentation Register to attend: https://www.tickettailor.com/events/melloeventslimited/1738551",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.25",
          "thread_title": "POLB at Mello!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1FB6780B-328C-431A-AE6C-32F39B2CAB45"
        },
        "ingested_at": "2026-01-21T01:13:59.387095Z"
      },
      {
        "event_id": "SOCIAL-16Jul20251019-BurtonD-30496995",
        "event_type": "social_post",
        "date": "2026-01-10T01:10:31.139736",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "POLB 001 is a Phase 2-ready, orally-administered p38 MAP Kinase inhibitor designed to prevent cancer immunotherapy-induced CRS, a severe, potentially life-threatening side effect of cancer immunotherapies. Check out our overview: \u2705Phase 2-ready oral small molecule \ud83d\udc49\u202fSelectively prevent excessive inflammation without immunosuppression \ud83d\udd2cFavourable safety and tolerability profile, and has demonstrated potent inhibition of CRS-related cytokines, such as TNF-\u03b1 and IL-6, in clinical and preclinical studies \ud83d\udcaaStrong patent portfolio \ud83d\ude80Awarded FDA Orphan Drug Designation \u26d4No approved therapy for CRS prevention \u2013 a >US$10bn market opportunity Learn more about POLB 001 in oncology here: https://www.poolbegpharma.com/pipeline/polb-001-oncology/",
          "sentiment": 0.0,
          "engagement": "2,699",
          "price_at_post": "3.15",
          "thread_title": "Worth some time to read\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=D0404776-88CF-4310-9280-2FEEECD69649"
        },
        "ingested_at": "2026-01-16T22:48:39.920450Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC--2943374",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-24T01:56:43.551535+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54-59869271",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-24T01:56:43.551572+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD-18700278",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-24T01:56:43.551608+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti--7895031",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551634+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-56307506",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551653+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--5391409",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551672+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66--7059426",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551690+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66--7059426",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551708+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--2726116",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-24T01:56:43.551726+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab-76753464",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-24T01:56:43.551744+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--1964829",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-24T01:56:43.551762+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD--1783711",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-24T01:56:43.551780+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce-18169106",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-24T01:56:43.551797+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--7839010",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551815+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--2808808",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-24T01:56:43.551832+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly-28590545",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-24T01:56:43.551851+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce-12865237",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-24T01:56:43.551869+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1-82595749",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551888+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19--3659331",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551906+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--3089892",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551924+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--8326126",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551942+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--7844851",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-24T01:56:43.551960+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce--5909161",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-24T01:56:43.551978+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--6378067",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-24T01:56:43.551995+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1--7261088",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-24T01:56:43.552014+00:00"
      },
      {
        "event_id": "RNS-28th Jan 2026-polb001l",
        "event_type": "rns_announcement",
        "date": "2026-01-29T10:02:49.380068+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "POLB 001 LPS Challenge Trial Paper Published",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/polb-001-lps-challenge-trial-paper-published-n3jxpmzsjn5eacj.html",
          "rns_number": "RNS Number : 6274Q",
          "full_content": "28 Jan 2026 07:00\nRNS Number : 6274Q\nPoolbeg Pharma PLC\n28 January 2026\nPoolbeg Pharma plc\nPeer-Reviewed POLB 001 LPS Challenge Trial Paper Published in\nFrontiers in Immunology\n28 January 2026-\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in\nFrontiers in Immunology.\nKey conclusions from the paper include:\n\u00b7\nPOLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers\n\u00b7\nPOLB 001 was safe and well tolerated across all dose levels\n\u00b7\nStudy confirms POLB 001 potently inhibits p38 MAPK driven cytokine responses\n\u00b7\nPublication endorses significant potential of POLB 001 with the interim data anticipated from the\nTOPICAL trial\nthis summer\nThe paper entitled,\n\"POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following\u00a0in vivo\u00a0LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study\"\nby Digna T. de Bruin, et al is available in\nFrontiers in Immunology\n,\nDOI:\nhttps://doi.org/10.3389/fimmu.2025.1684307\nThe bacterial lipopolysaccharide (\"LPS\") challenge trial was a randomised, double-blind, placebo-controlled study, examining POLB 001's ability to suppress both local and systematic inflammatory responses in healthy volunteers. Key findings include:\n\u00b7\nThe suppression of immune cell recruitment was most pronounced in neutrophils (72.4%-81.5%, p = 0.0091), classical monocytes (68.4%-73.6%, p = 0.0036), CD3+ T cells (56.4%-65.9%, p = 0.0047), and myeloid dendritic cells (59%-64.4%, p = 0.0174).\n\u00b7\nThe suppression of cytokine responses was most pronounced for TNF (35.3%-65.1%, p = 0.0099).\n\u00b7\nOverall, POLB 001 did not substantially modulate the intradermal LPS-driven increase in local erythema and perfusion.\n\u00b7\nPOLB 001 significantly reduced the IV LPS-driven increase in IL-6, IL-8, and TNF (37.7%-80.7%, all p < 0.0003), p38 MAPK phosphorylation levels in target cells (16.7%-60.9%, all p < 0.0001), and heart rate increase (4-9.3 bpm, p < 0.0001).\nAs\npreviously announced\n, the trial demonstrated that POLB 001 was safe and well-tolerated, with a clear dose-response relationship, inhibition of p38 MAPK activation, and reduction in all measured pro-inflammatory cytokines. The results agree with previous observations that POLB 001 has the potential to prevent an excessive immune response without ablating normal immune function.\nThe findings provide strong validation of POLB 001's method of action and supports its progression towards further clinical development. The publication further strengthens the rationale for POLB 001 as a potential solution for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (\"CRS\").\nPOLB 001 to prevent CRS\nThe Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of CRS, a potentially life-threatening side effect. As such, POLB 001 could make these treatments more accessible to a broader patient population, increase the number of patients that can receive these life-saving treatments, and reduce the burden on healthcare systems.\nJeremy Skillington, PhD, CEO of Poolbeg Pharma, said:\n\"The publication of peer-reviewed clinical data from our LPS challenge trial in Frontiers in Immunology is an important milestone for Poolbeg. The positive data from this trial highlights that oral treatment of POLB 001 holds great promise in addressing cancer immunotherapy-induced CRS and supports further clinical development of the asset, including the POLB 001 TOPICAL clinical trial.\"\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release S",
          "content_length": 8287
        },
        "ingested_at": "2026-01-29T10:02:49.380128+00:00"
      },
      {
        "event_id": "RNS-27th Jan 2026-exercise",
        "event_type": "rns_announcement",
        "date": "2026-01-29T10:02:49.380155+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Exercise of Options & Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/exercise-of-options-total-voting-rights-i2fpa9fcl6otpjl.html",
          "rns_number": "RNS Number : 5951Q",
          "full_content": "27 Jan 2026 14:30\nRNS Number : 5951Q\nPoolbeg Pharma PLC\n27 January 2026\nPoolbeg Pharma plc\nExercise of Options & Total Voting Rights\n27\nJanuary 2026 -\nPoolbeg Pharma\n(AIM: POLB, 'Poolbeg' or the 'Company'),\u00a0a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has issued and allotted a total of 7,903,778 new ordinary shares of 0.02 pence each in the capital of the Company (\"Ordinary Shares\") following the exercise of options by former employees of the Company.\nApplication has been made to the London Stock Exchange for the 7,903,778 new Ordinary Shares to be admitted to trading on AIM (\"Admission\") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2026.\nTotal Voting Rights\nAfter Admission, the total number of Ordinary Shares in issue will be\n705,103,778\nand the total number of voting rights will therefore be\n705,103,778\n. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n+44 (0) 207 183 1499\nir@poolbegpharma.com\nCavendish\u202fCapital Markets Ltd\u202f(NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward\u202f(ECM)\n+44 (0) 207 220 0500\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)Malachy McEntyre (Corporate Broking)\n+44 (0) 207 408 4090\nJ&E Davy\u202f(Joint Broker)\nAnthony Farrell,\u202fNiall Gilchrist\n+353 (0) 1 679 6363\nOptimum Strategic Communications\nNick Bastin,\u202fVici Rabbetts, Elena Bates\n+44 (0) 208 078 4357\npoolbeg@optimumcomms.com\nAbout Poolbeg Pharma plc\nPoolbeg Pharma\u00a0plc\u00a0(AIM: POLB) is a clinical-stage biopharmaceutical\u00a0company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).\u00a0As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.\nStay updated:\nWebsite\n|\nSign up for RNS alerts\n|\nPresentation\n|\nX\n|\nLinkedIn\nForward-Looking Statements\nThis announcement\u00a0may contain forward-looking statements and the words \"expect\", \"anticipate\", \"intends\", \"plan\", \"estimate\", \"aim\", \"forecast\", \"project\" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to ",
          "content_length": 5641
        },
        "ingested_at": "2026-01-29T10:02:49.380176+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma-43234291",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-01-29T10:03:02.376355+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris-75436015",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-01-29T10:03:02.376404+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti-58348313",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376447+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--4333512",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376487+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma-55398416",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376526+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb--2127725",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376565+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus--7024534",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376604+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD--2884947",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-29T10:03:02.376643+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--7397578",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-29T10:03:02.376682+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--3392273",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-29T10:03:02.376722+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-85705605",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-29T10:03:02.376759+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--5948562",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-29T10:03:02.376799+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab--2776877",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-29T10:03:02.376839+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD--6285854",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-29T10:03:02.376879+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130-82795855",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-29T10:03:02.376917+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66-67859939",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-29T10:03:02.376954+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly--4223815",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-29T10:03:02.376991+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD-27564859",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-01-29T10:03:02.377029+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma-24244474",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377068+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19--1220091",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377129+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma-88230001",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377169+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7--3609901",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377208+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54--1673465",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-29T10:03:02.377247+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54--4412362",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-29T10:03:02.377284+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti-14836487",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377335+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-66579839",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377372+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7--7219089",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377412+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug--8709241",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377450+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho-93733616",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377489+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD-33879647",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-29T10:03:02.377528+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan--2262948",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-29T10:03:02.377567+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD-37059445",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-29T10:03:02.377607+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit-35701269",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-29T10:03:02.377647+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD--1941868",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-29T10:03:02.377685+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC-26718919",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-01-29T10:03:02.377724+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan--5858580",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-29T10:03:02.377764+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19--6153405",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-01-29T10:03:02.377804+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly--1427060",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-01-29T10:03:02.377843+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-40353667",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.377882+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan--8577871",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-29T10:03:02.377921+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21--2368099",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.377959+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug--9179201",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.377998+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21--5948254",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.378038+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21-29904428",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.378077+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma--1321723",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.378132+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb--3325210",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.378170+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD--6908686",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-29T10:03:02.378209+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--2183216",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-01-29T10:03:02.378248+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19-80020320",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-01-29T10:03:02.378286+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD-66748964",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-01-29T10:03:02.378325+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC-37669126",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-29T10:03:02.378368+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54-36919426",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-29T10:03:02.378409+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD-41814922",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-29T10:03:02.378450+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-42637200",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378490+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-71904126",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378529+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti-75791484",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378568+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-22806348",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378608+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-22806348",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378647+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--1631259",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-29T10:03:02.378686+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--5351426",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-29T10:03:02.378725+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD-85501376",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-29T10:03:02.378764+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-16619696",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-29T10:03:02.378804+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce-56374791",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-29T10:03:02.378843+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--5154528",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.378882+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1-52943375",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-29T10:03:02.378920+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--5361558",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-29T10:03:02.378959+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce--6568442",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-29T10:03:02.379000+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1-48000305",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.379038+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19-71621567",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.379077+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--1123489",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.379131+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab-38749752",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.379171+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--6648248",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-29T10:03:02.379210+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-72706791",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-29T10:03:02.379250+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--2614022",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-29T10:03:02.379288+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-43977324",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-29T10:03:02.379327+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260755-Spuddyma-67230523",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:11.908857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-01-30T23:03:18.869310+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma-67230523",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-01-30T23:03:18.869345+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris-10535360",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-01-30T23:03:18.869366+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti-68581900",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869385+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--9032251",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869404+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma-47363078",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869427+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb-12616549",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869445+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus--1700715",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869464+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD-76886899",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-01-30T23:03:18.869482+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66-39833932",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-30T23:03:18.869500+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--5123543",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-30T23:03:18.869518+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb--6202177",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-30T23:03:18.869536+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--2291489",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-30T23:03:18.869554+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab--6118860",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-30T23:03:18.869573+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD--6620250",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-01-30T23:03:18.869591+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130-44221629",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-01-30T23:03:18.869609+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66-89593856",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-30T23:03:18.869627+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly--2264295",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-01-30T23:03:18.869645+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD-78692111",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-01-30T23:03:18.869663+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma-88888436",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869681+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19--2846389",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869699+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma-39458782",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869717+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7-75045466",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869734+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54--6750527",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-30T23:03:18.869752+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54-72397739",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-01-30T23:03:18.869770+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti--1612144",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869788+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-29086993",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869806+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7-85543776",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869825+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug-86965146",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869843+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho--3099710",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869861+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD--4324798",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-01-30T23:03:18.869879+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan-32795562",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-30T23:03:18.869897+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD--2650776",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-01-30T23:03:18.869915+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit-29208974",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-30T23:03:18.869933+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD-69937017",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-01-30T23:03:18.869951+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC-10403973",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-01-30T23:03:18.869968+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan--6517099",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-30T23:03:18.869986+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19-38747531",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-01-30T23:03:18.870003+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-47733039",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-01-30T23:03:18.870022+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6--2241189",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870040+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan-15811748",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-01-30T23:03:18.870058+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21--3821829",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870076+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug-46555068",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870095+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21-23018190",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870130+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21--8058315",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870149+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma-82295353",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870167+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb-44353597",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870185+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD-21307024",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-01-30T23:03:18.870204+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--1537316",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-01-30T23:03:18.870222+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19--5837344",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-01-30T23:03:18.870241+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD--7518079",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-01-30T23:03:18.870259+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC--8395521",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-30T23:03:18.870277+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54--8344084",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-30T23:03:18.870295+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD-25687149",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-01-30T23:03:18.870313+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti--3833033",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870331+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce--3266353",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870349+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti-38616483",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870367+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66--6028016",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870385+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66--6028016",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870404+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce-51061000",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-01-30T23:03:18.870422+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--4252875",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-30T23:03:18.870440+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--1914777",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-01-30T23:03:18.870458+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-25658148",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-01-30T23:03:18.870477+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce--3676351",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-01-30T23:03:18.870494+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--2925221",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870512+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--8090378",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-01-30T23:03:18.870530+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--3508908",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-30T23:03:18.870549+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce-12870658",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-01-30T23:03:18.870567+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--1068009",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870586+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19--3075896",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870607+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb-65522331",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870626+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab-55839504",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870644+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--2257027",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-01-30T23:03:18.870662+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-52498272",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-01-30T23:03:18.870680+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD-62269684",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-01-30T23:03:18.870698+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1--6232034",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-01-30T23:03:18.870716+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260916-BurtonD-42141636",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.134898",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udcc8 Positive momentum across biotech & pharma for 2026 \ud83e\ude7b\ud83d\udc8a\ud83d\udc89 @PoolbegPharma CEO Jeremy Skillington shared insights on the upbeat sentiment at this month\u2019s JPM Healthcare Week in San Francisco \u2014 featured in DDW Journal. The article highlights: \u2705 Strong sector-wide optimism \u2705 Growing confidence in pipelines & funding \u2705 A \u201cless talk, more action\u201d outlook for 2026 Great for #POLB and fantastic to be part of the conversation. \ud83d\udd17 Read more: https://www.ddw-online.com/jpm-2026-less-talk-and-more-action-40212-202601/",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Great article this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9D3089F2-D27A-4900-B678-C1DADCCCCB6D"
        },
        "ingested_at": "2026-02-06T22:59:41.594520+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260909-BurtonD--2518144",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.135371",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Big day coming up for leadership & innovation in pharma! @PoolbegPharma Executive Chairman Cathal Friel will be speaking at the Mini TED Talks session during the @PharmaMgrsInst Annual Pharma Summit 2026. \ud83d\udccd Croke Park, Dublin \ud83d\udcc5 26 March 2026 \u23f1\ufe0f 8:30am \u2013 4:00pm \ud83c\udfaf Theme: Transform & Thrive \u2014 exploring disruption, evolution & opportunity across healthcare. A great platform for #POLB \ud83d\udc49 Learn more & register: thepmi.com/events/pharma-\u2026",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Be good this. Should generate some buying interest\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F715B0E9-5710-4A5B-AEE3-D768F831F8AE"
        },
        "ingested_at": "2026-02-06T22:59:41.594561+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260755-Spuddyma-10907287",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:11.908857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-06T22:59:41.594600+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma-10907287",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-06T22:59:41.594638+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris--8801582",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-02-06T22:59:41.594674+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti--7068893",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594709+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--7968596",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594744+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma--9149477",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594781+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb--9456933",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594818+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus-83894723",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594857+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD--1559725",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-06T22:59:41.594896+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--3826270",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-06T22:59:41.594933+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe-44842925",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-06T22:59:41.594965+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-87135237",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-06T22:59:41.594999+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66-12865408",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-06T22:59:41.595032+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab--7146483",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-06T22:59:41.595063+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD--1947479",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-06T22:59:41.595093+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130-21302126",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-06T22:59:41.595134+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66-71472362",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-06T22:59:41.595168+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly--4211800",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-06T22:59:41.595200+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD-57123154",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-02-06T22:59:41.595229+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma-34410411",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595262+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19--6196309",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595293+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma--3986087",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595326+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7-24896078",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595359+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54-27739368",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-06T22:59:41.595393+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54--1972759",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-06T22:59:41.595426+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti--3876532",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595461+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug--7924731",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595495+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7--4346816",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595524+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug--9197721",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595554+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho-39065289",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595589+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD--4431384",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-06T22:59:41.595622+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan--5765778",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-06T22:59:41.595653+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD-13395422",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-06T22:59:41.595684+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit--6885503",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-06T22:59:41.595717+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD-28664491",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-06T22:59:41.595749+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC--6882296",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-02-06T22:59:41.595777+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan-15222146",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-06T22:59:41.595808+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19-38689603",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-02-06T22:59:41.595838+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-55626233",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-02-06T22:59:41.595864+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-75862798",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.595894+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan--4210266",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-06T22:59:41.595927+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21-54673173",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.595961+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug--5854582",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.595990+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21-61982828",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.596027+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21--8012296",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.596059+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma--8100916",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.596091+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb--3317034",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.596138+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD-70245404",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-06T22:59:41.596177+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--4686566",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-02-06T22:59:41.596217+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19-51745815",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-02-06T22:59:41.596256+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD--9220321",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-02-06T22:59:41.596295+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC--3801802",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-06T22:59:41.596334+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54--4209683",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-06T22:59:41.596359+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD--4010957",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-06T22:59:41.596382+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-32359178",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596421+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-91584231",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596457+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--1148406",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596478+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-15508881",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596509+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-15508881",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596542+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--7699882",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-06T22:59:41.596562+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--1520771",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-06T22:59:41.596580+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--3221554",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-06T22:59:41.596599+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD--6792502",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-02-06T22:59:41.596629+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce--8497038",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-02-06T22:59:41.596663+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--2391159",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596682+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--4890147",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-02-06T22:59:41.596701+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly-23756245",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-06T22:59:41.596719+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce--5749554",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-06T22:59:41.596738+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--9856108",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596773+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19-37406172",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596795+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb-11407862",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596814+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--4221589",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596832+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan--5727071",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-02-06T22:59:41.596851+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce--2572707",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-02-06T22:59:41.596869+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--4274876",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-06T22:59:41.596898+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-29193356",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-02-06T22:59:41.596923+00:00"
      },
      {
        "event_id": "RNS-9th Feb 2026-notifica",
        "event_type": "rns_announcement",
        "date": "2026-02-09T23:13:54.388619Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notification of Major Holdings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/POLB/notification-of-major-holdings-y7m4py9d7f1v43a.html",
          "rns_number": "RNS Number : 2957S",
          "full_content": "Today 15:13\nRNS Number : 2957S\nPoolbeg Pharma PLC\n09 February 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nPoolbeg Pharma PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nMichael Kelly\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n3 February 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n9 February 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.14%\n6.14%\n43,314,547\nPosition of previous notification (if\napplicable)\n5.03%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BKPG7Z60\n43,314,547\n6.14%\nSUBTOTAL 8. A\n43,314,547\n6.14%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMichael Kelly\n10. In case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nIreland\nDate of completion\n9 February 2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUPGPUPQGAB",
          "content_length": 4336
        },
        "ingested_at": "2026-02-09T23:13:54.388670Z"
      },
      {
        "event_id": "SOCIAL-Today1535-ThinIce-75320539",
        "event_type": "social_post",
        "date": "2026-02-09T23:13:59.256928",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Further good endorsement from Kelly.",
          "sentiment": 0.0,
          "engagement": "512",
          "price_at_post": "4.60",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5569C045-4288-4E20-A4D4-9C7CBAB4C4E2"
        },
        "ingested_at": "2026-02-09T23:14:05.555183+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260916-BurtonD-58325144",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.134898",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udcc8 Positive momentum across biotech & pharma for 2026 \ud83e\ude7b\ud83d\udc8a\ud83d\udc89 @PoolbegPharma CEO Jeremy Skillington shared insights on the upbeat sentiment at this month\u2019s JPM Healthcare Week in San Francisco \u2014 featured in DDW Journal. The article highlights: \u2705 Strong sector-wide optimism \u2705 Growing confidence in pipelines & funding \u2705 A \u201cless talk, more action\u201d outlook for 2026 Great for #POLB and fantastic to be part of the conversation. \ud83d\udd17 Read more: https://www.ddw-online.com/jpm-2026-less-talk-and-more-action-40212-202601/",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Great article this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9D3089F2-D27A-4900-B678-C1DADCCCCB6D"
        },
        "ingested_at": "2026-02-09T23:14:05.555219+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260909-BurtonD--1532930",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.135371",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Big day coming up for leadership & innovation in pharma! @PoolbegPharma Executive Chairman Cathal Friel will be speaking at the Mini TED Talks session during the @PharmaMgrsInst Annual Pharma Summit 2026. \ud83d\udccd Croke Park, Dublin \ud83d\udcc5 26 March 2026 \u23f1\ufe0f 8:30am \u2013 4:00pm \ud83c\udfaf Theme: Transform & Thrive \u2014 exploring disruption, evolution & opportunity across healthcare. A great platform for #POLB \ud83d\udc49 Learn more & register: thepmi.com/events/pharma-\u2026",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Be good this. Should generate some buying interest\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F715B0E9-5710-4A5B-AEE3-D768F831F8AE"
        },
        "ingested_at": "2026-02-09T23:14:05.555239+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260755-Spuddyma--7242628",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:11.908857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-09T23:14:05.555258+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma--7242628",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-09T23:14:05.555277+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris--7054287",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-02-09T23:14:05.555295+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti-50871846",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555314+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--7662355",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555331+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma--5907592",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555349+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb--1648782",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555368+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus--4223250",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555386+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD--8833086",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-09T23:14:05.555404+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--1697265",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-09T23:14:05.555422+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--9771610",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-09T23:14:05.555440+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb--4660419",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-09T23:14:05.555457+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--9111336",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-09T23:14:05.555475+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-29536052",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-09T23:14:05.555493+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD--9110935",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-09T23:14:05.555512+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130-81440637",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-09T23:14:05.555530+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66--5375515",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-09T23:14:05.555548+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly-72931513",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-09T23:14:05.555566+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD--8601353",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-02-09T23:14:05.555584+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma--3364111",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555603+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19-32365464",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555620+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma-51156604",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555638+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7-22406818",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555656+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54-12016488",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-09T23:14:05.555673+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54-65794054",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-09T23:14:05.555691+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti--1600763",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555709+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-23201708",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555727+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7-29504457",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555744+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug--6608780",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555762+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho--6833300",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555780+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD--1424042",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-09T23:14:05.555799+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan--7959156",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-09T23:14:05.555817+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD--4033476",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-09T23:14:05.555834+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit-22576012",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-09T23:14:05.555852+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD--7440248",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-09T23:14:05.555869+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC--5035556",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-02-09T23:14:05.555887+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan-11539644",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-09T23:14:05.555906+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19-21433822",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-02-09T23:14:05.555923+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-67773772",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-02-09T23:14:05.555942+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6--4809821",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.555960+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan--7712476",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-09T23:14:05.555978+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21-53071601",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.555995+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug--1343778",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556014+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21--2338806",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556032+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21-70571455",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556050+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma--5373945",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556068+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb-34022847",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556087+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD--2502740",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-09T23:14:05.556119+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19-83425570",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-02-09T23:14:05.556139+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19--6803081",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-02-09T23:14:05.556157+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD--2153560",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-02-09T23:14:05.556176+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC-65703724",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-09T23:14:05.556194+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54-72774377",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-09T23:14:05.556212+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD--6335452",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-09T23:14:05.556230+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-87415499",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556247+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-63900158",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556265+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--2970812",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556283+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-45970541",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556301+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-45970541",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556319+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce-86645272",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-09T23:14:05.556337+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--3070228",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-09T23:14:05.556355+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD-65483926",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-09T23:14:05.556373+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-26813489",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-02-09T23:14:05.556391+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce--6571828",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-02-09T23:14:05.556416+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--6440526",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556434+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1--3221190",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-02-09T23:14:05.556452+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--3321598",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-09T23:14:05.556471+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce-44671964",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-09T23:14:05.556489+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1-45107345",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556507+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19--3847717",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556525+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--3243401",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556543+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--4160271",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556561+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan-69828659",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-02-09T23:14:05.556579+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-35337142",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-02-09T23:14:05.556597+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD-83087769",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-09T23:14:05.556614+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-38376448",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-02-09T23:14:05.556632+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261535-ThinIce-29291382",
        "event_type": "social_post",
        "date": "2026-02-10T22:43:50.580315",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Further good endorsement from Kelly.",
          "sentiment": 0.0,
          "engagement": "514",
          "price_at_post": "4.60",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5569C045-4288-4E20-A4D4-9C7CBAB4C4E2"
        },
        "ingested_at": "2026-02-10T22:43:59.974888+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-ThinIce-29291382",
        "event_type": "social_post",
        "date": "2026-02-09T23:13:59.256928",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Further good endorsement from Kelly.",
          "sentiment": 0.0,
          "engagement": "512",
          "price_at_post": "4.60",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5569C045-4288-4E20-A4D4-9C7CBAB4C4E2"
        },
        "ingested_at": "2026-02-10T22:43:59.974932+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260916-BurtonD-66760858",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.134898",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udcc8 Positive momentum across biotech & pharma for 2026 \ud83e\ude7b\ud83d\udc8a\ud83d\udc89 @PoolbegPharma CEO Jeremy Skillington shared insights on the upbeat sentiment at this month\u2019s JPM Healthcare Week in San Francisco \u2014 featured in DDW Journal. The article highlights: \u2705 Strong sector-wide optimism \u2705 Growing confidence in pipelines & funding \u2705 A \u201cless talk, more action\u201d outlook for 2026 Great for #POLB and fantastic to be part of the conversation. \ud83d\udd17 Read more: https://www.ddw-online.com/jpm-2026-less-talk-and-more-action-40212-202601/",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Great article this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9D3089F2-D27A-4900-B678-C1DADCCCCB6D"
        },
        "ingested_at": "2026-02-10T22:43:59.974954+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260909-BurtonD-73368374",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.135371",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Big day coming up for leadership & innovation in pharma! @PoolbegPharma Executive Chairman Cathal Friel will be speaking at the Mini TED Talks session during the @PharmaMgrsInst Annual Pharma Summit 2026. \ud83d\udccd Croke Park, Dublin \ud83d\udcc5 26 March 2026 \u23f1\ufe0f 8:30am \u2013 4:00pm \ud83c\udfaf Theme: Transform & Thrive \u2014 exploring disruption, evolution & opportunity across healthcare. A great platform for #POLB \ud83d\udc49 Learn more & register: thepmi.com/events/pharma-\u2026",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Be good this. Should generate some buying interest\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F715B0E9-5710-4A5B-AEE3-D768F831F8AE"
        },
        "ingested_at": "2026-02-10T22:43:59.974973+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260755-Spuddyma-51189336",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:11.908857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-10T22:43:59.974993+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma-51189336",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-10T22:43:59.975012+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris-55526520",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-02-10T22:43:59.975030+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti-13587212",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975049+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--1227087",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975068+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma-33786897",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975086+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb--4344569",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975129+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus-69531091",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975153+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD-78895563",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-10T22:43:59.975172+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66--3585908",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-10T22:43:59.975190+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe--2039217",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-10T22:43:59.975208+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-64974022",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-10T22:43:59.975226+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--6665697",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-10T22:43:59.975244+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-22666999",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-10T22:43:59.975262+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD-78803867",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-10T22:43:59.975279+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130-41795800",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-10T22:43:59.975298+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66-62546369",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-10T22:43:59.975316+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly--6561981",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-10T22:43:59.975335+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD--2223937",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-02-10T22:43:59.975353+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma-29130417",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975371+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19-26657103",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975389+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma--1125141",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975407+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7-65074996",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975425+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54-89502890",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-10T22:43:59.975443+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54--7487401",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-10T22:43:59.975461+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti-29603231",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975478+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-62715396",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975496+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7--1059302",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975514+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug-79044823",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975532+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho--8621859",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975549+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD--1863620",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-10T22:43:59.975568+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan-84889570",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-10T22:43:59.975586+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD--4447949",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-10T22:43:59.975603+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit-71187635",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-10T22:43:59.975621+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD-12475816",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-10T22:43:59.975638+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC-24905516",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-02-10T22:43:59.975656+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan--2019268",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-10T22:43:59.975674+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19--5739440",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-02-10T22:43:59.975693+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-14017427",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-02-10T22:43:59.975711+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-25430694",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975729+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan-38400412",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-10T22:43:59.975748+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21--4877029",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975766+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug--6656888",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975784+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21-12850130",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975803+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21--5740755",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975820+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma-24545014",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975838+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb-93085601",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975856+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD--8886813",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-10T22:43:59.975874+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--3477837",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-02-10T22:43:59.975893+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19-71352545",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-02-10T22:43:59.975910+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD-38725187",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-02-10T22:43:59.975929+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC-53859619",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-10T22:43:59.975947+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54--3442094",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-10T22:43:59.975965+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD--3371188",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-10T22:43:59.975983+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti--1563083",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976001+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce-15997226",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976019+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti-75449470",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976038+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66--4699476",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976056+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66--4699476",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976075+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce--4553978",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-10T22:43:59.976093+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab--9613504",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-10T22:43:59.976132+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD--3067376",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-10T22:43:59.976150+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-14874317",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-02-10T22:43:59.976168+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce-71920487",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-02-10T22:43:59.976186+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6--1340026",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976204+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1-56554065",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-02-10T22:43:59.976222+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--5977646",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-10T22:43:59.976241+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce--8083168",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-10T22:43:59.976259+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--7811233",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976278+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19-16155720",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976296+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--3662508",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976314+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--1331812",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976338+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan-21524533",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-02-10T22:43:59.976357+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-53777349",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-02-10T22:43:59.976375+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--5367007",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-10T22:43:59.976393+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1-50638798",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-02-10T22:43:59.976412+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261535-ThinIce--4210585",
        "event_type": "social_post",
        "date": "2026-02-10T22:43:50.580315",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Further good endorsement from Kelly.",
          "sentiment": 0.0,
          "engagement": "514",
          "price_at_post": "4.60",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5569C045-4288-4E20-A4D4-9C7CBAB4C4E2"
        },
        "ingested_at": "2026-02-11T16:50:40.664581+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-ThinIce--4210585",
        "event_type": "social_post",
        "date": "2026-02-09T23:13:59.256928",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Further good endorsement from Kelly.",
          "sentiment": 0.0,
          "engagement": "512",
          "price_at_post": "4.60",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5569C045-4288-4E20-A4D4-9C7CBAB4C4E2"
        },
        "ingested_at": "2026-02-11T16:50:40.664607+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260916-BurtonD-31774984",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.134898",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udcc8 Positive momentum across biotech & pharma for 2026 \ud83e\ude7b\ud83d\udc8a\ud83d\udc89 @PoolbegPharma CEO Jeremy Skillington shared insights on the upbeat sentiment at this month\u2019s JPM Healthcare Week in San Francisco \u2014 featured in DDW Journal. The article highlights: \u2705 Strong sector-wide optimism \u2705 Growing confidence in pipelines & funding \u2705 A \u201cless talk, more action\u201d outlook for 2026 Great for #POLB and fantastic to be part of the conversation. \ud83d\udd17 Read more: https://www.ddw-online.com/jpm-2026-less-talk-and-more-action-40212-202601/",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Great article this for #POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9D3089F2-D27A-4900-B678-C1DADCCCCB6D"
        },
        "ingested_at": "2026-02-11T16:50:40.664631+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260909-BurtonD-33998055",
        "event_type": "social_post",
        "date": "2026-02-06T22:59:35.135371",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Big day coming up for leadership & innovation in pharma! @PoolbegPharma Executive Chairman Cathal Friel will be speaking at the Mini TED Talks session during the @PharmaMgrsInst Annual Pharma Summit 2026. \ud83d\udccd Croke Park, Dublin \ud83d\udcc5 26 March 2026 \u23f1\ufe0f 8:30am \u2013 4:00pm \ud83c\udfaf Theme: Transform & Thrive \u2014 exploring disruption, evolution & opportunity across healthcare. A great platform for #POLB \ud83d\udc49 Learn more & register: thepmi.com/events/pharma-\u2026",
          "sentiment": 0.0,
          "engagement": "2,719",
          "price_at_post": "4.40",
          "thread_title": "Be good this. Should generate some buying interest\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F715B0E9-5710-4A5B-AEE3-D768F831F8AE"
        },
        "ingested_at": "2026-02-11T16:50:40.664649+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260755-Spuddyma--2072966",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:11.908857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-11T16:50:40.664668+00:00"
      },
      {
        "event_id": "SOCIAL-Today0755-Spuddyma--2072966",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.434420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Https://youtu.be/-XDx2j4DlN8?si=HXItS9T0ptZxF68v",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.45",
          "thread_title": "Interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=A57A7F0F-BAC2-4024-91EE-9859971E7BF6"
        },
        "ingested_at": "2026-02-11T16:50:40.664686+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262122-Farris-84819598",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.435243",
        "source": "LSE_CHAT",
        "data": {
          "author": "Farris",
          "content": "Not currently involved with POLb ,but always followed, would like to invest,but no spare cash at the moment. I am currently invested in EGT, another Cathal friel company in which he is heavily invested,but news from EGT has been non existent , he said on ipo,that he was hoping to get to cash generative within a year, oh dear,that never happened, anyone on this thread care to enlighten me,thanks. I would ask on the EGT thread, but no one is there.",
          "sentiment": 0.0,
          "engagement": "420",
          "price_at_post": "4.40",
          "thread_title": "Egt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=8DBF275A-487D-440D-BB4B-FAEE5BDA3684"
        },
        "ingested_at": "2026-02-11T16:50:40.664705+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262114-Cashinti-80630460",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.436246",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "There will be a Proactive talk with Jeremy and Liam in the next couple of days which will tell of data being first given from April 1st to big Pharma who expressed an interest in a deal with Poolbeg. Trial preparation is said to be 80% complete and ready for 1st dosing with 001 already given to the hospitals. First data will be 2 weeks after 1st patient dosed so if positive result of the blocking of CRS big Pharma are waiting to deal. We will see what further information we will learn from the Proactive get together.",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664723+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262106-GeordieC--8718720",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437012",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Totally agree Spudd, positive tropical trial results and this should fly given a potential $5bn+ market for a life changing drug. Big Pharma will be all over this faster than an aussie bush fire....could send the SP into the stratosphere. If only I had more cash to invest in it right now...Roll on Summer !",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664741+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261451-Spuddyma--8424638",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.437784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "I would say it is more strong evidence of the effectiveness of Polb-001. A positive Topic trial with results due  this summer  will leave big Pharma jumping all over Poolbeg. Jmo !",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664759+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261421-stanleyb-88709382",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.438555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Was here previously from demerger but got out a couple of years back, just seen the RNS...more potential jam tomorrow? \ud83d\ude33 Success of Polb 001 will depend if there's enough cash left to get a JV before the cash pot is used?  JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664777+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261005-Sisyphus-45275594",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.439323",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "And yet the SP is staying the same, bizarre. Maybe we'll see a raise later today once the US wakes up?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "4.40",
          "thread_title": "RE: READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664796+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-BurtonD--7667579",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:54.440172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83e\uddea\ud83d\udd25 \u00a330m mkt cap vs $5bn+ peak sales potential?! \ud83e\udd2f @PoolbegPharma just landed peer-reviewed clinical data in Frontiers in Immunology \u2705 #POLB-001: \u2705 Cuts key inflammatory markers \u2705 Strong safety profile \u2705 Validates CRS prevention potential \u2705 Supports cancer immunotherapy rollout worldwide Interim TOPICAL data coming this summer\u2026 \ud83d\udc40 Still under the radar? Maybe not for long. \ud83d\ude80\ud83d\udc8a londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.05",
          "thread_title": "READ THIS RNS - CRAZY good this!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=36B0E779-9C59-4C61-AE32-20D9BB6358CF"
        },
        "ingested_at": "2026-02-11T16:50:40.664814+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251226-Lewis66-87356428",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.433269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Kenny, It seems that it's been intentionally being held down.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "3.60",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-11T16:50:40.664832+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-PurpleKe-38896612",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434045",
        "source": "LSE_CHAT",
        "data": {
          "author": "PurpleKenny",
          "content": "Its baffling , the share price went down",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "3.65",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-11T16:50:40.664849+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20250827-stanleyb-55391009",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.434789",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Current value sub 2p? Just a thought?",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.75",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-11T16:50:40.664867+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251138-Lewis66--8346101",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.435572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "I\u2019ll be annoyed if it doesn\u2019t jump up a good percentage today after this news. Yesterday\u2019s last minute drop was frustrating.",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.05",
          "thread_title": "RE: Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-11T16:50:40.664885+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251033-nessab-18500079",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.436342",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/971361/poolbeg-pharma-active-on-several-fronts-powered-by-capital-light-model-971361.html",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.05",
          "thread_title": "RE: POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-11T16:50:40.664903+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250740-BurtonD--2947538",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437161",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Great news that the European Patent Office has granted Poolbeg\u2019s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read it here: https://www.londonstockexchange.com/news-article/POLB/polb-001-european-patent-granted/17335887?showDisclaimer=true POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced CRS and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.68",
          "thread_title": "POLB 001 European Patent granted  -  Further strengthens Poolbeg's ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=44099CCA-181A-4866-8AF7-EE01CA184FBD"
        },
        "ingested_at": "2026-02-11T16:50:40.664920+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250721-Marty130--5627994",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.437920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "More timely news..  Patient granted..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "3.68",
          "thread_title": "Excellent news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=4B1C6815-9F42-4A06-ABE5-1F8673D55FF0"
        },
        "ingested_at": "2026-02-11T16:50:40.664938+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251053-Lewis66-66976374",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.438702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lewis66",
          "content": "Lets hope so. Although the trades aren't massive. - could just be a few people playing pump and dump?",
          "sentiment": 0.0,
          "engagement": "99",
          "price_at_post": "4.10",
          "thread_title": "RE: Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-11T16:50:40.664956+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251026-formerly-89682998",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.439491",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "News expected?",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "4.10",
          "thread_title": "Share Price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=1A935D17-79C6-4110-8639-532929E1B6DB"
        },
        "ingested_at": "2026-02-11T16:50:40.664974+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251135-BurtonD--5049583",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440359",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 Great feature in the Irish Examiner today as CEO Jeremy Skillington, PhD and Executive Chair Cathal Friel discuss all things @PoolbegPharma \ud83d\udc8a \ud83d\udd25 Highlights: \u2022\t\ud83c\uddec\ud83c\udde7 Upcoming UK clinical trial of POLB 001, aiming to prevent severe side effects from cancer immunotherapies \u2014 helping more patients access life-saving treatment closer to home. \u2022\t\ud83d\udca5 Progressing our oral GLP-1 therapy for obesity, with proof-of-concept data expected H1 2026. \u2022\t\ud83c\udfaf Strategy built on scientific excellence + smart deal-making, delivering value through innovation and patient-focused outcomes. Read more \ud83d\udc47 \ud83d\udd17 https://www.irishexaminer.com/business/companies/arid-41731050.html #POLB #Biotech #Immunotherapy #CancerResearch #Innovation #GLP1 #ClinicalTrials #Healthcare",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.15",
          "thread_title": "Great article out today\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=B19D2686-22AE-48EE-AE94-D670DB033D82"
        },
        "ingested_at": "2026-02-11T16:50:40.664992+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250909-Spuddyma-36605196",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.440911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Hello Mary Nice post. Where did the write  up come from. It is very positive indeed.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665009+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20250833-MaryBr19--6733492",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441391",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Key Recent Developments Investor Sentiment: Poolbeg's share price is experiencing positive movement, attributed to anticipated clinical trial progress and collaborations with established industry players like J&J. Phase 2a Trial: Poolbeg is set to commence a Phase 2a trial for POLB 001 to mitigate cytokine release syndrome, which could significantly enhance the safety profile of bispecific antibody therapies. Success in this trial has the potential to attract further investments and partnerships. Strategic Shift at J&J: J&J's announcement of spinning off its orthopaedics business indicates a strategic realignment, possibly affecting its partnerships and investment focus in biotech and pharmaceuticals. This shift could enhance J&J's capability to push innovative therapies forward, encouraging better collaboration opportunities with firms like Poolbeg. Market Evidence: Analysts suggest that J&J\u2019s recent financial performance and future plans might stabilize its stock while opening pathways for significant partnerships, particularly in immunotherapy domains, which aligns with Poolbeg's strategic interests. This combination of factors is likely influencing investor confidence and driving interest in Poolbeg Pharma's stock.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665027+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251107-Spuddyma-61157818",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.441832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Agree totally with you Doc. Well said.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665044+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250947-doc7--1900698",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442279",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Better to be gullible than just plain nasty.",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665061+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250819-Westy54--7925636",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.442770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Apologies, appears the word \" Groups\" Is too challenging for me on a new phone :)",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "RE: Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-11T16:50:40.665079+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20250817-Westy54-49192956",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Morning everyone, just wondering whether there are any telegram of WhatsApp groups for poolbeg, please? Would appreciate a link to either if they exist.  Many thanks",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "3.55",
          "thread_title": "Chat Grouos",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=AD9C0167-C10E-4D67-9D05-45AB53696670"
        },
        "ingested_at": "2026-02-11T16:50:40.665114+00:00"
      },
      {
        "event_id": "SOCIAL-18Oct20251246-Cashinti--4961437",
        "event_type": "social_post",
        "date": "2026-01-29T10:02:59.443627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Has anyone had confirmation from the company that the drug supplier partners in the upcoming trial for 001 are indeed Janssen a subsidiary of J&J. The other potential offer for supply was Pfizer .Two big heavy hitters in the Pharma world. If confirmed this trial will really be in the spotlight .",
          "sentiment": 0.0,
          "engagement": "853",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665138+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20250353-Marcboug-11394161",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.335973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "If you think the trial data will come in H1 you are even more gullible than you seem",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665156+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252311-doc7-61489677",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.336830",
        "source": "LSE_CHAT",
        "data": {
          "author": "doc7",
          "content": "Not a great guess at all Marcb, as you would know if you bothered to report the facts. There are two sets of clinical trial reports due in H1 2026.  If either is positive it will be transformational to the sp. The POLB001 trial has a good chance as phase 1 studies showed excellent dose-dependent effects on cytokines. Between now and then  the sp is likely to be a little stagnant, but fall to 2.5p?? No way.  ONLY if the trials are negative.  But not before data is out.  And expectation will push the sp before results say. Your negativity is unfounded and not based on fact. But presumably  your dialogue suits your needs so why let the truth get in the way?",
          "sentiment": 0.0,
          "engagement": "153",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665173+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20251152-Marcboug-61400397",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.337661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "Haha where are you getting that nonsense 95% from? Just meaningless hyping before you sell out. This has no meaningful news now for 1yr+ and aim abhors a vacuum. Below 2.5 in the next 12 months is a much better guess.",
          "sentiment": 0.0,
          "engagement": "116",
          "price_at_post": "3.50",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665191+00:00"
      },
      {
        "event_id": "SOCIAL-10Oct20251609-silverho-70044766",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.338470",
        "source": "LSE_CHAT",
        "data": {
          "author": "silverhorse",
          "content": "The chances of a good deal here is pretty high 95%  hopefully a buy out  20p would do or more the better",
          "sentiment": 0.0,
          "engagement": "3,637",
          "price_at_post": "3.55",
          "thread_title": "RE: Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665209+00:00"
      },
      {
        "event_id": "SOCIAL-6Oct20251424-BurtonD-11692399",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339319",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udd14 This Thursday, 9 Oct \u2014 14:15 #POLB CEO Jeremy Skillington on stage at Optimum\u2019s Healthcare Investor Conference (The King\u2019s Fund, London): \u201cThriving in the tough times: scaling smart and staying strong.\u201d With IBM Consulting & Oxford Nanopore. Register: optimumcomms.com/irconference20\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.40",
          "thread_title": "Don\u2019t miss this from the Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=E4FA1FE4-4C37-40B9-87D8-75E5887A8FD7"
        },
        "ingested_at": "2026-02-11T16:50:40.665227+00:00"
      },
      {
        "event_id": "SOCIAL-4Oct20251018-Troajan--8274791",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.339995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079690/poolbeg-pharma-ceo-on-polb001-glp-1-trial-plans-icymi-1079690.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "3.40",
          "thread_title": "RE: Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-11T16:50:40.665245+00:00"
      },
      {
        "event_id": "SOCIAL-1Oct20251214-BurtonD-26923053",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.340747",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "We will be attending a retail investor lunch and invite you to join the discussion. \ud83d\udcc5 7 October at 12:30pm \ud83d\udccdLondon City \ud83d\udd35Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to secure your seat at the table. We look forward to seeing you there. #POLB #Investors #AIM #InvestorLunch #London #Markets",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.60",
          "thread_title": "Fancy lunch with the #POLB Team?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=52910B8E-DD3D-4783-8237-09EC47E3103A"
        },
        "ingested_at": "2026-02-11T16:50:40.665262+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20251319-Bullsit--5722531",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.341474",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bullsit",
          "content": "Https://youtu.be/BngSgr6EQo8?si=7H2rwjSSXcmu4lUl",
          "sentiment": 0.0,
          "engagement": "1,346",
          "price_at_post": "3.85",
          "thread_title": "RE: IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-11T16:50:40.665280+00:00"
      },
      {
        "event_id": "SOCIAL-30Sep20250735-BurtonD--3537236",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.342278",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Follow #POLB \u2049\ufe0f\ud83d\udc40 Missed yesterday\u2019s @InvestorMeetCo webinar with @PoolbegPharma CEO Jeremy Skillington, PhD and Principal Scientist Liam Tremble? Catch the replay here : youtube.com/watch?v=BngSgr\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.00",
          "thread_title": "IMC Investor update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=12605ACC-1A1C-4018-A898-4333B09B97A8"
        },
        "ingested_at": "2026-02-11T16:50:40.665297+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20251749-GeordieC-38999076",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343073",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Great update from Jeremy and the team. They seem extremely positive the results will be favorable. I think this could be HUGE and the share price could potentially sky rocket !!! I'm definitely buying more, this price is a steal IMO. Sooooo much potential upside !",
          "sentiment": 0.5,
          "engagement": "193",
          "price_at_post": "3.95",
          "thread_title": "Update Presentation - very positive",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=78C98A5B-0FD0-4D2B-B19C-8B2944310917"
        },
        "ingested_at": "2026-02-11T16:50:40.665314+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250754-Troajan-27019929",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.343878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079306/poolbeg-pharma-ceo-on-active-h1-polb-001-glp-1-trial-plans-1079306.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "RE: Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-11T16:50:40.665332+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250715-MaryBr19--4881158",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.344676",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Outlook Our programmes are in areas of high interest within the pharmaceutical industry. We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients' homes and, as a result, making these life-saving treatments available to more patients. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS which can be potentially life threatening. This is supported by strong pre-clinical and clinical data generated to date, robust intellectual property, global rights, and FDA Orphan Drug Designation for POLB 001. In addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a differentiated approach within one of the world's largest markets. I am excited about Poolbeg's future; we've entered a catalyst-rich period, supported by a robust cash balance that provides runway through to 2027. With a clear plan to deliver shareholder value through our clinical programmes, we are led by a proven team with expertise in clinical execution and deal-making and we see strong potential to secure partnerships based on positive data from our upcoming trials.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.90",
          "thread_title": "Catalyst-rich period",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=F329F89D-0655-4329-A480-D477C6E33662"
        },
        "ingested_at": "2026-02-11T16:50:40.665350+00:00"
      },
      {
        "event_id": "SOCIAL-29Sep20250707-formerly-59633175",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.345472",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "\"Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones\" Most reassuring!  Just a matter of patience imo.",
          "sentiment": 0.0,
          "engagement": "1,647",
          "price_at_post": "3.90",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=57E78622-2E86-4DDB-8FA4-C0DDB4238556"
        },
        "ingested_at": "2026-02-11T16:50:40.665368+00:00"
      },
      {
        "event_id": "SOCIAL-27Sep20252156-Shreddy6-33096193",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.346248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "Yawn.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665387+00:00"
      },
      {
        "event_id": "SOCIAL-26Sep20250757-Troajan--3175340",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1079233/poolbeg-pharma-kicks-off-polb001-phase-2a-trial-with-specialist-partner-1079233.html",
          "sentiment": 0.0,
          "engagement": "125,642",
          "price_at_post": "4.00",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=3AB897BB-7B5F-4210-A951-D884D6259396"
        },
        "ingested_at": "2026-02-11T16:50:40.665405+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251046-Tii21--2685103",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.347790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Another bell end nob jockey",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665424+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251043-Marcboug-82249937",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.348556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marcbought",
          "content": "So people realise the little rise is done and this will now drift for a year? Buy on expectation, sell on news.",
          "sentiment": -0.5,
          "engagement": "116",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665442+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251040-Tii21--7093207",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.349334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "How Ironic Stanley puts on the end of his post 'dyor'!!",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665460+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251037-Tii21-10743372",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "Well if you looked at the RNS dated 20/05/2025 on that placing, they raised \u00a34.715 million, and cash runway is until 2027. Also, since then a director increased her holding! Maybe if you looked instead of just turning up and not investing you wouldnt look so stupid. I just dont understand why people keep going on boards saying placing/funds needed when they have no intention on investing? What is wrong with some people??!! Sharebel end rings to mind, the biggest 'b'anker of them all.",
          "sentiment": 0.0,
          "engagement": "450",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665477+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251036-Spuddyma--7198966",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.350879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Spuddymadrid",
          "content": "Would absolutely not agree with you. This company will be bought by a big Pharma or else a very handsome contract for Polb-001 will  be signed. No need for cash until 2027. It will be game set and match in 2026",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665495+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20251025-stanleyb-10025287",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.351639",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "Another round of fundraising before any income for Polb-001 don't you think? JAO Adyor \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "3,715",
          "price_at_post": "3.90",
          "thread_title": "RE: Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665513+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250902-BurtonD--1103369",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.352464",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\ude80 @PoolbegPharma (#POLB 3.9p) update \u2022 POLB 001 Phase 2a trial agreement signed with specialist blood cancer org \u2022 BsAb drug secured at NO cost (multi-million \u00a3 value) \u2022 Trial at The Christie NHS Foundation Trust led by Dr Emma Searle \u2022 Data 2026 | Cash runway into 2027 \u2022 Targeting CRS \u2013 a life-threatening side effect in cancer immunotherapy \u2022 Potential to transform treatment delivery & patient outcomes Full RNS \ud83d\udc49 londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "4.30",
          "thread_title": "Great news for POLB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=7DE597E1-E2F5-4667-8BD2-59ADEF0B2E6C"
        },
        "ingested_at": "2026-02-11T16:50:40.665531+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250811-MaryBr19--6663823",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.353300",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Market Opportunity The demand for effective CRS prevention solutions is driven by the rapid growth of CRS-inducing cancer immunotherapies with more than 70% of patients receiving certain cancer immunotherapies affected. Independent research has identified a market opportunity of >US$10 billion for POLB 001 and as such, the Company sees strong potential for partnering on positive data from the forthcoming trial. The recent FDA Orphan Drug Designation further validates POLB 001's scientific rationale and enhances its commercial appeal for prospective partners. Investor presentation Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform on Monday 29 September 2025 at 5pm. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Presentation Monday 29th 5pm - should track higher for the next days",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=95FCAF19-4166-4DD6-ACB4-AB270AB713C5"
        },
        "ingested_at": "2026-02-11T16:50:40.665549+00:00"
      },
      {
        "event_id": "SOCIAL-25Sep20250808-MaryBr19--4048255",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354182",
        "source": "LSE_CHAT",
        "data": {
          "author": "MaryBr190",
          "content": "Https://www.londonstockexchange.com/news-article/POLB/polb-001-phase-2a-trial-update/17247751 ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (\"ACT\"), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate. The Phase 2a first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, in particular its ability to reduce the incidence of Cytokine Release Syndrome (\"CRS\") in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. The Company already has sufficient supply of Good Manufacturing Practice (\"GMP\") grade POLB 001 and this agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The Company's forecast cash runway extends into 2027, providing more than adequate funding to achieve key clinical development milestones. The Directors believe that POLB 001 has the potential to transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: \"The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the Company, are major milestones for the upcoming POLB 001 Phase 2a trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our share",
          "sentiment": 0.5,
          "engagement": "10,827",
          "price_at_post": "3.65",
          "thread_title": "Great news : No wonder this is flying today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=90D68B5F-95CA-40A4-BF66-773F99D62BAD"
        },
        "ingested_at": "2026-02-11T16:50:40.665566+00:00"
      },
      {
        "event_id": "SOCIAL-23Sep20250639-BurtonD-63874111",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:02.354985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\u201c\u2026this means we could potentially prevent crs before it starts. patients could take polb 001, then receive their cancer immunotherapy, then go home, without the hospital stay\u2026\u201d **********************************/2025/09/poolbeg-pharma-plc-3/",
          "sentiment": 0.0,
          "engagement": "2,710",
          "price_at_post": "3.90",
          "thread_title": "Feature Article From @TMsreach ;POLB 001 : Tackling Cancer Therapy\ufffd...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&share=POLB&thread=C2B1FC4B-46BF-4A20-9ADA-1ECD31116068"
        },
        "ingested_at": "2026-02-11T16:50:40.665584+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261601-GeordieC-23893162",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.532982",
        "source": "LSE_CHAT",
        "data": {
          "author": "GeordieChris",
          "content": "Westy, I think 2026 could be game changing for POLB (assuming positive trail data). Hopefully we are all off to the races later this year..",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "4.25",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-11T16:50:40.665603+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260735-Westy54--1968421",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Westy54",
          "content": "Https://www.youtube.com/watch?v=pplOropUODQ",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "4.30",
          "thread_title": "RE: Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-11T16:50:40.665622+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261028-BurtonD--1133996",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.533906",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "\ud83d\udc40 #POLB CEO Jeremy Skillington caught up after JP Morgan Healthcare Week in San Francisco to discuss key themes shaping biotech & pharma into 2026. Key takeaways: \u2022 Growing optimism, deal flow & rising biotech influence from China \u2022 Pharma focused on replenishing pipelines ahead of patent cliffs \u2022 Cancer immunotherapies a major focus across JPM \u2022 Strong momentum behind GLP-1 transitioning to oral formats \u2022 Poolbeg\u2019s strategy heading into 2026 Watch the full @PoolbegPharma interview \ud83d\udc47 youtube.com/watch?v=pplOro\u2026 #Biotech #Healthcare #Pharma #JPMorgan #LifeSciences #Poolbeg",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.65",
          "thread_title": "Worth a watch - POLB / JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=2522E953-ECCC-4514-B51D-17F54EBDFFE4"
        },
        "ingested_at": "2026-02-11T16:50:40.665640+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261045-Cashinti-23899430",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "We dont know the exact start date and the company have said it won't be RNS'd but i think once it has started we will get an indication through some other avenue that people will pick up on. Sentiment seems to be building once more and it is surprising that since J&J have thrown their hat in the ring that there has not been any major sudden movement of shareprice.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665658+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261011-ThinIce--1756566",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.534873",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Not large volumes either.  Wonder whether we can expect an update on the forthcoming trial soon? Do we know the start date?",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665676+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261009-Cashinti--5123518",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashintime",
          "content": "Looking good over the last couple of days.",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "5.00",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665695+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261128-Fly66-54721260",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.535718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665713+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-Fly66-54721260",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fly66",
          "content": "Buyers and sellers, all 7 of them in 4 hours",
          "sentiment": 0.0,
          "engagement": "44",
          "price_at_post": "4.30",
          "thread_title": "RE: Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665731+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260859-ThinIce-27252625",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536555",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Buyers coming in\u2026",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Going blue\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=BF4CBF72-CB01-4BF3-9068-4309E11EBCF6"
        },
        "ingested_at": "2026-02-11T16:50:40.665749+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251004-nessab-10921758",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.536971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Https://x.com/Share_Talk/status/2006272907509653692",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "4.00",
          "thread_title": "RE: 10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-11T16:50:40.665767+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20250719-BurtonD-51758050",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537436",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "10 Companies to follow in 2026 2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty. It\u2019s been the market\u2019s best year for fundraising since the boom year of 2021: by the end of August AIM-listed companies had raised \u00a32.1bn from IPOs and secondary fundraisings (shares sold by current shareholders rather than issued by the company itself), more than double the \u00a3889m raised in the previous 12 months. AIM has continued to dominate Europe\u2019s growth markets, accounting for 53pc of all capital raised across European small cap indices over the past five years: more money than its five nearest European rivals combined. IPOs on London\u2019s junior market rebounded through the 2024/25 financial year, 16 companies listing so far against just nine last year. The average amount of new money raised per IPO was \u00a39.9m, up from the low of \u00a36.8m recorded in 2022/23. And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London\u2019s markets and direct more investment into UK assets. In his annual review of the small cap sector Investors\u2019 Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples. The prospect of lower interest rates and \u2013 in due course \u2013 market reform augur well for AIM\u2019s continued recovery in 2026. And though investors rightly look to the junior market for short-term gains they should not lose sight of one of the most well observed market patterns, frequently highlighted by TMS: the tendency of small caps to outperform their larger counterparts over time. The pattern has asserted itself in recent history, small and mid-sized companies generating a return premium over their larger peers of 6pc between 2009 and 2021. AIM was designed precisely to provide a framework for small cap growth over extended periods. For investors willing to do their homework, manage risk, spread their money over different sectors, and hold on to promising shares through tough times, AIM offers as many opportunities as it ever has. Here, we look at 10 Companies from a variety of sectors that have performed in 2025 or which may be positioned for a better year ahead. Also look out for our roundup of new year selections for Oil & Gas plus mining st",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.10",
          "thread_title": "10 Companies to follow in 2026 from @TMSreach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=5C2F48FA-9109-456F-A548-9507030EB50A"
        },
        "ingested_at": "2026-02-11T16:50:40.665785+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251113-BurtonD-36250471",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.537885",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Good morning, We published our letter to shareholders, providing an overview of the significant progress made in 2025 and our outlook for 2026, which is lined up to be a catalyst-rich year for Poolbeg. See full announcement here: https://www.londonstockexchange.com/news-article/POLB/letter-to-shareholders-2025-a-year-of-progress/17379476 During 2025, we made significant advances in the preparation of the POLB 001 TOPICAL trial, achieving several important milestones in quick succession. These included securing access to a bispecific antibody from Johnson & Johnson at no cost to Poolbeg, appointing ACT to conduct the trial, finalising the clinical trial protocol, and one of the main new updates included in the release is that we have confirmed participation from a number of additional cancer centres for the POLB 001 TOPICAL clinical trial, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. The trial has been designed to deliver rapid insights and having a number of sites participating in the trial will help to speed up recruitment, with interim data anticipated in summer 2026. The team attended the ASH Conference recently and the two key takeaways from the conference were 1. Making innovative cancer treatments available to all, and 2. Expanding these treatments from specialist cancer centres to community care. POLB 001 has the potential to address both of these key priorities of the blood cancer community. The POLB 001 progress coupled with advancements in our oral GLP-1 programme, with proof-of-concept data expected in H1 2026, highlights the serious momentum gained by the team throughout the year. 2025 has been a remarkable year of significant achievement, positioning Poolbeg strongly to deliver on a series of exciting clinical milestones in 2026.  We look forward to reporting on our progress in 2026. Kind regards,",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "4.00",
          "thread_title": "Letter to shareholders from Management...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F4EC08E4-3787-4E26-A8D6-664A59AC9C34"
        },
        "ingested_at": "2026-02-11T16:50:40.665803+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250717-ThinIce--5981905",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538318",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Succinctly put! Bodes well for 2026.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=307D7884-3502-49E2-9873-2F4403876ACF"
        },
        "ingested_at": "2026-02-11T16:50:40.665821+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251342-Shreddy6-42975233",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.538734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shreddy6",
          "content": "If you wouldnt touch this why are you here you complete bell end.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "3.80",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.665839+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-NBucky1-88399129",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539370",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Why This The Latest RNS Good for POLB Shareholders 1. POLB-001 is being included in a major, government-funded research programme The RISE programme involves: \u2022\tThe University of Manchester \u2022\tThe Christie NHS Foundation Trust (world-leading cancer centre) \u2022\tJohnson & Johnson \u2022\t\u00a33.4 million Medical Research Council (MRC) grant POLB hasn\u2019t had to pay for this \u2014 but their drug is being used. This gives huge validation to POLB-001. \u2e3b 2. Johnson & Johnson supplying a key antibody (teclistamab) This means: \u2022\tJ&J recognises POLB-001 as potentially useful in reducing CRS \u2022\tBig Pharma involvement massively increases credibility \u2022\tIt doesn\u2019t guarantee a future deal \u2014 but it makes one far more likely For a micro-cap AIM stock, partnership exposure with J&J is a major green flag. \u2e3b 3. It strengthens the scientific case for POLB-001 The RISE programme will study: \u2022\tWhy dangerous cytokine storms happen in cancer immunotherapy \u2022\tHow POLB-001 might prevent or reduce CRS \u2022\tAdditional research beyond their own clinical trial This is effectively free R&D that makes POLB-001 a more valuable asset. \u2e3b 4. It does NOT delay or affect the main POLB-001 clinical trial Important line: \u201cRISE will not impact the delivery of data from the POLB-001 clinical trial, anticipated in summer 2026.\u201d So: \u2022\tNo delay \u2022\tNo loss of focus \u2022\tExtra research on top of their main plan \u2e3b 5. It extends the company\u2019s financial runway They state: \u201cPoolbeg\u2019s participation\u2026 will not impact the Company\u2019s cash runway into 2027.\u201d This is rare on AIM \u2014 many small biotechs constantly raise money. POLB not needing to raise capital soon is a positive sign. \u2e3b 6. It positions POLB as a key partner in a huge unmet medical need Cytokine Release Syndrome (CRS) is one of the biggest problems in cancer immunotherapy \u2014 a multi-billion-dollar field. If POLB-001 shows it can prevent CRS, even partially, it could have very large value. \u2e3b \ud83d\udcc8 Overall Impact In short: \u2714 Adds credibility \u2714 Adds big-name partners (J&J, NHS, major university) \u2714 Adds non-dilutive funding \u2714 Adds more data to strengthen 2026 results \u2714 Keeps cash runway strong \u2714 Shows POLB-001 is being taken seriously by top institutions For a small AIM biotech like Poolbeg, this is exactly the kind of news long-term holders want.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "4.25",
          "thread_title": "Latest RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6A59A54E-9FDE-4D97-9D72-7424D1CC584B"
        },
        "ingested_at": "2026-02-11T16:50:40.665856+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251056-formerly--5322460",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.539782",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Under the radar is great imo.",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "4.25",
          "thread_title": "RE: Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-11T16:50:40.665875+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251002-ThinIce-88334470",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540210",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "\u2026..if this creeps up 5-10% a week under the radar for a few months as we near more substantial milestones. Stanley thinks he knows more than J&J. Proper turnip. Plenty on here.",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "4.25",
          "thread_title": "Don\u2019t be surprised \u2026.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=96E89A79-4BF4-4352-B60E-14A4F61B55FA"
        },
        "ingested_at": "2026-02-11T16:50:40.665893+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252335-NBucky1--6582959",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.540631",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Its always odd when people spend time talking about shares they don't like. Always means that they want to talk the price down so they can get cheaper shares. Always a good sign that the shares will be going up in value!",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.665911+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20252115-Brooko19--2927605",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brooko19",
          "content": "You constantly post on a something you wouldn\u2019t touch\u2026 so boring",
          "sentiment": 0.0,
          "engagement": "4,593",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.665929+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251425-stanleyb--7844130",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541463",
        "source": "LSE_CHAT",
        "data": {
          "author": "stanleyb",
          "content": "All smoke and mirrors it seems just like Hvivo turned out to be don't you think? Wouldn't touch this with the old barg pole. Always do your own research!!!",
          "sentiment": 0.0,
          "engagement": "3,679",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.665947+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251109-nessab--3019380",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "nessab",
          "content": "Article from Irish Independent https://x.com/PoolbegPharma/status/1997985506450092455/photo/1",
          "sentiment": 0.0,
          "engagement": "727",
          "price_at_post": "3.85",
          "thread_title": "RE: MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.665966+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250757-Troajan-37882708",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1083935/poolbeg-pharma-in-mrc-backed-cancer-immunotherapy-study-1083935.html",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "3.60",
          "thread_title": "Polb interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=9B3DE22B-0733-4076-8C2B-4E6DAFCA5834"
        },
        "ingested_at": "2026-02-11T16:50:40.665983+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250747-ThinIce-30146110",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.542711",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThinIce",
          "content": "Company making RNS!",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "3.65",
          "thread_title": "Fantastic endorsement by J&J",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=6C9C83E1-60EB-49F1-8289-18396B08379C"
        },
        "ingested_at": "2026-02-11T16:50:40.666001+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250735-BurtonD--6657784",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543198",
        "source": "LSE_CHAT",
        "data": {
          "author": "BurtonD",
          "content": "Major update from @PoolbegPharma (AIM: #POLB) Poolbeg\u2019s upcoming POLB 001 TOPICAL trial will feature as a key component of RISE \u2014 a groundbreaking cancer-immunotherapy-induced CRS research programme led by The Christie & University of Manchester. \ud83d\udd25 Key reveals: \ud83d\udd39 Johnson & Johnson are supplying the multimillion-euro bispecific antibody free of charge for the trial \u2014 now publicly confirmed for the first time. \ud83d\udd39 RISE deepens global understanding of immunotherapy-induced CRS \u2014 without affecting POLB 001 trial timelines (data expected summer 2026). \ud83d\udd39 No impact to cash runway \u2014 funded into 2027. \ud83d\udca1 Why #POLB 001 matters: CRS is the dangerous side-effect of \u201cwonder drug\u201d cancer immunotherapies (bispecifics, CAR-T, etc.) that limits patient access and forces late-stage patients into specialist centres for 2\u20133 weeks at a time. POLB 001 aims to prevent CRS before it occurs, potentially allowing these life-saving therapies to be delivered: \ud83c\udfe5 outside specialist centres \ud83e\ude7a in local hospitals or GP clinics \ud83c\udfe1 and eventually from home A breakthrough that could transform how late-stage cancer patients receive treatment. One of the most important programmes underway in European oncology. londonstockexchange.com/news-article/P\u2026",
          "sentiment": 0.0,
          "engagement": "2,705",
          "price_at_post": "3.65",
          "thread_title": "MASSIVE update from POLB :)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=3B0FE811-B844-4A5B-BD4B-A01DBF6C405D"
        },
        "ingested_at": "2026-02-11T16:50:40.666019+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250730-NBucky1--4594690",
        "event_type": "social_post",
        "date": "2026-01-24T01:56:43.543655",
        "source": "LSE_CHAT",
        "data": {
          "author": "NBucky1",
          "content": "Poolbeg Pharma plc has confirmed that its lead cancer therapy candidate, POLB-001, will be included in a major new research initiative (the RISE programme) studying cytokine release syndrome (CRS) \u2014 a serious side effect of some cancer immunotherapies. The RISE programme is led by The University of Manchester and The Christie NHS Foundation Trust, and is partially funded by a \u00a33.4 million Medical Research Council grant. Poolbeg will act as the lead industry partner alongside companies including Johnson & Johnson. \u2022\tThe focus is on better understanding and managing CRS to improve the safety and delivery of advanced cancer treatments. \u2022\tData from Poolbeg\u2019s ongoing POLB-001 TOPICAL trial is still expected in summer 2026 and this research collaboration will not delay that or impact the company\u2019s cash runway into 2027. \u2022\tThe programme will gather clinical data from patients receiving bispecific antibodies and CAR-T therapies and will look at POLB-001\u2019s potential to help prevent CRS. \u2022\tCRS is recognised as a major hurdle in wider use of immunotherapies. \u2022\tPoolbeg is partnering with academic and industry leaders to address this challenge.  \ufffc In short: POLB-001 is now part of a high-profile UK research effort to tackle treatment-limiting side effects of cancer immunotherapy, while Poolbeg remains on track with its own trial timelines.",
          "sentiment": 0.0,
          "engagement": "1,036",
          "price_at_post": "3.65",
          "thread_title": "Great POLB news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=POLB&thread=F9085024-1827-4B06-93E1-3922B1A059C7"
        },
        "ingested_at": "2026-02-11T16:50:40.666037+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2026-01-15"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "POLB.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 37.0,
      "signal": "MILD_CONCERN",
      "interpretation": "\ud83d\udfe2 Normal volatility - not a crash signal",
      "breakdown": {
        "price_destruction": 11.0,
        "volume_death": 10,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\ude10 Normal market conditions - no crash signal"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "CONFIRMED",
        "icon": "\u2705",
        "text": "Confirmed",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Notification of Major Holdings",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "POLB 001 LPS Challenge Trial Paper Published",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Exercise of Options & Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Letter to Shareholders \u2013 2025 a year of progress",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "POLB 001 to feature in CRS research programme",
        "status": "published",
        "icon": "\ud83d\udce2"
      }
    ],
    "decision_matrix": {
      "decision": "AVOID",
      "reason": "\u274c HOLD/WATCH - timing CONFIRMED",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "37/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "CONFIRMED",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "47/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "2 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 16,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 7,
          "max": 40,
          "signals_30d": 2,
          "signals_60d": 3,
          "signals_90d": 4,
          "signals_per_week": 0.31,
          "total_signals": 5,
          "rsi_extreme_count": 2,
          "rsi_ultra_count": 0,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 4,
          "escalation_score": 0,
          "description": "0.3 signals/week | 2 RSI<20 | Early stage"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 0,
          "max": 15,
          "relative_volume": 1.98,
          "description": "Normal volume"
        },
        "pop_potential": {
          "score": 4,
          "max": 15,
          "best_historical_rally": 98.0,
          "avg_rally": 92.1,
          "signal_count": 5,
          "description": "Baseline mover (98%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "POLB.L",
      "signal_date": "2025-08-08",
      "total_signals_history": 5
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +12 (AI_Technical_Score=10.0/20)",
      "Drawdown reversion potential: +16 (Drawdown_Pct=80.7%)",
      "Volume confirmation: +6 (Relative_Volume=2.0)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +8 (best_rally_pct=98%)"
    ],
    "technical_score": {
      "points": 12,
      "ai_score": 10.0,
      "reason": "AI Technical Score 10.0/20 translates to 12/25 points"
    },
    "drawdown_score": {
      "points": 16,
      "drawdown_pct": 80.68,
      "reason": "Drawdown of 80.7% gives 16/20 points"
    },
    "volume_score": {
      "points": 6,
      "rel_volume": 1.98,
      "reason": "Relative volume 1.98x gives 6 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 98.04,
      "reason": "Best rally of 98% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-08-08"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "HOLD/WATCH",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CONFIRMED",
    "run_multiple": 0.68,
    "current_run_pct": 66.59,
    "avg_historical_run_pct": 98.04
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CONFIRMED timing with 47/100 APEX score. Historical data shows 1 rallies averaging 98% upside. Current position: +66.6%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Limited upside case without catalysts"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Momentum confirmed. This is the trade zone if thesis holds.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 47,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "APEX Score: 47/100",
    "components": {
      "setup": {
        "score": 48,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 37.0,
        "weight": 0.3
      },
      "compression": {
        "score": 16,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "CONFIRMED",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
